Glucokinase activators

ABSTRACT

Compounds of the following formula are provided for use with glucokinase: 
                         
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

RELATED APPLICATION

This application is a divisional of U.S. Ser. No. 11/958,271, filed Dec.17, 2007, now U.S. Pat. No. 8,163,779, which claims the benefit of U.S.Provisional Application No. 60/870,929, filed Dec. 20, 2006, which areincorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to compounds that may be used to activatehexokinases, as well as compositions of matter, kits and articles ofmanufacture comprising these compounds. The invention also relates tomethods for activating hexokinases and treatment methods using compoundsaccording to the present invention. In addition, the invention relatesto methods of making the compounds of the present invention, as well asintermediates useful in such methods. In particular, the presentinvention relates to glucokinase activators; compositions of matter,kits and articles of manufacture comprising these compounds; methods foractivating glucokinase; and methods and intermediates useful for makingthe glucokinase activators.

BACKGROUND OF THE INVENTION

Glucokinase (GK, Hexokinase IV) is one of four hexokinases that arefound in mammals (Colowick, S. P., in The Enzymes, Vol. 9 (P. Boyer,ed.) Academic Press, New York, N.Y., pages 1-48, 1973). The hexokinasescatalyze the first step in the metabolism of glucose, i.e., theconversion of glucose to glucose-6-phosphate. Glucokinase is foundprincipally in pancreatic β-cells and liver parenchymal cells, two celltypes that are known to play critical roles in whole-body glucosehomeostasis. Specifically, GK is a rate-controlling enzyme for glucosemetabolism in these two cell types (Chipkin, S. R., Kelly, K. L., andRuderman, N. B. in Joslin's Diabetes (C. R. Khan and G. C. Wier, eds.),Lea and Febiger, Philadelphia, Pa., pages 97-115, 1994).

The concentration of glucose at which GK demonstrates half-maximalactivity is approximately 8 mM. The other three hexokinases aresaturated with glucose at much lower concentrations (<1 mM). Therefore,the flux of glucose through the GK pathway rises as the concentration ofglucose in the blood increases from fasting levels (5 mM) topostprandial levels following a carbohydrate-containing meal (about10-15 mM) (Printz, R. G., Magnuson, M. A., and Granner, D. K. in Ann.Rev. Nutrition Vol. 13 (R. E. Olson, D. M. Bier, and D. B. McCormick,eds.), Annual Review, Inc., Palo Alto, Calif., pages 463-496, 1993).These findings suggest that GK functions as a glucose sensor in β-cellsand hepatocytes (Meglasson, M. D. and Matschinsky, F. M. Amer. J.Physiol. 246, E1-E13, 1984).

More recently, studies in transgenic animals confirmed that GK doesindeed play a critical role in whole-body glucose homeostasis. Animalsthat do not express GK die within days of birth with severe diabetes,while animals overexpressing GK have improved glucose tolerance (Grupe,A., Hultgren, B., Ryan, A. et al., Cell 83, 69-78, 1995; Ferrie, T.,Riu, E., Bosch, F. et al., FASEB J., 10, 1213-1218, 1996). An increasein glucose exposure is coupled through GK in β-cells to increasedinsulin secretion and in hepatocytes to increased glycogen depositionand perhaps decreased glucose production.

The finding that type II maturity-onset diabetes of the young (MODY-2)is caused by loss of function mutations in the GK gene suggests that GKalso functions as a glucose sensor in humans (Liang, Y., Kesavan, P.,Wang, L. et al., Biochem. J. 309, 167-173, 1995). Additional evidencesupporting an important role for GK in the regulation of glucosemetabolism in humans was provided by the identification of patients thatexpress a mutant form of GK with increased enzymatic activity. Thesepatients exhibit a fasting hypoglycemia associated with aninappropriately elevated level of plasma insulin (Glaser, B., Kesavan,P., Heyman, M. et al., New England J. Med. 338, 226-230, 1998).Accordingly, compounds that activate GK and, thereby, increase thesensitivity of the GK sensor system are expected to be useful in thetreatment of the hyperglycemia characteristic of all type II diabetes.Glucokinase activators should increase the flux of glucose metabolism inβ-cells and hepatocytes, which will be coupled to increased insulinsecretion.

There is a continued need to find new therapeutic agents to treat humandiseases. The hexokinases, specifically but not limited to glucokinase,are especially attractive targets for the discovery of new therapeuticsdue to their important role in diabetes, hyperglycemia and otherdiseases.

SUMMARY OF THE INVENTION

The present invention relates to compounds that activate glucokinase.The present invention also provides compositions, articles ofmanufacture and kits comprising these compounds. In addition, theinvention relates to methods of making the compounds of the presentinvention, as well as intermediates useful in such methods.

In one embodiment, a pharmaceutical composition is provided thatcomprises a glucokinase activator according to the present invention asan active ingredient. Pharmaceutical compositions according to theinvention may optionally comprise 0.001%-100% of one or more activatorsof this invention. These pharmaceutical compositions may be administeredor coadministered by a wide variety of routes, including for example,orally, parenterally, intraperitoneally, intravenously, intraarterially,transdermally, sublingually, intramuscularly, rectally, transbuccally,intranasally, liposomally, via inhalation, vaginally, intraoccularly,via local delivery (for example by catheter or stent), subcutaneously,intraadiposally, intraarticularly, or intrathecally. The compositionsmay also be administered or coadministered in slow release dosage forms.

The invention is also directed to kits and other articles of manufacturefor treating disease states associated with glucokinase.

In one embodiment, a kit is provided that comprises a compositioncomprising at least one glucokinase activator of the present inventionin combination with instructions. The instructions may indicate thedisease state for which the composition is to be administered, storageinformation, dosing information and/or instructions regarding how toadminister the composition. The kit may also comprise packagingmaterials. The packaging material may comprise a container for housingthe composition. The kit may also optionally comprise additionalcomponents, such as syringes for administration of the composition. Thekit may comprise the composition in single or multiple dose forms.

In another embodiment, an article of manufacture is provided thatcomprises a composition comprising at least one glucokinase activator ofthe present invention in combination with packaging materials. Thepackaging material may comprise a container for housing the composition.The container may optionally comprise a label indicating the diseasestate for which the composition is to be administered, storageinformation, dosing information and/or instructions regarding how toadminister the composition. The kit may also optionally compriseadditional components, such as syringes for administration of thecomposition. The kit may comprise the composition in single or multipledose forms.

Also provided are methods for preparing compounds, compositions and kitsaccording to the present invention. For example, several syntheticschemes are provided herein for synthesizing compounds according to thepresent invention.

Also provided are methods for using compounds, compositions, kits andarticles of manufacture according to the present invention.

In one embodiment, the compounds, compositions, kits and articles ofmanufacture are used to modulate glucokinase. In particular, thecompounds, compositions, kits and articles of manufacture can be used toactivate glucokinase.

In another embodiment, the compounds, compositions, kits and articles ofmanufacture are used to treat a disease state for which increasingglucokinase activity ameliorates the pathology and/or symptomology ofthe disease state.

In another embodiment, a compound is administered to a subject whereinglucokinase activity within the subject is altered and, in oneembodiment, increased.

In another embodiment, a prodrug of a compound is administered to asubject that is converted to the compound in vivo where it activatesglucokinase.

In another embodiment, a method of activating glucokinase is providedthat comprises contacting glucokinase with a compound according to thepresent invention.

In another embodiment, a method of activating glucokinase is providedthat comprises causing a compound according to the present invention tobe present in a subject in order to activate glucokinase in vivo.

In another embodiment, a method of activating glucokinase is providedthat comprises administering a first compound to a subject that isconverted in vivo to a second compound wherein the second compoundactivates glucokinase in vivo. It is noted that the compounds of thepresent invention may be the first or second compounds.

In another embodiment, a therapeutic method is provided that comprisesadministering a compound according to the present invention.

In another embodiment, a method of treating a condition in a patientthat is known to be mediated by glucokinase, or which is known to betreated by glucokinase activators, is provided comprising administeringto the patient a therapeutically effective amount of a compoundaccording to the present invention.

In another embodiment, a method is provided for treating a disease statefor which increasing glucokinase activity ameliorates the pathologyand/or symptomology of the disease state, the method comprising: causinga compound according to the present invention to be present in a subjectin a therapeutically effective amount for the disease state.

In another embodiment, a method is provided for treating a disease statefor which increasing glucokinase activity ameliorates the pathologyand/or symptomology of the disease state, the method comprising:administering a first compound to a subject that is converted in vivo toa second compound such that the second compound is present in thesubject in a therapeutically effective amount for the disease state. Itis noted that the compounds of the present invention may be the first orsecond compounds.

In another embodiment, a method is provided for treating a disease statefor which increasing glucokinase activity ameliorates the pathologyand/or symptomology of the disease state, the method comprising:administering a compound according to the present invention to a subjectsuch that the compound is present in the subject in a therapeuticallyeffective amount for the disease state.

In another embodiment, a method is provided for using a compoundaccording to the present invention in order to manufacture a medicamentfor use in the treatment of a disease state that is known to be mediatedby glucokinase, or that is known to be treated by glucokinaseactivators.

It is noted in regard to all of the above embodiments that the presentinvention is intended to encompass all pharmaceutically acceptableionized forms (e.g., salts) and solvates (e.g., hydrates) of thecompounds, regardless of whether such ionized forms and solvates arespecified since it is well known in the art to administer pharmaceuticalagents in an ionized or solvated form. It is also noted that unless aparticular stereochemistry is specified, recitation of a compound isintended to encompass all possible stereoisomers (e.g., enantiomers ordiastereomers depending on the number of chiral centers), independent ofwhether the compound is present as an individual isomer or a mixture ofisomers. Further, unless otherwise specified, recitation of a compoundis intended to encompass all possible resonance forms and tautomers.With regard to the claims, the language “compound comprising theformula,” “compound having the formula” and “compound of the formula” isintended to encompass the compound and all pharmaceutically acceptableionized forms and solvates, all possible stereoisomers, and all possibleresonance forms and tautomers unless otherwise specifically specified inthe particular claim.

It is further noted that prodrugs may also be administered which arealtered in vivo and become a compound according to the presentinvention. The various methods of using the compounds of the presentinvention are intended, regardless of whether prodrug delivery isspecified, to encompass the administration of a prodrug that isconverted in vivo to a compound according to the present invention. Itis also noted that certain compounds of the present invention may bealtered in vivo prior to activating glucokinase and thus may themselvesbe prodrugs for another compound. Such prodrugs of another compound mayor may not themselves independently have glucokinase activity.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates SEQ. ID No. 1 referred to in this application.

DEFINITIONS

Unless otherwise stated, the following terms used in the specificationand claims shall have the following meanings for the purposes of thisApplication.

“Alicyclic” means a moiety comprising a non-aromatic ring structure.Alicyclic moieties may be saturated or partially unsaturated with one,two or more double or triple bonds. Alicyclic moieties may alsooptionally comprise heteroatoms such as nitrogen, oxygen and sulfur. Thenitrogen atoms can be optionally quaternerized or oxidized and thesulfur atoms can be optionally oxidized. Examples of alicyclic moietiesinclude, but are not limited to moieties with (C₃₋₈) rings such ascyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene,cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene,cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene.

“Aliphatic” means a moiety characterized by a straight or branched chainarrangement of constituent carbon atoms and may be saturated orpartially unsaturated with one, two or more double or triple bonds.

“Alkenyl” means a straight or branched, carbon chain that contains atleast one carbon-carbon double bond (—CR═CR′— or —CR═CR′R″, wherein R,R′ and R″ are each independently hydrogen or further substituents).Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl,hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and thelike. In particular embodiments, “alkenyl,” either alone or representedalong with another radical, can be a (C₂₋₂₀)alkenyl, a (C₂₋₁₅)alkenyl, a(C₂₋₁₀)alkenyl, a (C₂₋₅)alkenyl or a (C₂₋₃)alkenyl. Alternatively,“alkenyl,” either alone or represented along with another radical, canbe a (C₂)alkenyl, a (C₃)alkenyl or a (C₄)alkenyl.

“Alkenylene” means a straight or branched, divalent carbon chain havingone or more carbon-carbon double bonds (—CR═CR′—, wherein R and R′ areeach independently hydrogen or further substituents). Examples ofalkenylene include ethene-1,2-diyl, propene-1,3-diyl,methylene-1,1-diyl, and the like. In particular embodiments,“alkenylene,” either alone or represented along with another radical,can be a (C₂₋₂₀) alkenylene, a (C₂₋₁₅) alkenylene, a (C₂₋₁₀ alkenylene,a (C₂₋₅) alkenylene or a (C₂₋₃) alkenylene. Alternatively, “alkenylene,”either alone or represented along with another radical, can be a (C₂)alkenylene, a (C₃) alkenylene or a (C₄) alkenylene.

“Alkoxy” means an oxygen moiety having a further alkyl substituent. Thealkoxy groups of the present invention can be optionally substituted.

“Alkyl” represented by itself means a straight or branched, saturated orunsaturated, aliphatic radical having a chain of carbon atoms,optionally with one or more of the carbon atoms being replaced withoxygen (See “oxaalkyl”), a carbonyl group (See “oxoalkyl”), sulfur (See“thioalkyl”), and/or nitrogen (See “azaalkyl”). (C_(X))alkyl and(C_(X-Y))alkyl are typically used where X and Y indicate the number ofcarbon atoms in the chain. For example, (C₁₋₆)alkyl includes alkyls thathave a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl,isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl,1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl,ethynyl, 1-propynyl, 2-propynyl, and the like). Alkyl represented alongwith another radical (e.g., as in arylalkyl, heteroarylalkyl and thelike) means a straight or branched, saturated or unsaturated aliphaticdivalent radical having the number of atoms indicated or when no atomsare indicated means a bond (e.g., (C₆₋₁₀)aryl(C₁₋₃)alkyl includes,benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl,2-pyridinylmethyl and the like). In particular embodiments, “alkyl,”either alone or represented along with another radical, can be a(C₁₋₂₀)alkyl, a (C₁₋₁₅)alkyl, a (C₁₋₁₀)alkyl, a (C₁₋₅)alkyl or a(C₁₋₃)alkyl. Alternatively, “alkyl,” either alone or represented alongwith another radical, can be a (C₁)alkyl, a (C₂)alkyl or a (C₃)alkyl.

“Alkylene”, unless indicated otherwise, means a straight or branched,saturated or unsaturated, aliphatic, divalent radical. (C_(X))alkyleneand (C_(X-Y))alkylene are typically used where X and Y indicate thenumber of carbon atoms in the chain. For example, (C₁₋₆)alkyleneincludes methylene (—CH₂—), ethylene (—CH₂CH₂—), trimethylene(—CH₂CH₂CH₂—), tetramethylene (—CH₂CH₂CH₂CH₂—) 2-butenylene(—CH₂CH═CHCH₂—), 2-methyltetramethylene (—CH₂CH(CH₃)CH₂CH₂—),pentamethylene (—CH₂CH₂CH₂CH₂CH₂—) and the like. In particularembodiments, “alkylene,” either alone or represented along with anotherradical, can be a (C₁₋₂₀)alkylene, a (C₁₋₁₅)alkylene, a (C₁₋₁₀)alkylene,a (C₁₋₅)alkylene or a (C₁₋₃)alkylene. Alternatively, “alkylene,” eitheralone or represented along with another radical, can be a (C₁)alkylene,a (C₂)alkylene or a (C₃)alkylene.

“Alkylidene” means a straight or branched, saturated or unsaturated,aliphatic radical connected to the parent molecule by a double bond.(C_(X))alkylidene and (C_(X-Y))alkylidene are typically used where X andY indicate the number of carbon atoms in the chain. For example,(C₁₋₆)alkylidene includes methylene (═CH₂), ethylidene (═CHCH₃),isopropylidene (═C(CH₃)₂), propylidene (═CHCH₂CH₃), allylidene(═CH—CH═CH₂), and the like. In particular embodiments, “alkylidene,”either alone or represented along with another radical, can be a(C₁₋₂₀)alkylidene, a (C₁₋₁₅)alkylidene, a (C₁₋₁₀)alkylidene, a(C₁₋₅)alkylidene or a (C₁₋₃)alkylidene. Alternatively, “alkylidene,”either alone or represented along with another radical, can be a(C₁)alkylidene, a (C₂)alkylidene or a (C₃)alkylidene.

“Alkynyl” means a straight or branched, carbon chain that contains atleast one carbon-carbon triple bond (—C≡C— or —C≡CR, wherein R ishydrogen or a further substituent). Examples of alkynyl include ethynyl,propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like. In particularembodiments, “alkynyl,” either alone or represented along with anotherradical, can be a (C₂₋₂₀)alkynyl, a (C₂₋₁₅)alkynyl, a (C₂₋₁₀)alkynyl, a(C₂₋₅)alkynyl or a (C₂₋₃)alkynyl. Alternatively, “alkynyl,” either aloneor represented along with another radical, can be a (C₂)alkynyl, a(C₃)alkynyl or a (C₄)alkynyl.

“Alkynylene” means a straight or branched, divalent carbon chain havingone or more carbon-carbon triple bonds (—CR≡CR′—, wherein R and R′ areeach independently hydrogen or further substituents). Examples ofalkynylene include ethyne-1,2-diyl, propyne-1,3-diyl, and the like. Inparticular embodiments, “alkynylene,” either alone or represented alongwith another radical, can be a (C₂₋₂₀) alkynylene, a (C₂₋₁₅) alkynylene,a (C₂₋₁₀) alkynylene, a (C₂₋₅) alkynylene or a (C₂₋₃) alkynylene.Alternatively, “alkynylene,” either alone or represented along withanother radical, can be a (C₂) alkynylene, a (C₃) alkynylene or a (C₄)alkynylene.

“Amido” means the radical —C(═O)—NR—, —C(═O)—NRR′, —NR—C(═O)— and/or—NR—C(═O)R′, wherein each R and R′ are independently hydrogen or afurther substituent.

“Amino” means a nitrogen moiety having two further substituents where,for example, a hydrogen or carbon atom is attached to the nitrogen. Forexample, representative amino groups include —NH₂, —NHCH₃, —N(CH₃)₂,—NH((C₁₋₁₀)alkyl), —N((C₁₋₁₀)alkyl)₂, —NH(aryl), —NH(heteroaryl),—N(aryl)₂, —N(heteroaryl)₂, and the like. Optionally, the twosubstituents together with the nitrogen may also form a ring. Unlessindicated otherwise, the compounds of the invention containing aminomoieties may include protected derivatives thereof. Suitable protectinggroups for amino moieties include acetyl, tert-butoxycarbonyl,benzyloxycarbonyl, and the like.

“Animal” includes humans, non-human mammals (e.g., dogs, cats, rabbits,cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals(e.g., birds, and the like).

“Aromatic” means a moiety wherein the constituent atoms make up anunsaturated ring system, all atoms in the ring system are sp² hybridizedand the total number of pi electrons is equal to 4n+2. An aromatic ringmay be such that the ring atoms are only carbon atoms or may includecarbon and non-carbon atoms (See “heteroaryl”).

“Aryl” means a monocyclic or polycyclic ring assembly wherein each ringis aromatic or when fused with one or more rings forms an aromatic ringassembly. If one or more ring atoms is not carbon (e.g., N, S), the arylis a heteroaryl. (C_(X))aryl and (C_(X-Y))aryl are typically used whereX and Y indicate the number of carbon atoms in the ring. In particularembodiments, “aryl,” either alone or represented along with anotherradical, can be a (C₃₋₁₄)aryl, a (C₃₋₁₀)aryl, a (C₃₋₇)aryl, a(C₈₋₁₀)aryl or a (C₅₋₇)aryl. Alternatively, “aryl,” either alone orrepresented along with another radical, can be a (C₅)aryl, a (C₆)aryl, a(C₇)aryl, a (C₈)aryl., a (C₉)aryl or a (C₁₀)aryl.

“Azaalkyl” and “aminoalkyl” mean an alkyl, as defined above, exceptwhere one or more of the carbon atoms forming the alkyl chain arereplaced with substituted or unsubstituted nitrogen atoms (—NR— or—NRR′, wherein R and R′ are each independently hydrogen or furthersubstituents). For example, a (C₁₋₁₀)azaalkyl refers to a chaincomprising between 1 and 10 carbons and one or more nitrogen atoms.

“Bicycloalkyl” means a saturated or partially unsaturated fused, spiroor bridged bicyclic ring assembly. In particular embodiments,“bicycloalkyl,” either alone or represented along with another radical,can be a (C₄₋₁₅)bicycloalkyl, a (C₄₋₁₀)bicycloalkyl, a(C₆₋₁₀)bicycloalkyl or a (C₈₋₁₀)bicycloalkyl. Alternatively,“bicycloalkyl,” either alone or represented along with another radical,can be a (C₈)bicycloalkyl, a (C₉)bicycloalkyl or a (C₁₀)bicycloalkyl.

“Bicycloaryl” means a fused, spiro or bridged bicyclic ring assemblywherein at least one of the rings comprising the assembly is aromatic.(C_(X))bicycloaryl and (C_(X-Y))bicycloaryl are typically used where Xand Y indicate the number of carbon atoms in the bicyclic ring assemblyand directly attached to the ring. In particular embodiments,“bicycloaryl,” either alone or represented along with another radical,can be a (a (C₄₋₁₅)bicycloaryl, a (C₄₋₁₀)bicycloaryl, a(C₆₋₁₀)bicycloaryl or a (C₈₋₁₀)bicycloaryl. Alternatively,“bicycloalkyl,” either alone or represented along with another radical,can be a (C₈)bicycloaryl, a (C₉)bicycloaryl or a (C₁₀)bicycloaryl.

“Bridging ring” and “bridged ring” as used herein refer to a ring thatis bonded to another ring to form a compound having a bicyclic orpolycyclic structure where two ring atoms that are common to both ringsare not directly bound to each other. Non-exclusive examples of commoncompounds having a bridging ring include borneol, norbornane,7-oxabicyclo[2.2.1]heptane, and the like. One or both rings of thebicyclic system may also comprise heteroatoms.

“Carbamoyl” means the radical —OC(O)NRR′, wherein R and R′ are eachindependently hydrogen or further substituents.

“Carbocycle” means a ring consisting of carbon atoms.

“Carbonyl” means the radical —C(═O)— and/or —C(═O)R, wherein R ishydrogen or a further substituent. It is noted that the carbonyl radicalmay be further substituted with a variety of substituents to formdifferent carbonyl groups including acids, acid halides, aldehydes,amides, esters, and ketones.

“Carboxy” means the radical —C(═O)—O— and/or —C(═O)—OR, wherein R ishydrogen or a further substituent. It is noted that compounds of theinvention containing carboxy moieties may include protected derivativesthereof, i.e., where the oxygen is substituted with a protecting group.Suitable protecting groups for carboxy moieties include benzyl,tert-butyl, and the like.

“Cyano” means the radical —CN.

“Cycloalkyl” means a non-aromatic, saturated or partially unsaturated,monocyclic, bicyclic or polycyclic ring assembly. (C_(X))cycloalkyl and(C_(X-Y))cycloalkyl are typically used where X and Y indicate the numberof carbon atoms in the ring assembly. For example, (C₃₋₁₀)cycloalkylincludes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl,decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl,2-oxobicyclo[2.2.1]hept-1-yl, and the like. In particular embodiments,“cycloalkyl,” either alone or represented along with another radical,can be a (C₃₋₁₄)cycloalkyl, a (C₃₋₁₀)cycloalkyl, a (C₃₋₇)cycloalkyl, a(C₈₋₁₀)cycloalkyl or a (C₅₋₇)cycloalkyl. Alternatively, “cycloalkyl,”either alone or represented along with another radical, can be a(C₅)cycloalkyl, a (C₆)cycloalkyl, a (C₇)cycloalkyl, a (C₈)cycloalkyl., a(C₉)cycloalkyl or a (C₁₀)cycloalkyl.

“Cycloalkylene” means a divalent, saturated or partially unsaturated,monocyclic, bicyclic or polycyclic ring assembly. (C_(X))cycloalkyleneand (C_(X-Y))cycloalkylene are typically used where X and Y indicate thenumber of carbon atoms in the ring assembly. In particular embodiments,“cycloalkylene,” either alone or represented along with another radical,can be a (C₃₋₁₄)cycloalkylene, a (C₃₋₁₀)cycloalkylene, a(C₃₋₇)cycloalkylene, a (C₈₋₁₀)cycloalkylene or a (C₅₋₇)cycloalkylene.Alternatively, “cycloalkylene,” either alone or represented along withanother radical, can be a (C₅)cycloalkylene, a (C₆)cycloalkylene, a(C₇)cycloalkylene, a (C₈)cycloalkylene., a (C₉)cycloalkylene or a(C₁₀)cycloalkylene.

“Disease” specifically includes any unhealthy condition of an animal orpart thereof and includes an unhealthy condition that may be caused by,or incident to, medical or veterinary therapy applied to that animal,i.e., the “side effects” of such therapy.

“Fused ring” as used herein refers to a ring that is bonded to anotherring to form a compound having a bicyclic structure where the ring atomsthat are common to both rings are directly bound to each other.Non-exclusive examples of common fused rings include decalin,naphthalene, anthracene, phenanthrene, indole, furan, benzofuran,quinoline, and the like. Compounds having fused ring systems may besaturated, partially saturated, carbocyclics, heterocyclics, aromatics,heteroaromatics, and the like.

“Halo” means fluoro, chloro, bromo or iodo.

“Heteroalkyl” means alkyl, as defined in this Application, provided thatone or more of the atoms within the alkyl chain is a heteroatom. Inparticular embodiments, “heteroalkyl,” either alone or represented alongwith another radical, can be a hetero(C₁₋₂₀)alkyl, a hetero(C₁₋₁₅)alkyl,a hetero(C₁₋₁₀)alkyl, a hetero(C₁₋₅)alkyl, a hetero(C₁₋₃)alkyl or ahetero(C₁₋₂)alkyl. Alternatively, “heteroalkyl,” either alone orrepresented along with another radical, can be a hetero(C₁)alkyl, ahetero(C₂)alkyl or a hetero(C₃)alkyl.

“Heteroaryl” means a monocyclic, bicyclic or polycyclic aromatic groupwherein at least one ring atom is a heteroatom and the remaining ringatoms are carbon. Monocyclic heteroaryl groups include, but are notlimited to, cyclic aromatic groups having five or six ring atoms,wherein at least one ring atom is a heteroatom and the remaining ringatoms are carbon. The nitrogen atoms can be optionally quaternerized andthe sulfur atoms can be optionally oxidized. Heteroaryl groups of thisinvention include, but are not limited to, those derived from furan,imidazole, isothiazole, isoxazole, oxadiazole, oxazole,1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine,pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole.“Heteroaryl” also includes, but is not limited to, bicyclic or tricyclicrings, wherein the heteroaryl ring is fused to one or two ringsindependently selected from the group consisting of an aryl ring, acycloalkyl ring, a cycloalkenyl ring, and another monocyclic heteroarylor heterocycloalkyl ring. These bicyclic or tricyclic heteroarylsinclude, but are not limited to, those derived from benzo[b]furan,benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline,thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine,indolizine, imidazo[1,2a]pyridine, quinoline, isoquinoline, phthalazine,quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole,indoline, benzoxazole, benzopyrazole, benzothiazole,imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine,imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine,imidazo[1,5-a]pyrimidine, imidazo[1,5-c]pyrimidine,pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine,pyrrolo[3,2-b]pyridine, pyrrolo[2,3-d]pyrimidine,pyrrolo[3,2-d]pyrimidine, pyrrolo[2,3-b]pyrazine,pyrazolo[1,5-a]pyridine, pyrrolo[1,2-b]pyridazine,pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine,pyrrolo[1,2-a]pyrazine, triazo[1,5-a]pyridine, pteridine, purine,carbazole, acridine, phenazine, phenothiazene, phenoxazine,1,2-dihydropyrrolo[3,2,1-hi]indole, indolizine, pyrido[1,2-a]indole and2(1H)-pyridinone. The bicyclic or tricyclic heteroaryl rings can beattached to the parent molecule through either the heteroaryl groupitself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl groupto which it is fused. The heteroaryl groups of this invention can besubstituted or unsubstituted. In particular embodiments, “heteroaryl,”either alone or represented along with another radical, can be ahetero(C₁₋₁₃)aryl, a hetero(C₂₋₁₃)aryl, a hetero(C₂₋₆)aryl, ahetero(C₃₋₉)aryl or a hetero(C₅₋₉)aryl. Alternatively, “heteroaryl,”either alone or represented along with another radical, can be ahetero(C₃)aryl, a hetero(C₄)aryl, a hetero(C₅)aryl, a hetero(C₆)aryl., ahetero(C₇)aryl, a hetero(C₈)aryl or a hetero(C₉)aryl.

“Heteroatom” refers to an atom that is not a carbon atom. Particularexamples of heteroatoms include, but are not limited to, nitrogen,oxygen, and sulfur.

“Heteroatom moiety” includes a moiety where the atom by which the moietyis attached is not a carbon. Examples of heteroatom moieties include—NR—, —N⁺(O⁻)═, —O—, —S— or —S(O)₂—, wherein R is hydrogen or a furthersubstituent.

“Heterobicycloalkyl” means bicycloalkyl, as defined in this Application,provided that one or more of the atoms within the ring is a heteroatom.For example hetero(C₉₋₁₂)bicycloalkyl as used in this applicationincludes, but is not limited to, 3-aza-bicyclo[4.1.0]hept-3-yl,2-aza-bicyclo[3.1.0]hex-2-yl, 3-aza-bicyclo[3.1.0]hex-3-yl, and thelike. In particular embodiments, “heterobicycloalkyl,” either alone orrepresented along with another radical, can be ahetero(C₁₋₁₄)bicycloalkyl, a hetero(C₄₋₁₄)bicycloalkyl, ahetero(C₄₋₉)bicycloalkyl or a hetero(C₅₋₉)bicycloalkyl. Alternatively,“heterobicycloalkyl,” either alone or represented along with anotherradical, can be a hetero(C₅)bicycloalkyl, hetero(C₆)bicycloalkyl,hetero(C₇)bicycloalkyl, hetero(C₈)bicycloalkyl or ahetero(C₉)bicycloalkyl.

“Heterobicycloaryl” means bicycloaryl, as defined in this Application,provided that one or more of the atoms within the ring is a heteroatom.For example, hetero(C₄₋₁₂)bicycloaryl as used in this Applicationincludes, but is not limited to, 2-amino-4-oxo-3,4-dihydropteridin-6-yl,tetrahydroisoquinolinyl, and the like. In particular embodiments,“heterobicycloaryl,” either alone or represented along with anotherradical, can be a hetero(C₁₋₁₄)bicycloaryl, a hetero(C₄₋₁₄)bicycloaryl,a hetero(C₄₋₉)bicycloarylor a hetero(C₅₋₉)bicycloaryl. Alternatively,“heterobicycloaryl,” either alone or represented along with anotherradical, can be a hetero(C₅)bicycloaryl, hetero(C₆)bicycloaryl,hetero(C₇)bicycloaryl, hetero(C₈)bicycloaryl or a hetero(C₉)bicycloaryl.

“Heterocycloalkyl” means cycloalkyl, as defined in this Application,provided that one or more of the atoms forming the ring is a heteroatomselected, independently from N, O, or S, Non-exclusive examples ofheterocycloalkyl include piperidyl, 4-morpholyl, 4-piperazinyl,pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl,1,3-dioxanyl, 1,4-dioxanyl and the like. In particular embodiments,“heterocycloalkyl,” either alone or represented along with anotherradical, can be a hetero(C₁₋₁₃)cycloalkyl, a hetero(C₁₋₉)cycloalkyl, ahetero(C₁₋₆)cycloalkyl, a hetero(C₅₋₉)cycloalkyl or ahetero(C₂₋₆)cycloalkyl. Alternatively, “heterocycloalkyl,” either aloneor represented along with another radical, can be ahetero(C₂)cycloalkyl, a hetero(C₃)cycloalkyl, a hetero(C₄)cycloalkyl, ahetero(C₅)cycloalkyl, a hetero(C₆)cycloalkyl, hetero(C₇)cycloalkyl,hetero(C₈)cycloalkyl or a hetero(C₉)cycloalkyl.

“Heterocycloalkylene” means cycloalkylene, as defined in thisApplication, provided that one or more of the ring member carbon atomsis replaced by a heteroatom. In particular embodiments,“heterocycloalkylene,” either alone or represented along with anotherradical, can be a hetero(C₁₋₁₃)cycloalkylene, ahetero(C₁₋₉)cycloalkylene, a hetero(C₁₋₆)cycloalkylene, ahetero(C₅₋₉)cycloalkylene or a hetero(C₂₋₆)cycloalkylene. Alternatively,“heterocycloalkylene,” either alone or represented along with anotherradical, can be a hetero(C₂)cycloalkylene, a hetero(C₃)cycloalkylene, ahetero(C₄)cycloalkylene, a hetero(C₅)cycloalkylene, ahetero(C₆)cycloalkylene, hetero(C₇)cycloalkylene,hetero(C₈)cycloalkylene or a hetero(C₉)cycloalkylene.

“Hydroxy” means the radical —OH.

“IC₅₀” means the molar concentration of an inhibitor that produces 50%inhibition of the target enzyme.

“Imino” means the radical —CR(═NR′) and/or —C(═NR′)—, wherein R and R′are each independently hydrogen or a further substituent.

“Isomers” means compounds having identical molecular formulae butdiffering in the nature or sequence of bonding of their atoms or in thearrangement of their atoms in space. Isomers that differ in thearrangement of their atoms in space are termed “stereoisomers.”Stereoisomers that are not mirror images of one another are termed“diastereomers” and stereoisomers that are nonsuperimposable mirrorimages are termed “enantiomers” or sometimes “optical isomers.” A carbonatom bonded to four nonidentical substituents is termed a “chiralcenter.” A compound with one chiral center has two enantiomeric forms ofopposite chirality. A mixture of the two enantiomeric forms is termed a“racemic mixture.” A compound that has more than one chiral center has2^(n-1) enantiomeric pairs, where n is the number of chiral centers.Compounds with more than one chiral center may exist as ether anindividual diastereomer or as a mixture of diastereomers, termed a“diastereomeric mixture.” When one chiral center is present astereoisomer may be characterized by the absolute configuration of thatchiral center. Absolute configuration refers to the arrangement in spaceof the substituents attached to the chiral center. Enantiomers arecharacterized by the absolute configuration of their chiral centers anddescribed by the R- and S-sequencing rules of Cahn, Ingold and Prelog.Conventions for stereochemical nomenclature, methods for thedetermination of stereochemistry and the separation of stereoisomers arewell known in the art (e.g., see “Advanced Organic Chemistry”, 4thedition, March, Jerry, John Wiley & Sons, New York, 1992).

“Leaving group” means the group with the meaning conventionallyassociated with it in synthetic organic chemistry, i.e., an atom orgroup displaceable under reaction (e.g., alkylating) conditions.Examples of leaving groups include, but are not limited to, halo (e.g.,F, Cl, Br and I), alkyl (e.g., methyl and ethyl) and sulfonyloxy (e.g.,mesyloxy, ethanesulfonyloxy, benzenesulfonyloxy and tosyloxy),thiomethyl, thienyloxy, dihalophosphinoyloxy, tetrahalophosphoxy,benzyloxy, isopropyloxy, acyloxy, and the like.

“Moiety providing X atom separation” and “linker providing X atomseparation” between two other moieties mean that the chain of atomsdirectly linking the two other moieties is X atoms in length. When X isgiven as a range (e.g., X₁-X₂), then the chain of atoms is at least X₁and not more than X₂ atoms in length. It is understood that the chain ofatoms can be formed from a combination of atoms including, for example,carbon, nitrogen, sulfur and oxygen atoms. Further, each atom canoptionally be bound to one or more substituents, as valencies allow. Inaddition, the chain of atoms can form part of a ring. Accordingly, inone embodiment, a moiety providing X atom separation between two othermoieties (R and R′) can be represented by R-(L)_(X)-R′ where each L isindependently selected from the group consisting of CR′R″, NR″″, O, S,CO, CS, C═NR′″″, SO, SO₂, and the like, where any two or more of R″,R′″, R″″ and R can be taken together to form a substituted orunsubstituted ring.

“Nitro” means the radical —NO₂.

“Oxaalkyl” means an alkyl, as defined above, except where one or more ofthe carbon atoms forming the alkyl chain are replaced with oxygen atoms(—O— or —OR, wherein R is hydrogen or a further substituent). Forexample, an oxa(C₁₋₁₀)alkyl refers to a chain comprising between 1 and10 carbons and one or more oxygen atoms.

“Oxoalkyl” means an alkyl, as defined above, except where one or more ofthe carbon atoms forming the alkyl chain are replaced with carbonylgroups (—C(═O)— or —C(═O)—R, wherein R is hydrogen or a furthersubstituent). The carbonyl group may be an aldehyde, ketone, ester,amide, acid or acid halide. For example, an oxo(C₁₋₁₀)alkyl refers to achain comprising between 1 and 10 carbon atoms and one or more carbonylgroups.

“Oxy” means the radical —O— or —OR, wherein R is hydrogen or a furthersubstituent. Accordingly, it is noted that the oxy radical may befurther substituted with a variety of substituents to form different oxygroups including hydroxy, alkoxy, aryloxy, heteroaryloxy or carbonyloxy.

“Pharmaceutically acceptable” means that which is useful in preparing apharmaceutical composition that is generally safe, non-toxic and neitherbiologically nor otherwise undesirable and includes that which isacceptable for veterinary use as well as human pharmaceutical use.

“Pharmaceutically acceptable salts” means salts of compounds of thepresent invention which are pharmaceutically acceptable, as definedabove, and which possess the desired pharmacological activity. Suchsalts include acid addition salts formed with inorganic acids such ashydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like; or with organic acids such as aceticacid, propionic acid, hexanoic acid, heptanoic acid,cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid,malonic acid, succinic acid, malic acid, maleic acid, fumaric acid,tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoicacid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonicacid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,benzenesulfonic acid, p-chlorobenzenesulfonic acid,2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonicacid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonicacid, 4,4′-methylenebis(3-hydroxy-2-ene-1-carboxylic acid),3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid,lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoicacid, salicylic acid, stearic acid, muconic acid and the like.

Pharmaceutically acceptable salts also include base addition salts whichmay be formed when acidic protons present are capable of reacting withinorganic or organic bases. Acceptable inorganic bases include sodiumhydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide andcalcium hydroxide. Acceptable organic bases include ethanolamine,diethanolamine, triethanolamine, tromethamine, N-methylglucamine and thelike.

“Polycyclic ring” includes bicyclic and multi-cyclic rings. Theindividual rings comprising the polycyclic ring can be fused, spiro orbridging rings.

“Prodrug” means a compound that is convertible in vivo metabolicallyinto an active species according to the present invention. The prodrugitself may or may not also have activity with respect to a given targetprotein. For example, a compound comprising a hydroxy group may beadministered as an ester that is converted by hydrolysis in vivo to thehydroxy compound. Suitable esters that may be converted in vivo intohydroxy compounds include acetates, citrates, lactates, phosphates,tartrates, malonates, oxalates, salicylates, propionates, succinates,fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates,isethionates, di-p-toluoyltartrates, methanesulfonates,ethanesulfonates, benzenesulfonates, p-toluenesulfonates,cyclohexylsulfamates, quinates, esters of amino acids, and the like.Similarly, a compound comprising an amine group may be administered asan amide that is converted by hydrolysis in vivo to the amine compound.

“Protected derivatives” means derivatives of compounds in which areactive site or sites are blocked with protecting groups. Protectedderivatives are useful in the preparation of pharmaceutical agents or inthemselves may be active as pharmaceutical agents. A comprehensive listof suitable protecting groups can be found in T. W. Greene, ProtectingGroups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.

“Ring” and “ring assembly” means a carbocyclic or a heterocyclic systemand includes aromatic and non-aromatic systems. The system can bemonocyclic, bicyclic or polycyclic. In addition, for bicyclic andpolycyclic systems, the individual rings comprising the polycyclic ringcan be fused, spiro or bridging rings.

“Subject” and “patient” includes humans, non-human mammals (e.g., dogs,cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like)and non-mammals (e.g., birds, and the like).

“Substituent convertible to hydrogen in vivo” means any group that isconvertible to a hydrogen atom by enzymological or chemical meansincluding, but not limited to, hydrolysis and hydrogenolysis. Examplesinclude hydrolyzable groups, such as acyl groups, groups having anoxycarbonyl group, amino acid residues, peptide residues,o-nitrophenylsulfenyl, trimethylsilyl, tetrahydro-pyranyl,diphenylphosphinyl, and the like. Examples of acyl groups includeformyl, acetyl, trifluoroacetyl, and the like. Examples of groups havingan oxycarbonyl group include ethoxycarbonyl, t-butoxycarbonyl[(CH₃)₃C—OCO—], benzyloxycarbonyl, p-methoxybenzyloxycarbonyl,vinyloxycarbonyl, β-(p-toluenesulfonyl)ethoxycarbonyl, and the like.Examples of suitable amino acid residues include amino acid residues perse and amino acid residues that are protected with a protecting group.Suitable amino acid residues include, but are not limited to, residuesof Gly (glycine), Ala (alanine; CH₃CH(NH₂)CO—), Arg (arginine), Asn(asparagine), Asp (aspartic acid), Cys (cysteine), Glu (glutamic acid),H is (histidine), Ile (isoleucine), Leu (leucine;(CH₃)₂CHCH₂CH(NH₂)CO—), Lys (lysine), Met (methionine), Phe(phenylalanine), Pro (proline), Ser (serine), Thr (threonine), Trp(tryptophan), Tyr (tyrosine), Val (valine), Nva (norvaline), Hse(homoserine), 4-Hyp (4-hydroxyproline), 5-Hyl (5-hydroxylysine), Orn(ornithine) and β-Ala. Examples of suitable protecting groups includethose typically employed in peptide synthesis, including acyl groups(such as formyl and acetyl), arylmethyloxycarbonyl groups (such asbenzyloxycarbonyl and p-nitrobenzyloxycarbonyl), t-butoxycarbonyl groups[(CH₃)₃C—OCO—], and the like. Suitable peptide residues include peptideresidues comprising two to five, and optionally two to three, of theaforesaid amino acid residues. Examples of such peptide residuesinclude, but are not limited to, residues of such peptides as Ala-Ala[CH₃CH(NH₂)CO—NHCH(CH₃)CO—], Gly-Phe, Nva-Nva, Ala-Phe, Gly-Gly,Gly-Gly-Gly, Ala-Met, Met-Met, Leu-Met and Ala-Leu. The residues ofthese amino acids or peptides can be present in stereochemicalconfigurations of the D-form, the L-form or mixtures thereof. Inaddition, the amino acid or peptide residue may have an asymmetriccarbon atom. Examples of suitable amino acid residues having anasymmetric carbon atom include residues of Ala, Leu, Phe, Trp, Nva, Val,Met, Ser, Lys, Thr and Tyr. Peptide residues having an asymmetric carbonatom include peptide residues having one or more constituent amino acidresidues having an asymmetric carbon atom. Examples of suitable aminoacid protecting groups include those typically employed in peptidesynthesis, including acyl groups (such as formyl and acetyl),arylmethyloxycarbonyl groups (such as benzyloxycarbonyl andp-nitrobenzyloxycarbonyl), t-butoxycarbonyl groups [(CH₃)₃C—OCO—], andthe like. Other examples of substituents “convertible to hydrogen invivo” include reductively eliminable hydrogenolyzable groups. Examplesof suitable reductively eliminable hydrogenolyzable groups include, butare not limited to, arylsulfonyl groups (such as o-toluenesulfonyl);methyl groups substituted with phenyl or benzyloxy (such as benzyl,trityl and benzyloxymethyl); arylmethoxycarbonyl groups (such asbenzyloxycarbonyl and o-methoxy-benzyloxycarbonyl); andhalogenoethoxycarbonyl groups (such as β,β,β-trichloroethoxycarbonyl andβ-iodoethoxycarbonyl).

“Substituted or unsubstituted” means that a given moiety may consist ofonly hydrogen substituents through available valencies (unsubstituted)or may further comprise one or more non-hydrogen substituents throughavailable valencies (substituted) that are not otherwise specified bythe name of the given moiety. For example, isopropyl is an example of anethylene moiety that is substituted by —CH₃. In general, a non-hydrogensubstituent may be any substituent that may be bound to an atom of thegiven moiety that is specified to be substituted. Examples ofsubstituents include, but are not limited to, aldehyde, alicyclic,aliphatic, (C₁₋₁₀)alkyl, alkylene, alkylidene, amide, amino, aminoalkyl,aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl,carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo,heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl,heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl,and oxoalkyl moieties, each of which may optionally also be substitutedor unsubstituted. In one particular embodiment, examples of substituentsinclude, but are not limited to, hydrogen, halo, nitro, cyano, thio,oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy,hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino,(C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,halo(C₁₋₁₀)alkyl, hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl,(C₁₋₁₀)azaalkyl, imino(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,(C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl andhetero(C₄₋₁₂)bicycloaryl. In addition, the substituent is itselfoptionally substituted by a further substituent. In one particularembodiment, examples of the further substituent include, but are notlimited to, hydrogen, halo, nitro, cyano, thio, oxy, hydroxy,carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy,carbonyl, oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino,sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, (C₁₋₁₀)azaalkyl,imino(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,(C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl andhetero(C₄₋₁₂)bicycloaryl.

“Sulfinyl” means the radical —SO— and/or —SO—R, wherein R is hydrogen ora further substituent. It is noted that the sulfinyl radical may befurther substituted with a variety of substituents to form differentsulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters,and sulfoxides.

“Sulfonyl” means the radical —SO₂— and/or —SO₂—R, wherein R is hydrogenor a further substituent. It is noted that the sulfonyl radical may befurther substituted with a variety of substituents to form differentsulfonyl groups including sulfonic acids, sulfonamides, sulfonateesters, and sulfones.

“Therapeutically effective amount” means that amount which, whenadministered to an animal for treating a disease, is sufficient toeffect such treatment for the disease.

“Thio” denotes replacement of an oxygen by a sulfur and includes, but isnot limited to, —SR, —S— and ═S containing groups.

“Thioalkyl” means an alkyl, as defined above, except where one or moreof the carbon atoms forming the alkyl chain are replaced with sulfuratoms (—S— or —S—R, wherein R is hydrogen or a further substituent). Forexample, a thio(C₁₋₁₀)alkyl refers to a chain comprising between 1 and10 carbons and one or more sulfur atoms.

“Thiocarbonyl” means the radical —C(═S)— and/or —C(═S)—R, wherein R ishydrogen or a further substituent. It is noted that the thiocarbonylradical may be further substituted with a variety of substituents toform different thiocarbonyl groups including thioacids, thioamides,thioesters, and thioketones.

“Treatment” or “treating” means any administration of a compound of thepresent invention and includes:

(1) preventing the disease from occurring in an animal which may bepredisposed to the disease but does not yet experience or display thepathology or symptomatology of the disease,

(2) inhibiting the disease in an animal that is experiencing ordisplaying the pathology or symptomatology of the diseased (i.e.,arresting further development of the pathology and/or symptomatology),or

(3) ameliorating the disease in an animal that is experiencing ordisplaying the pathology or symptomatology of the diseased (i.e.,reversing the pathology and/or symptomatology).

It is noted in regard to all of the definitions provided herein that thedefinitions should be interpreted as being open ended in the sense thatfurther substituents beyond those specified may be included. Hence, a C₁alkyl indicates that there is one carbon atom but does not indicate whatare the substituents on the carbon atom. Hence, a (C₁)alkyl comprisesmethyl (i.e., —CH₃) as well as —CRR′R″ where R, R′, and R″ may eachindependently be hydrogen or a further substituent where the atomattached to the carbon is a heteroatom or cyano. Hence, CF₃, CH₂OH andCH₂CN, for example, are all (C₁)alkyls. Similarly, terms such asalkylamino and the like comprise dialkylamino and the like.

A compound having a formula that is represented with a dashed bond isintended to include the formulae optionally having zero, one or moredouble bonds, as exemplified and shown below:

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds that may be used to activatehexokinases and, in particular glucokinase (referred to herein as GK).The present invention also relates to pharmaceutical compositions, kitsand articles of manufacture comprising such compounds. In addition, thepresent invention relates to methods and intermediates useful for makingthe compounds. Further, the present invention relates to methods ofusing said compounds. It is noted that the compounds of the presentinvention may also possess activity for other hexokinase family membersand thus may be used to address disease states associated with theseother family members.

Glucokinase Activators

In one of its aspects, the present invention relates to compounds thatare useful as glucokinase activators. In one embodiment, glucokinaseactivators of the present invention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   n is selected from the group consisting of 3, 4 and 5;    -   V₁ is selected from the group consisting of CR₄ and N;    -   V₂ is selected from the group consisting of CR₆ and N;    -   each X is independently selected from the group consisting of        CR₈R₉, CO, CS, NR₁₀, O, S, SO and SO₂;    -   R₁ is selected from the group consisting of hydrogen and a        substituent convertible to hydrogen in vivo;    -   R₂ and R₃ are each independently selected from the group        consisting of hydrogen, carbonyl, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₂ and R₃ are taken together to form a substituted or        unsubstituted ring;    -   R₄, R₅, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₅, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   R₈ and R₉ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₉ is absent when the atom to which it is        bound forms part of a double bond; and    -   R₁₀ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₁₀ is absent when the atom to which it is        bound forms part of a double bond,    -   or any two R₈, R₉ and R₁₀ are taken together to form a        substituted or unsubstituted ring.

In another embodiment, glucokinase activators of the present inventionhave the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof.

In still another embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   m is selected from the group consisting of 0, 1, 2, 3 and 4; and    -   each R₁₁ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₁₁ and R₆ or two R₁₁ are taken together to form a        substituted or unsubstituted ring.

In yet another embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   m is selected from the group consisting of 0, 1, 2, 3 and 4; and    -   each R₁₁ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₁₁ and R₆ or two R₁₁ are taken together to form a        substituted or unsubstituted ring.

In a further embodiment, glucokinase activators of the present inventionhave the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof.

In still a further embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   p is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6,        7, 8, 9, 10 and 11;    -   L is a linker providing 0, 1, 2, 3, 4, 5 or 6 atom separation        between the C and the ring to which L is attached, wherein the        atoms of the linker providing the separation are selected from        the group consisting of carbon, oxygen, nitrogen, and sulfur;        and    -   each R₁₂ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₂ are taken together to form a substituted or        unsubstituted ring.

In yet a further embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   p is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6,        7, 8, 9, 10 and 11;    -   m is selected from the group consisting of 0, 1, 2, 3 and 4;    -   each R₁₁ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₁ are taken together to form a substituted or        unsubstituted ring; and    -   each R₁₂ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₂ are taken together to form a substituted or        unsubstituted ring.

In another embodiment, glucokinase activators of the present inventionhave the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   q is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6,        7, 8 and 9;    -   L is a linker providing 0, 1, 2, 3, 4, 5 or 6 atom separation        between the C and the ring to which L is attached, wherein the        atoms of the linker providing the separation are selected from        the group consisting of carbon, oxygen, nitrogen, and sulfur;        and    -   each R₁₂ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₂ are taken together to form a substituted or        unsubstituted ring.

In still another embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   q is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6,        7, 8 and 9;    -   m is selected from the group consisting of 0, 1, 2, 3 and 4;    -   each R₁₁ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₁ are taken together to form a substituted or        unsubstituted ring; and    -   each R₁₂ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₂ are taken together to form a substituted or        unsubstituted ring.

In yet another embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   Y₁, Y₂, Y₃ and Y₄ are each independently selected from the group        consisting of CR₁₃ and N; and    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₃ are taken together to form a substituted or        unsubstituted ring.

In a further embodiment, glucokinase activators of the present inventionhave the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   Y₁ and Y₂ are each independently selected from the group        consisting of CR₁₃ and N;    -   Z is selected from the group consisting of CR₁₃R₁₄, NR₁₅, O and        S;    -   each R₁₃ and R₁₄ is independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₁₃ and R₁₄ are taken together to form a        substituted or unsubstituted ring, or R₁₃ and R₁₄ are taken        together to form C═O, C═S or C═NR₁₅; and    -   R₁₅ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,    -   or any two R₁₃, R₁₄ and R₁₅ are taken together to form a        substituted or unsubstituted ring.

In still a further embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   t is selected from the group consisting of 0, 1 and 2;    -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₄, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero        (C₈₋₁₂)bicyclo aryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero        (C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₁₆ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero        (C₈₋₁₂)bicyclo aryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero        (C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In yet a further embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   s is selected from the group consisting of 0, 1, 2, 3 and 4;    -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₄, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   R₁₆ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo (C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₂₀ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,        carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In another embodiment, glucokinase activators of the present inventionhave the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   s is selected from the group consisting of 0, 1, 2, 3 and 4;    -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₄, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   R₁₆ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₂₀ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,        carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyclo aryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In a further embodiment, glucokinase activators of the present inventionhave the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   t is selected from the group consisting of 0, 1 and 2;    -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₄, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyoloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₁₆ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo (C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In still another embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

t is selected from the group consisting of 0, 1 and 2;

-   -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₄, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyoloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₁₆ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo (C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In yet another embodiment, glucokinase activators of the presentinvention have the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   t is selected from the group consisting of 0, 1 and 2;    -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₄, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₁₆ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyclo aryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In a further embodiment, glucokinase activators of the present inventionhave the formula:

or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceuticallyacceptable salt or prodrug thereof, wherein

-   -   t is selected from the group consisting of 0, 1 and 2;    -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₄, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₁₆ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo (C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In another of its aspects, the present invention relates to methods ofmaking compounds that are useful as glucokinase activators. In oneembodiment, the methods comprise the steps of:

reacting a compound having the formula

with a compound having the formula

under conditions that form a first reaction product having the formula

and

reacting the first reaction product with a compound having the formula

under conditions that form a product having the formula

wherein

-   -   n is selected from the group consisting of 3, 4 and 5;    -   V₁ is selected from the group consisting of CR₄ and N;    -   V₂ is selected from the group consisting of CR₆ and N;    -   each X is independently selected from the group consisting of        CR₈R₉, CO, CS, NR₁₀, O, S, SO and SO₂;    -   R₁ is selected from the group consisting of hydrogen and a        substituent convertible to hydrogen in vivo;    -   R₂ and R₃ are each independently selected from the group        consisting of hydrogen, carbonyl, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₂ and R₃ are taken together to form a substituted or        unsubstituted ring;    -   R₄, R₅, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₅, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   R₈ and R₉ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₉ is absent when the atom to which it is        bound forms part of a double bond; and    -   R₁₀ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₁₀ is absent when the atom to which it is        bound forms part of a double bond.

In another embodiment, the methods comprise the steps of:

treating a compound having the formula

under conditions that form a first reaction product having the formula

treating the first reaction product under conditions that form a secondreaction product having the formula

treating the second reaction product under conditions that form a thirdreaction product having the formula

reacting the third reaction product with a compound having the formulaR₅—R_(a)under conditions that form a fourth reaction product having the formula

treating the fourth reaction product under conditions that form a fifthreaction product having the formula

and

reacting the fifth reaction product with a compound having the formula

under conditions that form a product having the formula

wherein

-   -   n is selected from the group consisting of 3, 4 and 5;    -   each X is independently selected from the group consisting of        CR₈R₉, CO, CS, NR₁₀, O, S, SO and SO₂;    -   R_(a) is a metal;    -   R₁ is selected from the group consisting of hydrogen and a        substituent convertible to hydrogen in vivo;    -   R₂ and R₃ are each independently selected from the group        consisting of hydrogen, carbonyl, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₂ and R₃ are taken together to form a substituted or        unsubstituted ring;    -   R₅ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,        carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyoloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₈ and R₉ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyoloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₉ is absent when the atom to which it is        bound forms part of a double bond; and    -   R₁₀ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₁₀ is absent when the atom to which it is        bound forms part of a double bond.

In still another embodiment, the methods comprise the steps of:

treating a compound having the formula

under conditions that form a first reaction product having the formula

treating the first reaction product under conditions that form a secondreaction product having the formula

treating the second reaction product under conditions that form a thirdreaction product having the formula

and

reacting the third reaction product with a compound having the formula

under conditions that form a product having the formula

wherein

-   -   n is selected from the group consisting of 3, 4 and 5;    -   V₁ is selected from the group consisting of CR₄ and N;    -   each X is independently selected from the group consisting of        CR₈R₉, CO, CS, NR₁₀, O, S, SO and SO₂;    -   R_(b) is a (C₁₋₃)alkyl;    -   R₁ is selected from the group consisting of hydrogen and a        substituent convertible to hydrogen in vivo;    -   R₄ and R₅ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₄ and R₅ are taken together to form a substituted or        unsubstituted ring;    -   R₈ and R₉ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₉ is absent when the atom to which it is        bound forms part of a double bond;    -   R₁₀ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₁₀ is absent when the atom to which it is        bound forms part of a double bond; and    -   R₂₁ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C_(s-12))bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted.

In yet another embodiment, the methods comprise the steps of:

reacting a compound having the formula

with a compound having the formula

under conditions that form a first reaction product having the formula

treating the first reaction product under conditions that form a secondreaction product having the formula

and

reacting the second reaction product with a compound having the formula

under conditions that form a product having the formula

wherein

-   -   n is selected from the group consisting of 3, 4 and 5;    -   V₁ is selected from the group consisting of CR₄ and N;    -   V₂ is selected from the group consisting of CR₆ and N;    -   each X is independently selected from the group consisting of        CR₈R₉, CO, CS, NR₁₀, O, S, SO and SO₂;    -   R_(b) is a (C₁₋₃)alkyl;    -   R_(c) and R_(d) are each independently a leaving group;    -   R₁ is selected from the group consisting of hydrogen and a        substituent convertible to hydrogen in vivo;    -   R₂ is selected from the group consisting of hydrogen, carbonyl,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;    -   R₄, R₅, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₅, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   R₈ and R₉ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyoloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₉ is absent when the atom to which it is        bound forms part of a double bond; and    -   R₁₀ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo (C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₁₀ is absent when the atom to which it is        bound forms part of a double bond.

In a further embodiment, the methods comprise the steps of:

reacting a compound having the formula

with a compound having the formula

under conditions that form a first reaction product having the formula

reacting the first reaction product with a compound having the formulaR₂₁CHOunder conditions that form a second reaction product having the formula

treating the second reaction product under conditions that form a thirdreaction product having the formula

and

reacting the third reaction product with a compound having the formula

under conditions that form a product having the formula

wherein

-   -   n is selected from the group consisting of 3, 4 and 5;    -   V₁ is selected from the group consisting of CR₄ and N;    -   V₂ is selected from the group consisting of CR₆ and N;    -   each X is independently selected from the group consisting of        CR₈R₉, CO, CS, NR₁₀, O, S, SO and SO₂;    -   R_(b) is a (C₁₋₃)alkyl;    -   R_(c) and R_(d) are each independently a leaving group;    -   R₁ is selected from the group consisting of hydrogen and a        substituent convertible to hydrogen in vivo;    -   R₄, R₅, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₅, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   R₈ and R₉ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₉ is absent when the atom to which it is        bound forms part of a double bond;    -   R₁₀ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₁₀ is absent when the atom to which it is        bound forms part of a double bond; and    -   R₂₁ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted.

In still a further embodiment, the methods comprise the steps of:

reacting a compound having the formula

with a compound having the formula

under conditions that form a first reaction product having the formula

reacting the first reaction product with a compound having the formulaR₂₁CH₂R_(e)under conditions that form a second reaction product having the formula

treating the second reaction under conditions that form a third reactionproduct having the formula

and

reacting the third reaction product with a compound having the formula

under conditions that form a product having the formula

wherein

-   -   n is selected from the group consisting of 3, 4 and 5;    -   V₁ is selected from the group consisting of CR₄ and N;    -   V₂ is selected from the group consisting of CR₆ and N;    -   each X is independently selected from the group consisting of        CR₈R₉, CO, CS, NR₁₀, O, S, SO and SO₂;    -   R_(b) is a (C₁₋₃)alkyl;    -   R_(c), R_(d) and R_(e) are each independently a leaving group;    -   R₁ is selected from the group consisting of hydrogen and a        substituent convertible to hydrogen in vivo;    -   R₄, R₅, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₅, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring;    -   R₈ and R₉ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₉ is absent when the atom to which it is        bound forms part of a double bond;    -   R₁₀ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        with the proviso that R₁₀ is absent when the atom to which it is        bound forms part of a double bond; and    -   R₂₁ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,        (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,        aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,        thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,        sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,        (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,        hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,        (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,        (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each        substituted or unsubstituted.

In still another of its aspects, the present invention relates tointermediates that are useful in making glucokinase activators. In oneembodiment, the intermediates have the formula

wherein

-   -   V₁ is selected from the group consisting of CR₄ and N;    -   V₂ is selected from the group consisting of CR₆ and N;    -   R₂ and R₃ are each independently selected from the group        consisting of hydrogen, carbonyl, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₂ and R₃ are taken together to form a substituted or        unsubstituted ring; and    -   R₄, R₅, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicyclo aryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₅, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring.

In another embodiment, the intermediates have the formula

wherein

-   -   V₁ is selected from the group consisting of CR₄ and N;    -   V₂ is selected from the group consisting of CR₆ and N;    -   R_(b) is a (C₁₋₃)alkyl;    -   R₂ and R₃ are each independently selected from the group        consisting of hydrogen, carbonyl, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or R₂ and R₃ are taken together to form a substituted or        unsubstituted ring; and    -   R₄, R₅, R₆ and R₇ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two of R₄, R₅, R₆ and R₇ are taken together to form a        substituted or unsubstituted ring.

In one variation of each of the above embodiments, ring A is asubstituted or unsubstituted heteroaryl. In another variation of each ofthe above embodiments, ring A is selected from the group consisting ofthiazolyl and pyridyl; each substituted or unsubstituted. In stillanother variation of each of the above embodiments, ring A is selectedfrom the group consisting of thiazol-2-yl; 2-pyridyl;5-methyl-thiazol-2-yl; 6-methyl-pyrid-2-yl; 4-methyl-pyrid-2-yl;5-bromo-6-methyl-pyrid-2-yl; 5-phenyl-pyrid-2-yl; benzothiazol-2-yl; anicotinic acid methyl ester; and 5-bromo-pyrid-2-yl.

In yet another variation of each of the above embodiments, ring Acomprises:

wherein

-   -   l is selected from the group consisting of 1 and 2;    -   r is selected from the group consisting of 0, 1, 2, 3, 4, 5, 6,        7 and 8;    -   W is selected from the group consisting of CR₁₂ or N;    -   each R₁₁ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or any two R₁₁ are taken together to form a ring; and    -   R₁₂ is selected from the group consisting of hydrogen,        (C₁₋₃)alkyl, aryl and heteroaryl, each substituted or        unsubstituted, or R₁₁ and R₁₂ are taken together to form a ring.

In a further variation of each of the above embodiments, ring Acomprises:

wherein

-   -   Y₁ and Y₂ are each independently selected from the group        consisting of CR₁₃ and N; and    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two R₁₃ are taken together to form a substituted or        unsubstituted ring.

In still a further variation of each of the above embodiments, ring Acomprises:

wherein

-   -   t is selected from the group consisting of 0, 1 and 2; and    -   each R₁₃ is independently selected from the group consisting of        hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,        heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,        imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In yet a further variation of each of the above embodiments, ring Acomprises:

wherein

-   -   R₁₃ is selected from the group consisting of hydrogen, halo,        nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,        carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,        sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,        carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,        sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl,        imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In another variation of each of the above embodiments, ring A comprises:

wherein

-   -   R_(13a), R_(13b), R_(13c) and R_(13d) are each independently        selected from the group consisting of hydrogen, halo, nitro,        cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl,        amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl,        sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,        or two of R_(13a), R_(13b), R_(13c) and R_(13d) are taken        together to form a substituted or unsubstituted ring.

In another variation of each of the above embodiments and variations, Y₁is CR₁₃. In still another variation of each of the above embodiments andvariations, Y₂ is CR₁₃. In yet another variation of each of the aboveembodiments and variations, Y₃ is CR₁₃. In a further variation of eachof the above embodiments and variations, Y₄ is CR₁₃.

In still a further variation of each of the above embodiments andvariations, Z is S.

In yet a further variation of each of the above embodiments andvariations, n is 3 or 4.

In another variation of each of the above embodiments and variations, R₁is hydrogen.

In still another variation of each of the above embodiments andvariations, W is CR₁₂.

In yet another variation of each of the above embodiments andvariations, 1 is 1.

In a further variation of each of the above embodiments and variations,r is 1.

In still a further variation of each of the above embodiments andvariations, R₂ is hydrogen. In yet a further variation of each of theabove embodiments and variations, R₂ comprises —CH₂R₂₁ and R₂₁ isselected from the group consisting of hydrogen, halo, nitro, cyano,thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy,hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino,(C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,halo(C₁₋₁₀)alkyl, hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl,aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In another variation of each of the above embodiments and variations, R₂comprises

wherein

-   -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicyoloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In still another variation of each of the above embodiments andvariations, R₂ comprises

-   -   Q is selected from the group consisting of O, S, CS, CO, SO,        SO₂, CR₁₇R₁₈ and NR₁₉;    -   R₁₇ and R₁₈ are each independently selected from the group        consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;        and    -   R₁₉ is selected from the group consisting of hydrogen, hydroxy,        alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,        (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,        (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,        thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,        sulfinyl(C₁₋₃)alkyl, amino (C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,        (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,        hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,        heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,        hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,        hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,        hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl        and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In yet another variation of each of the above embodiments andvariations, R₃ is selected from the group consisting of carbonyl,(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In a further variation of each of the above embodiments and variations,R₃ is selected from the group consisting of hydrogen, (C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,aryl(C₁₋₁₀)alkyl, and heteroaryl(C₁₋₅)alkyl, each substituted orunsubstituted. In still a further variation of each of the aboveembodiments and variations, R₃ is selected from the group consisting of(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, andheteroaryl(C₁₋₅)alkyl, each substituted or unsubstituted. In yet afurther variation of each of the above embodiments and variations, R₃ isselected from the group consisting of hydrogen; butyl; cyclohexylmethyl;benzyl; imidazol-4-ylmethyl and phenyl. In another variation of each ofthe above embodiments and variations, R₃ is selected from the groupconsisting of butyl; cyclohexylmethyl; benzyl; imidazol-4-ylmethyl andphenyl.

In still another variation of each of the above embodiments andvariations, R₄ is selected from the group consisting of halo,(C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, —CO—NH—R₁₆, —NH—CO—R₁₆, —SO₂—R₁₆,—NH—SO₂—R₁₆ and —SO₂—NH—R₁₆; and R₁₆ is selected from the groupconsisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy,carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy,carbonyl, oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino,sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl,(C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In yet another variation of each of the above embodiments andvariations, R₄ is a substituted or unsubstituted (C₁₋₅)alkyl. In afurther variation of each of the above embodiments and variations, R₄ ismethyl. In still a further variation of each of the above embodimentsand variations, R₄ is halo and, in particular, chloro.

In still a further variation of each of the above embodiments andvariations, R₄ and R₇ are taken together to form a ring.

In yet a further variation of each of the above embodiments andvariations, R₅ is selected from the group consisting of halo,(C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, —CO—R₁₆, —CO—NH—R₁₆, —NH—CO—R₁₆, —SO₂—R₁₆,—NH—SO₂—R₁₆ and —SO₂—NH—R₁₆; and R₁₆ is selected from the groupconsisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy,carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy,carbonyl, oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino,sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl,(C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In another variation of each of the above embodiments and variations, R₅is a substituted or unsubstituted (C₁₋₅)alkyl. In still anothervariation of each of the above embodiments and variations, R₅ is—SO₂—R₁₆; and R₁₆ is selected from the group consisting of hydrogen,halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy,(C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl,aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl,sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, hydroxy(C₁₋₁₀)alkyl,carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl,sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl,imino(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, aryl(C₁₋₁₀)alkyl,hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl, hetero(C₁₋₁₀)aryl,(C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted orunsubstituted.

In yet another variation of each of the above embodiments andvariations, R₅ is —CO—R₁₆; and R₁₆ is selected from the group consistingof hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,(C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl,oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl,(C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In a further variation of each of the above embodiments and variations,R₅ is —NH—SO₂—R₁₆; and R₁₆ is selected from the group consisting ofhydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy,(C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy, carbonyl,oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl,(C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In still a further variation of each of the above embodiments andvariations, R₅ is —NH—CO—R₁₆; and R₁₆ is selected from the groupconsisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy,carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy,carbonyl, oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino,sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl,(C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In still a further variation of each of the above embodiments andvariations, R₅ is halo and, in particular, chloro. In yet a furthervariation of each of the above embodiments and variations, R₅ is(C₁₋₃)alkyl and, in particular, methyl.

In yet a further variation of each of the above embodiments andvariations, R₆ is selected from the group consisting of hydrogen, halo,(C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, —CO—NH—R₁₆, —NH—CO—R₁₆, —SO₂—R₁₆,—NH—SO₂—R₁₆ and —SO₂—NH—R₁₆; and R₁₆ is selected from the groupconsisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy,carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy,carbonyl, oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino,sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl,(C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In another variation of each of the above embodiments and variations, R₆is hydrogen. In still another variation of each of the above embodimentsand variations, R₆ is a substituted or unsubstituted (C₁₋₅)alkyl. In yetanother variation of each of the above embodiments and variations, R₆ ismethyl.

In a further variation of each of the above embodiments and variations,R₇ is selected from the group consisting of hydrogen, halo,(C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, —CO—NH—R₁₆, —NH—CO—R₁₆, —SO₂—R₁₆,—NH—SO₂—R₁₆ and —SO₂—NH—R₁₆; and R₁₆ is selected from the groupconsisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy,carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy, hetero(C₁₋₁₀)aryloxy,carbonyl, oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino,sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl, thiocarbonyl(C₁₋₁₀)alkyl,sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl,(C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted. In still a further variation of each ofthe above embodiments and variations, R₇ is methyl. In another variationof each of the above embodiments and variations, R₇ is selected from thegroup consisting of hydrogen and a substituted or unsubstituted(C₁₋₁₀)alkyl.

In still a further variation of each of the above embodiments andvariations, R₇ is halo and, in particular, chloro. In yet a furthervariation of each of the above embodiments and variations, R₇ is(C₁₋₃)alkyl and, in particular, methyl.

In yet a further variation of each of the above embodiments andvariations, R₈ is selected from the group consisting of hydrogen, halo,(C₁₋₅)alkyl and carboxamido, each substituted or unsubstituted.

In another variation of each of the above embodiments and variations, R₉is selected from the group consisting of hydrogen, halo and asubstituted or unsubstituted (C₁₋₅)alkyl.

In still another variation of each of the above embodiments andvariations, R₁₀ is (C₁₋₅)alkyl.

In yet another variation of each of the above embodiments andvariations, R₁₁ is selected from the group consisting of hydrogen, halo,cyano, —OR₁₆, —SO₂—R₁₆, —NH—SO₂—R₁₆ and —SO₂—NH—R₁₆; and R₁₆ is selectedfrom the group consisting of hydrogen, halo, nitro, cyano, thio, oxy,hydroxy, carbonyloxy, (C₁₋₁₀)alkoxy, (C₄₋₁₂)aryloxy,hetero(C₁₋₁₀)aryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino,(C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,halo(C₁₋₁₀)alkyl, hydroxy(C₁₋₁₀)alkyl, carbonyl(C₁₋₁₀)alkyl,thiocarbonyl(C₁₋₁₀)alkyl, sulfonyl(C₁₋₁₀)alkyl, sulfinyl(C₁₋₁₀)alkyl,aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl, (C₁₋₁₀)oxoalkyl, imino(C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,aryl(C₁₋₁₀)alkyl, hetero(C₁₋₁₀)aryl(C₁₋₅)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl,hetero(C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, (C₄₋₁₂)aryl,hetero(C₁₋₁₀)aryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, eachsubstituted or unsubstituted.

In a further variation of each of the above embodiments and variations,m is 1 or 2.

In still a further variation of each of the above embodiments andvariations, R₁₂ is selected from the group consisting of halo,(C₁₋₅)alkyl, oxa(C₁₋₅)alkyl and oxo(C₁₋₅)alkyl, each substituted orunsubstituted.

In yet a further variation of each of the above embodiments andvariations, p is 1 or 2.

In another variation of each of the above embodiments and variations, qis 1 or 2.

In still another variation of each of the above embodiments andvariations, each R₁₃ is independently selected from the group consistingof halo, (C₁₋₅)alkyl and carboxamido, each substituted or unsubstituted.In yet another variation of each of the above embodiments andvariations, each R₁₃ is independently selected from the group consistingof halo, (C₁₋₅)alkyl and carboxamido, each substituted or unsubstituted.In a further variation of each of the above embodiments and variations,R₁₃ is hydrogen.

In still a further variation of each of the above embodiments andvariations, R_(13a) is selected from the group consisting of halo,(C₁₋₅)alkyl and carboxamido, each substituted or unsubstituted. In yet afurther variation of each of the above embodiments and variations,R_(13a) is hydrogen.

In still a further variation of each of the above embodiments andvariations, R_(13b) is selected from the group consisting of halo,(C₁₋₅)alkyl and carboxamido, each substituted or unsubstituted. In yet afurther variation of each of the above embodiments and variations,R_(13b) is hydrogen.

In still a further variation of each of the above embodiments andvariations, R_(13c) is selected from the group consisting of halo,(C₁₋₅)alkyl and carboxamido, each substituted or unsubstituted. In yet afurther variation of each of the above embodiments and variations,R_(13c) is hydrogen.

In still a further variation of each of the above embodiments andvariations, R_(13d) is selected from the group consisting of halo,(C₁₋₅)alkyl and carboxamido, each substituted or unsubstituted. In yet afurther variation of each of the above embodiments and variations,R_(13d) is hydrogen.

In another variation of each of the above embodiments and variations,R₁₄ is selected from the group consisting of halo and a substituted orunsubstituted (C₁₋₅)alkyl.

In still another variation of each of the above embodiments andvariations, R₁₅ is a substituted or unsubstituted (C₁₋₅)alkyl.

In yet another variation of each of the above embodiments andvariations, L is selected from the group consisting of —CH₂—, —CH₂CH₂—,—CH₂CH₂CH₂—, —C(O)—, —CH₂C(O)—, —C(O)CH₂—, —CH₂—C(O)CH₂—, —C(O)CH₂CH₂—,—CH₂CH₂C(O)—, —O—, —OCH₂—, —CH₂O—, —CH₂OCH₂—, —OCH₂CH₂—, —CH₂CH₂O—,—N(CH₃)—, —NHCH₂—, —CH₂NH—, —CH₂NHCH₂—, —NHCH₂CH₂—, —CH₂CH₂NH—,—NH—C(O)—, —NCH₃—C(O)—, —C (O)NH—, —C(O)NCH₃—, —NHC(O)CH₂—, —C(O)NHCH₂—,—C(O)CH₂NH—, —CH₂NHC(O)—, —CH₂C(O) NH—, —NHCH₂C(O)—, —S—, —SCH₂—,—CH₂S—, —SCH₂CH₂—, —CH₂SCH₂—, —CH₂CH₂S—, —C(O)S—, —C(O) SCH₂—,—CH₂C(O)S—, —C(O)CH₂S—, and —CH₂SC(O)—, each substituted orunsubstituted.

In a further variation of each of the above embodiments and variations,Q is —CR₁₇R₁₈—. In still a further variation of each of the aboveembodiments and variations, Q is —CH₂—. In yet a further variation ofeach of the above embodiments and variations, Q is —NR₁₉—. In anothervariation of each of the above embodiments and variations, Q is —NH—.

Particular examples of compounds according to the present inventioninclude, but are not limited to:

-   3-cyclohexyl-2-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclohexyl-2-(4-methoxy-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclohexyl-2-(6-methyl-4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclohexyl-2-(4-(ethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   6-(3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamido)nicotinamide;-   2-(6-methyl-4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-(2-chloro-5-fluorophenyl)-N-(5-chlorothiazol-2-yl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)-3-p-tolylpropanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-4-methyl-N-(thiazol-2-yl)pentanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclopropyl-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclopentyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(thiophen-3-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-(2,6-dichlorophenyl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)hexanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-5-methyl-N-(thiazol-2-yl)hexanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(3-methoxyphenyl)-N-(thiazol-2-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(furan-2-yl)-N-(thiazol-2-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-(3,5-dimethylphenyl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-4,4-dimethylpentanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)hex-4-ynamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(4-methoxyphenyl)-N-(thiazol-2-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(4-hydroxyphenyl)-N-(thiazol-2-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-fluorothiazol-2-yl)-4,4-dimethyl-2-(6-methyl-2-oxo-4-tosylpyridin-1(2H)-yl)pentanamide;-   (R)-methyl    2-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)thiazole-5-carboxylate;-   (S)-methyl    2-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)thiazole-5-carboxylate;-   (S)-6-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;-   (R)-6-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;-   (R)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-fluorothiazol-2-yl)-2-(2-oxo-4-(pyridin-2-ylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazolo[5,4-b]pyridin-2-yl)propanamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazolo[5,4-b]pyridin-2-yl)propanamide;-   3-(2-(2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)thiazol-5-yl)propanoic    acid;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)-yl)propanamide;-   2-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-N-(5-methylthiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-cyanothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-cyanothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   (S)-2-(4-bromo-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)—N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(3-hydroxypropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   (R)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(3-hydroxypropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(3-hydroxypropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   (S)-2-(3-chloro-4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-cyclohexylpropanamide;-   (R)-2-(3-chloro-4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-cyclohexylpropanamide;-   3-cyclohexyl-2-(6-methyl-4-morpholino-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2-ylmethylsulfonyl)pyridin-1(2H)-yl)propanamide;-   3-cyclohexyl-2-(4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-(4-fluorobenzyl)thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(4-(2,5-dimethylfuran-3-ylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(6-hydroxybenzo[d]thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2-ylmethylsulfonyl)pyridin-1(2H)-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2-ylmethylsulfonyl)pyridin-1(2H)-yl)propanamide;-   3-cyclohexyl-2-(6-methyl-2-oxo-4-(pyrrolidin-1-yl)pyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   2-(4-(4-methoxy-2-methylbutan-2-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-(morpholinomethyl)thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-2-oxo-4-phenylpyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(2-chlorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(3-chlorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(4-chlorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(2-methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(3-methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(4-methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(3-cyanophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(4-cyanophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(furan-3-yl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(pyridin-3-yl)pyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-4-(4-(methylsulfonyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(4-(ethylsulfonyl)phenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(5-chloro-2-methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(benzofuran-2-yl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(4-fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(3-chloro-4-fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(benzo[b]thiophen-3-yl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-2-(4-(benzo[b]thiophen-2-yl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(3-fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(2-fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-4-(4-methylthiophen-2-yl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-4-(3-(methylsulfonamido)phenyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(1H-pyrazol-4-yl)pyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-4-(3-(N-methylsulfamoyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-4-(4-(N-methylsulfamoyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   ethyl    2-(2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)thiazole-5-carboxylate;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-(2-hydroxypropan-2-yl)thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(2,5-dichlorothiophen-3-ylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(4-methoxy-2-methylbutan-2-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(4-methoxy-2-methylbutan-2-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   2-(7-chloro-4-oxothieno[3,2-c]pyridin-5(4H)-yl)-N-(5-chlorothiazol-2-yl)-3-cyclohexylpropanamide;-   2-(4-((S)-3-hydroxypyrrolidin-1-yl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-3-cyclohexyl-2-(6-methyl-4-(3-(methylsulfonyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(6-methoxybenzo[d]thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-(dimethylamino)thiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(2-oxo-4-(pyrrolidine-1-carbonyl)pyridin-1(2H)-yl)propanamide;-   N-(6-chlorobenzo[d]thiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(6-fluorobenzo[d]thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-(2-methoxypropan-2-yl)thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-(2-methoxypropan-2-yl)thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(thiophen-2-ylmethylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(3-hydroxyprop-1-ynyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-(4-fluorobenzypthiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(2-oxo-5-(pyrrolidin-1-ylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(2-oxo-5-(pyrrolidin-1-ylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-4-(oxazol-2-yl)-2-oxopyridin-1(2H)-yl)propanamide;-   N-(5-(4-fluorobenzyl)thiazol-2-yl)-2-(4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-(morpholinomethyl)thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(2-oxo-4-(2,2,2-trifluoroethylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-((4-methylpiperazin-1-yl)methyl)thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(2-oxo-4-(2,2,2-trifluoroethylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(2-oxo-4-(2,2,2-trifluoroethylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-((4-(2-(dimethylamino)-2-oxoethyl)piperazin-1-yl)methyl)thiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-5,6-dimethyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopentylsulfonyl)-5,6-dimethyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(3-amino-4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclopentyl-N-(5-fluorothiazol-2-yl)propanamide;-   (S)-2-(3-amino-4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclopentyl-N-(5-fluorothiazol-2-yl)propanamide;-   2-(5-acetamido-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(3-fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(3-fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(1,1-dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexylpropanamide;-   N-(5-fluorothiazol-2-yl)-2-(4-(1,1-dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexylpropanamide;-   (S)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)propanamide;-   (R)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)propanamide;-   (R)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluoropyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluoropyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(3-chlorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(3-chlorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)propanamide;-   (S)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   3-cyclopentyl-N-(5-fluorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamide;-   2-(5-chloro-4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-6-(3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamido)nicotinamide;-   (R)-6-(2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;-   (S)-6-(2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;-   (S)—N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamide;-   2-(5-chloro-4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   2-(5-chloro-4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(1,1-dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexylpropanamide;-   (R)—N-(5-chlorothiazol-2-yl)-2-(4-(1,1-dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexylpropanamide;-   (S)-2-(4-(3-fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(3-fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   (R)—N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   (S)-3-cyclopentyl-N-(5-fluorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   (R)-3-cyclopentyl-N-(5-fluorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   (R)-2-(5-chloro-4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(5-chloro-4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(5-chloro-4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(5-chloro-4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   3-cyclohexyl-2-(1-oxoisoquinolin-2(1H)-yl)-N-(thiazol-2-yl)propanamide;    and-   2-(2-oxo-1,6-naphthyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazol-2-yl)propanamide.

In addition, particular examples of compounds according to the presentinvention include, but are not limited to:

-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   6-(3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamido)nicotinamide;-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-4-methyl-N-(thiazol-2-yl)pentanamide;-   (S)-3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclopentyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-4,4-dimethylpentanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-methyl    2-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)thiazole-5-carboxylate;-   (S)-6-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;-   (S)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-fluorothiazol-2-yl)-2-(2-oxo-4-(pyridin-2-ylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2-ylsulfonyl)pyridin-1(2H)-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   (S)-2-(3-chloro-4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-cyclohexylpropanamide;-   3-cyclohexyl-2-(4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-(4-fluorobenzyl)thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(4-(2,5-dimethylfuran-3-ylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2-ylmethylsulfonyl)pyridin-1(2H)-yl)propanamide;-   3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-(morpholinomethyl)thiazol-2-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-3-cyclohexyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin-2-yl)propanamide;-   2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5-(dimethylamino)thiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(thiophen-2-ylmethylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(cyclopentylsulfonyl)-5,6-dimethyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (R)-2-(4-(cyclopentylsulfonyl)-5,6-dimethyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-2-(4-(3-fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)propanamide;-   (S)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)-2-(4-(3-chlorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   (S)—N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;-   N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamide;    and-   (S)—N-(5-chlorothiazol-2-yl)-3-cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamide.

It is noted that the compounds of the present invention may be in theform of a pharmaceutically acceptable salt, biohydrolyzable ester,biohydrolyzable amide, biohydrolyzable carbamate, solvate, hydrate orprodrug thereof. For example, the compound optionally comprises asubstituent that is convertible in vivo to a different substituent, suchas hydrogen.

It is further noted that the compound may be present as a mixture ofstereoisomers, or the compound may be present as a single stereoisomer.

In another of its aspects, there is provided a pharmaceuticalcomposition comprising as an active ingredient a compound according toany one of the above embodiments and variations. In one particularvariation, the composition is a solid formulation adapted for oraladministration. In another particular variation, the composition is aliquid formulation adapted for oral administration. In yet anotherparticular variation, the composition is a tablet. In still anotherparticular variation, the composition is a liquid formulation adaptedfor parenteral administration.

In another of its aspects, there is provided a pharmaceuticalcomposition comprising a compound according to any one of the aboveembodiments and variations, wherein the composition is adapted foradministration by a route selected from the group consisting of orally,parenterally, intraperitoneally, intravenously, intraarterially,transdermally, sublingually, intramuscularly, rectally, transbuccally,intranasally, liposomally, via inhalation, vaginally, intraoccularly,via local delivery (for example by catheter or stent), subcutaneously,intraadiposally, intraarticularly, and intrathecally.

In yet another of its aspects, there is provided a kit comprising acompound of any one of the above embodiments and variations; andinstructions which comprise one or more forms of information selectedfrom the group consisting of indicating a disease state for which thecomposition is to be administered, storage information for thecomposition, dosing information and instructions regarding how toadminister the composition. In one particular variation, the kitcomprises the compound in a multiple dose form.

In still another of its aspects, there is provided an article ofmanufacture comprising a compound of any one of the above embodimentsand variations; and packaging materials. In one variation, the packagingmaterial comprises a container for housing the compound. In oneparticular variation, the container comprises a label indicating one ormore members of the group consisting of a disease state for which thecompound is to be administered, storage information, dosing informationand/or instructions regarding how to administer the compound. In anothervariation, the article of manufacture comprises the compound in amultiple dose form.

In a further of its aspects, there is provided a therapeutic methodcomprising administering a compound of any one of the above embodimentsand variations to a subject.

In another of its aspects, there is provided a method of activatingglucokinase comprising contacting glucokinase with a compound of any oneof the above embodiments and variations.

In yet another of its aspects, there is provided a method of activatingglucokinase comprising causing a compound of any one of the aboveembodiments and variations to be present in a subject in order toactivate glucokinase in vivo.

In a further of its aspects, there is provided a method of activatingglucokinase comprising administering a first compound to a subject thatis converted in vivo to a second compound wherein the second compoundactivates glucokinase in vivo, the second compound being a compoundaccording to any one of the above embodiments and variations.

In another of its aspects, there is provided a method of treating adisease state for which increasing glucokinase activity ameliorates thepathology and/or symptomology of the disease state, the methodcomprising causing a compound of any one of the above embodiments andvariations to be present in a subject in a therapeutically effectiveamount for the disease state.

In yet another of its aspects, there is provided a method of treating adisease state for which increasing glucokinase activity ameliorates thepathology and/or symptomology of the disease state, the methodcomprising administering a compound of any one of the above embodimentsand variations to a subject, wherein the compound is present in thesubject in a therapeutically effective amount for the disease state.

In a further of its aspects, there is provided a method of treating adisease state for which increasing glucokinase activity ameliorates thepathology and/or symptomology of the disease state, the methodcomprising administering a first compound to a subject that is convertedin vivo to a second compound wherein the second compound activatesglucokinase in vivo, the second compound being a compound according toany one of the above embodiments and variations.

In one variation of each of the above methods the disease state isselected from the group consisting of hyperglycemia, diabetes,dyslipidaemia, obesity, insulin resistance, metabolic syndrome X,impaired glucose tolerance, polycystic ovary syndrome, andcardiovascular disease.

Salts, Hydrates, and Prodrugs of Glucokinase Activators

It should be recognized that the compounds of the present invention maybe present and optionally administered in the form of salts, hydratesand prodrugs that are converted in vivo into the compounds of thepresent invention. For example, it is within the scope of the presentinvention to convert the compounds of the present invention into and usethem in the form of their pharmaceutically acceptable salts derived fromvarious organic and inorganic acids and bases in accordance withprocedures well known in the art.

When the compounds of the present invention possess a free base form,the compounds can be prepared as a pharmaceutically acceptable acidaddition salt by reacting the free base form of the compound with apharmaceutically acceptable inorganic or organic acid, e.g.,hydrohalides such as hydrochloride, hydrobromide, hydroiodide; othermineral acids and their corresponding salts such as sulfate, nitrate,phosphate, etc.; and alkyl and monoarylsulfonates such asethanesulfonate, toluenesulfonate and benzenesulfonate; and otherorganic acids and their corresponding salts such as acetate, tartrate,maleate, succinate, citrate, benzoate, salicylate and ascorbate. Furtheracid addition salts of the present invention include, but are notlimited to: adipate, alginate, arginate, aspartate, bisulfate,bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate,chloride, chlorobenzoate, cyclopentanepropionate, digluconate,dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate,galacterate (from mucic acid), galacturonate, glucoheptonate, gluconate,glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate,hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide,2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate,lactobionate, malate, malonate, mandelate, metaphosphate,methanesulfonate, methylbenzoate, monohydrogenphosphate,2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate,pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate,phosphonate and phthalate. It should be recognized that the free baseforms will typically differ from their respective salt forms somewhat inphysical properties such as solubility in polar solvents, but otherwisethe salts are equivalent to their respective free base forms for thepurposes of the present invention.

When the compounds of the present invention possess a free acid form, apharmaceutically acceptable base addition salt can be prepared byreacting the free acid form of the compound with a pharmaceuticallyacceptable inorganic or organic base. Examples of such bases are alkalimetal hydroxides including potassium, sodium and lithium hydroxides;alkaline earth metal hydroxides such as barium and calcium hydroxides;alkali metal alkoxides, e.g., potassium ethanolate and sodiumpropanolate; and various organic bases such as ammonium hydroxide,piperidine, diethanolamine and N-methylglutamine. Also included are thealuminum salts of the compounds of the present invention. Further basesalts of the present invention include, but are not limited to: copper,ferric, ferrous, lithium, magnesium, manganic, manganous, potassium,sodium and zinc salts. Organic base salts include, but are not limitedto, salts of primary, secondary and tertiary amines, substituted aminesincluding naturally occurring substituted amines, cyclic amines andbasic ion exchange resins, e.g., arginine, betaine, caffeine,chloroprocaine, choline, N,N′-dibenzylethylenediamine (benzathine),dicyclohexylamine, diethanolamine, 2-diethylaminoethanol,2-dimethylaminoethanol, ethanolamine, ethylenediamine,N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine,hydrabamine, iso-propylamine, lidocaine, lysine, meglumine,N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamineresins, procaine, purines, theobromine, triethanolamine, triethylamine,trimethylamine, tripropylamine and tris-(hydroxymethyl)-methylamine(tromethamine). It should be recognized that the free acid forms willtypically differ from their respective salt forms somewhat in physicalproperties such as solubility in polar solvents, but otherwise the saltsare equivalent to their respective free acid forms for the purposes ofthe present invention.

Compounds of the present invention that comprise basicnitrogen-containing groups may be quaternized with such agents as (C₁₋₄)alkyl halides, e.g., methyl, ethyl, iso-propyl and tert-butyl chlorides,bromides and iodides; di (C₁₋₄) alkyl sulfates, e.g., dimethyl, diethyland diamyl sulfates; (C₁₀₋₁₈) alkyl halides, e.g., decyl, dodecyl,lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl(C₁₋₄) alkyl halides, e.g., benzyl chloride and phenethyl bromide. Suchsalts permit the preparation of both water-soluble and oil-solublecompounds of the present invention.

N-oxides of compounds according to the present invention can be preparedby methods known to those of ordinary skill in the art. For example,N-oxides can be prepared by treating an unoxidized form of the compoundwith an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid,perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or thelike) in a suitable inert organic solvent (e.g., a halogenatedhydrocarbon such as dichloromethane) at approximately 0° C.Alternatively, the N-oxides of the compounds can be prepared from theN-oxide of an appropriate starting material.

Prodrug derivatives of compounds according to the present invention canbe prepared by modifying substituents of compounds of the presentinvention that are then converted in vivo to a different substituent. Itis noted that in many instances, the prodrugs themselves also fallwithin the scope of the range of compounds according to the presentinvention. For example, prodrugs can be prepared by reacting a compoundwith a carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate,para-nitrophenyl carbonate, or the like) or an acylating agent. Furtherexamples of methods of making prodrugs are described in Saulnier et al.(1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985.

Protected derivatives of compounds of the present invention can also bemade. Examples of techniques applicable to the creation of protectinggroups and their removal can be found in T. W. Greene, Protecting Groupsin Organic Synthesis, 3^(rd) edition, John Wiley & Sons, Inc. 1999.

Compounds of the present invention may also be conveniently prepared, orformed during the process of the invention, as solvates (e.g.,hydrates). Hydrates of compounds of the present invention may beconveniently prepared by recrystallization from an aqueous/organicsolvent mixture, using organic solvents such as dioxin, tetrahydrofuranor methanol.

A “pharmaceutically acceptable salt”, as used herein, is intended toencompass any compound according to the present invention that isutilized in the form of a salt thereof, especially where the saltconfers on the compound improved pharmacokinetic properties as comparedto the free form of compound or a different salt form of the compound.The pharmaceutically acceptable salt form may also initially conferdesirable pharmacokinetic properties on the compound that it did notpreviously possess, and may even positively affect the pharmacodynamicsof the compound with respect to its therapeutic activity in the body. Anexample of a pharmacokinetic property that may be favorably affected isthe manner in which the compound is transported across cell membranes,which in turn may directly and positively affect the absorption,distribution, biotransformation and excretion of the compound. While theroute of administration of the pharmaceutical composition is important,and various anatomical, physiological and pathological factors cancritically affect bioavailability, the solubility of the compound isusually dependent upon the character of the particular salt formthereof, which it utilized. One of skill in the art will appreciate thatan aqueous solution of the compound will provide the most rapidabsorption of the compound into the body of a subject being treated,while lipid solutions and suspensions, as well as solid dosage forms,will result in less rapid absorption of the compound.

Compositions Comprising Glucokinase Activators

A wide variety of compositions and administration methods may be used inconjunction with the compounds of the present invention. Suchcompositions may include, in addition to the compounds of the presentinvention, conventional pharmaceutical excipients, and otherconventional, pharmaceutically inactive agents. Additionally, thecompositions may include active agents in addition to the compounds ofthe present invention. These additional active agents may includeadditional compounds according to the invention, and/or one or moreother pharmaceutically active agents.

The compositions may be in gaseous, liquid, semi-liquid or solid form,formulated in a manner suitable for the route of administration to beused. For oral administration, capsules and tablets are typically used.For parenteral administration, reconstitution of a lyophilized powder,prepared as described herein, is typically used.

Compositions comprising compounds of the present invention may beadministered or coadministered orally, parenterally, intraperitoneally,intravenously, intraarterially, transdermally, sublingually,intramuscularly, rectally, transbuccally, intranasally, liposomally, viainhalation, vaginally, intraoccularly, via local delivery (for exampleby catheter or stent), subcutaneously, intraadiposally,intraarticularly, or intrathecally. The compounds and/or compositionsaccording to the invention may also be administered or coadministered inslow release dosage forms.

The glucokinase activators and compositions comprising them may beadministered or coadministered in any conventional dosage form.Co-administration in the context of this invention is intended to meanthe administration of more than one therapeutic agent, one of whichincludes a glucokinase activator, in the course of a coordinatedtreatment to achieve an improved clinical outcome. Suchco-administration may also be coextensive, that is, occurring duringoverlapping periods of time.

Solutions or suspensions used for parenteral, intradermal, subcutaneous,or topical application may optionally include one or more of thefollowing components: a sterile diluent, such as water for injection,saline solution, fixed oil, polyethylene glycol, glycerine, propyleneglycol or other synthetic solvent; antimicrobial agents, such as benzylalcohol and methyl parabens; antioxidants, such as ascorbic acid andsodium bisulfite; chelating agents, such as ethylenediaminetetraaceticacid (EDTA); buffers, such as acetates, citrates and phosphates; agentsfor the adjustment of tonicity such as sodium chloride or dextrose, andagents for adjusting the acidity or alkalinity of the composition, suchas alkaline or acidifying agents or buffers like carbonates,bicarbonates, phosphates, hydrochloric acid, and organic acids likeacetic and citric acid. Parenteral preparations may optionally beenclosed in ampules, disposable syringes or single or multiple dosevials made of glass, plastic or other suitable material.

When compounds according to the present invention exhibit insufficientsolubility, methods for solubilizing the compounds may be used. Suchmethods are known to those of skill in this art, and include, but arenot limited to, using cosolvents, such as dimethylsulfoxide (DMSO),using surfactants, such as TWEEN, or dissolution in aqueous sodiumbicarbonate. Derivatives of the compounds, such as prodrugs of thecompounds may also be used in formulating effective pharmaceuticalcompositions.

Upon mixing or adding compounds according to the present invention to acomposition, a solution, suspension, emulsion or the like may be formed.The form of the resulting composition will depend upon a number offactors, including the intended mode of administration, and thesolubility of the compound in the selected carrier or vehicle. Theeffective concentration needed to ameliorate the disease being treatedmay be empirically determined.

Compositions according to the present invention are optionally providedfor administration to humans and animals in unit dosage forms, such astablets, capsules, pills, powders, dry powders for inhalers, granules,sterile parenteral solutions or suspensions, and oral solutions orsuspensions, and oil-water emulsions containing suitable quantities ofthe compounds, particularly the pharmaceutically acceptable salts,preferably the sodium salts, thereof. The pharmaceuticallytherapeutically active compounds and derivatives thereof are typicallyformulated and administered in unit-dosage forms or multiple-dosageforms. Unit-dose forms, as used herein, refers to physically discreteunits suitable for human and animal subjects and packaged individuallyas is known in the art. Each unit-dose contains a predetermined quantityof the therapeutically active compound sufficient to produce the desiredtherapeutic effect, in association with the required pharmaceuticalcarrier, vehicle or diluent. Examples of unit-dose forms includeampoules and syringes individually packaged tablet or capsule. Unit-doseforms may be administered in fractions or multiples thereof. Amultiple-dose form is a plurality of identical unit-dosage formspackaged in a single container to be administered in segregatedunit-dose form. Examples of multiple-dose forms include vials, bottlesof tablets or capsules or bottles of pint or gallons. Hence, multipledose form is a multiple of unit-doses that are not segregated inpackaging.

In addition to one or more compounds according to the present invention,the composition may comprise: a diluent such as lactose, sucrose,dicalcium phosphate, or carboxymethylcellulose; a lubricant, such asmagnesium stearate, calcium stearate and talc; and a binder such asstarch, natural gums, such as gum acaciagelatin, glucose, molasses,polyvinylpyrrolidine, celluloses and derivatives thereof, povidone,crospovidones and other such binders known to those of skill in the art.Liquid pharmaceutically administrable compositions can, for example, beprepared by dissolving, dispersing, or otherwise mixing an activecompound as defined above and optional pharmaceutical adjuvants in acarrier, such as, for example, water, saline, aqueous dextrose,glycerol, glycols, ethanol, and the like, to form a solution orsuspension. If desired, the pharmaceutical composition to beadministered may also contain minor amounts of auxiliary substances suchas wetting agents, emulsifying agents, or solubilizing agents, pHbuffering agents and the like, for example, acetate, sodium citrate,cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodiumacetate, triethanolamine oleate, and other such agents. Actual methodsof preparing such dosage forms are known in the art, or will beapparent, to those skilled in this art; for example, see Remington'sPharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15thEdition, 1975. The composition or formulation to be administered will,in any event, contain a sufficient quantity of an activator of thepresent invention to increase glucokinase activity in vivo, therebytreating the disease state of the subject.

Dosage forms or compositions may optionally comprise one or morecompounds according to the present invention in the range of 0.005% to100% (weight/weight) with the balance comprising additional substancessuch as those described herein. For oral administration, apharmaceutically acceptable composition may optionally comprise any oneor more commonly employed excipients, such as, for examplepharmaceutical grades of mannitol, lactose, starch, magnesium stearate,talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose,magnesium carbonate, sodium saccharin, talcum. Such compositions includesolutions, suspensions, tablets, capsules, powders, dry powders forinhalers and sustained release formulations, such as, but not limitedto, implants and microencapsulated delivery systems, and biodegradable,biocompatible polymers, such as collagen, ethylene vinyl acetate,polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid andothers. Methods for preparing these formulations are known to thoseskilled in the art. The compositions may optionally contain 0.01%-100%(weight/weight) of one or more glucokinase activators, optionally0.1-95%, and optionally 1-95%.

Salts, preferably sodium salts, of the activators may be prepared withcarriers that protect the compound against rapid elimination from thebody, such as time release formulations or coatings. The formulationsmay further include other active compounds to obtain desiredcombinations of properties.

Formulations for Oral Administration

Oral pharmaceutical dosage forms may be as a solid, gel or liquid.Examples of solid dosage forms include, but are not limited to tablets,capsules, granules, and bulk powders. More specific examples of oraltablets include compressed, chewable lozenges and tablets that may beenteric-coated, sugar-coated or film-coated. Examples of capsulesinclude hard or soft gelatin capsules. Granules and powders may beprovided in non-effervescent or effervescent forms. Each may be combinedwith other ingredients known to those skilled in the art.

In certain embodiments, compounds according to the present invention areprovided as solid dosage forms, preferably capsules or tablets. Thetablets, pills, capsules, troches and the like may optionally containone or more of the following ingredients, or compounds of a similarnature: a binder; a diluent; a disintegrating agent; a lubricant; aglidant; a sweetening agent; and a flavoring agent.

Examples of binders that may be used include, but are not limited to,microcrystalline cellulose, gum tragacanth, glucose solution, acaciamucilage, gelatin solution, sucrose, and starch paste.

Examples of lubricants that may be used include, but are not limited to,talc, starch, magnesium or calcium stearate, lycopodium and stearicacid.

Examples of diluents that may be used include, but are not limited to,lactose, sucrose, starch, kaolin, salt, mannitol, and dicalciumphosphate.

Examples of glidants that may be used include, but are not limited to,colloidal silicon dioxide.

Examples of disintegrating agents that may be used include, but are notlimited to, crosscarmellose sodium, sodium starch glycolate, alginicacid, corn starch, potato starch, bentonite, methylcellulose, agar andcarboxymethylcellulose.

Examples of coloring agents that may be used include, but are notlimited to, any of the approved certified water-soluble FD and C dyes,mixtures thereof; and water insoluble FD and C dyes suspended on aluminahydrate.

Examples of sweetening agents that may be used include, but are notlimited to, sucrose, lactose, mannitol and artificial sweetening agentssuch as sodium cyclamate and saccharin, and any number of spray-driedflavors.

Examples of flavoring agents that may be used include, but are notlimited to, natural flavors extracted from plants such as fruits andsynthetic blends of compounds that produce a pleasant sensation, suchas, but not limited to peppermint and methyl salicylate.

Examples of wetting agents that may be used include, but are not limitedto, propylene glycol monostearate, sorbitan monooleate, diethyleneglycol monolaurate, and polyoxyethylene lauryl ether.

Examples of anti-emetic coatings that may be used include, but are notlimited to, fatty acids, fats, waxes, shellac, ammoniated shellac andcellulose acetate phthalates.

Examples of film coatings that may be used include, but are not limitedto, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethyleneglycol 4000 and cellulose acetate phthalate.

If oral administration is desired, the salt of the compound mayoptionally be provided in a composition that protects it from the acidicenvironment of the stomach. For example, the composition can beformulated in an enteric coating that maintains its integrity in thestomach and releases the active compound in the intestine. Thecomposition may also be formulated in combination with an antacid orother such ingredient.

When the dosage unit form is a capsule, it may optionally additionallycomprise a liquid carrier such as a fatty oil. In addition, dosage unitforms may optionally additionally comprise various other materials thatmodify the physical form of the dosage unit, for example, coatings ofsugar and other enteric agents.

Compounds according to the present invention may also be administered asa component of an elixir, suspension, syrup, wafer, sprinkle, chewinggum or the like. A syrup may optionally comprise, in addition to theactive compounds, sucrose as a sweetening agent and certainpreservatives, dyes and colorings and flavors.

The compounds of the present invention may also be mixed with otheractive materials that do not impair the desired action, or withmaterials that supplement the desired action, such as antacids, H2blockers, and diuretics. For example, if a compound is used for treatingasthma or hypertension, it may be used with other bronchodilators andantihypertensive agents, respectively.

Examples of pharmaceutically acceptable carriers that may be included intablets comprising compounds of the present invention include, but arenot limited to binders, lubricants, diluents, disintegrating agents,coloring agents, flavoring agents, and wetting agents. Enteric-coatedtablets, because of the enteric-coating, resist the action of stomachacid and dissolve or disintegrate in the neutral or alkaline intestines.Sugar-coated tablets may be compressed tablets to which different layersof pharmaceutically acceptable substances are applied. Film-coatedtablets may be compressed tablets that have been coated with polymers orother suitable coating. Multiple compressed tablets may be compressedtablets made by more than one compression cycle utilizing thepharmaceutically acceptable substances previously mentioned. Coloringagents may also be used in tablets. Flavoring and sweetening agents maybe used in tablets, and are especially useful in the formation ofchewable tablets and lozenges.

Examples of liquid oral dosage forms that may be used include, but arenot limited to, aqueous solutions, emulsions, suspensions, solutionsand/or suspensions reconstituted from non-effervescent granules andeffervescent preparations reconstituted from effervescent granules.

Examples of aqueous solutions that may be used include, but are notlimited to, elixirs and syrups. As used herein, elixirs refer to clear,sweetened, hydroalcoholic preparations. Examples of pharmaceuticallyacceptable carriers that may be used in elixirs include, but are notlimited to solvents. Particular examples of solvents that may be usedinclude glycerin, sorbitol, ethyl alcohol and syrup. As used herein,syrups refer to concentrated aqueous solutions of a sugar, for example,sucrose. Syrups may optionally further comprise a preservative.

Emulsions refer to two-phase systems in which one liquid is dispersed inthe form of small globules throughout another liquid. Emulsions mayoptionally be oil-in-water or water-in-oil emulsions. Examples ofpharmaceutically acceptable carriers that may be used in emulsionsinclude, but are not limited to non-aqueous liquids, emulsifying agentsand preservatives.

Examples of pharmaceutically acceptable substances that may be used innon-effervescent granules, to be reconstituted into a liquid oral dosageform, include diluents, sweeteners and wetting agents.

Examples of pharmaceutically acceptable substances that may be used ineffervescent granules, to be reconstituted into a liquid oral dosageform, include organic acids and a source of carbon dioxide.

Coloring and flavoring agents may optionally be used in all of the abovedosage forms.

Particular examples of preservatives that may be used include glycerin,methyl and propylparaben, benzoic add, sodium benzoate and alcohol.

Particular examples of non-aqueous liquids that may be used in emulsionsinclude mineral oil and cottonseed oil.

Particular examples of emulsifying agents that may be used includegelatin, acacia, tragacanth, bentonite, and surfactants such aspolyoxyethylene sorbitan monooleate.

Particular examples of suspending agents that may be used include sodiumcarboxymethylcellulose, pectin, tragacanth, Veegum and acacia. Diluentsinclude lactose and sucrose. Sweetening agents include sucrose, syrups,glycerin and artificial sweetening agents such as sodium cyclamate andsaccharin.

Particular examples of wetting agents that may be used include propyleneglycol monostearate, sorbitan monooleate, diethylene glycol monolaurate,and polyoxyethylene lauryl ether.

Particular examples of organic acids that may be used include citric andtartaric acid.

Sources of carbon dioxide that may be used in effervescent compositionsinclude sodium bicarbonate and sodium carbonate. Coloring agents includeany of the approved certified water soluble FD and C dyes, and mixturesthereof.

Particular examples of flavoring agents that may be used include naturalflavors extracted from plants such fruits, and synthetic blends ofcompounds that produce a pleasant taste sensation.

For a solid dosage form, the solution or suspension, in for examplepropylene carbonate, vegetable oils or triglycerides, is preferablyencapsulated in a gelatin capsule. Such solutions, and the preparationand encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245;4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g.,for example, in a polyethylene glycol, may be diluted with a sufficientquantity of a pharmaceutically acceptable liquid carrier, e.g., water,to be easily measured for administration.

Alternatively, liquid or semi-solid oral formulations may be prepared bydissolving or dispersing the active compound or salt in vegetable oils,glycols, triglycerides, propylene glycol esters (e.g., propylenecarbonate) and other such carriers, and encapsulating these solutions orsuspensions in hard or soft gelatin capsule shells. Other usefulformulations include those set forth in U.S. Pat. Nos. Re 28,819 and4,358,603.

Injectables, Solutions, and Emulsions

The present invention is also directed to compositions designed toadminister the compounds of the present invention by parenteraladministration, generally characterized by subcutaneous, intramuscularor intravenous injection. Injectables may be prepared in anyconventional form, for example as liquid solutions or suspensions, solidforms suitable for solution or suspension in liquid prior to injection,or as emulsions.

Examples of excipients that may be used in conjunction with injectablesaccording to the present invention include, but are not limited towater, saline, dextrose, glycerol or ethanol. The injectablecompositions may also optionally comprise minor amounts of non-toxicauxiliary substances such as wetting or emulsifying agents, pH bufferingagents, stabilizers, solubility enhancers, and other such agents, suchas for example, sodium acetate, sorbitan monolaurate, triethanolamineoleate and cyclodextrins. Implantation of a slow-release orsustained-release system, such that a constant level of dosage ismaintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplatedherein. The percentage of active compound contained in such parenteralcompositions is highly dependent on the specific nature thereof, as wellas the activity of the compound and the needs of the subject.

Parenteral administration of the formulations includes intravenous,subcutaneous and intramuscular administrations. Preparations forparenteral administration include sterile solutions ready for injection,sterile dry soluble products, such as the lyophilized powders describedherein, ready to be combined with a solvent just prior to use, includinghypodermic tablets, sterile suspensions ready for injection, sterile dryinsoluble products ready to be combined with a vehicle just prior to useand sterile emulsions. The solutions may be either aqueous ornonaqueous.

When administered intravenously, examples of suitable carriers include,but are not limited to physiological saline or phosphate buffered saline(PBS), and solutions containing thickening and solubilizing agents, suchas glucose, polyethylene glycol, and polypropylene glycol and mixturesthereof.

Examples of pharmaceutically acceptable carriers that may optionally beused in parenteral preparations include, but are not limited to aqueousvehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents,buffers, antioxidants, local anesthetics, suspending and dispersingagents, emulsifying agents, sequestering or chelating agents and otherpharmaceutically acceptable substances.

Examples of aqueous vehicles that may optionally be used include SodiumChloride Injection, Ringers Injection, Isotonic Dextrose Injection,Sterile Water Injection, Dextrose and Lactated Ringers Injection.

Examples of nonaqueous parenteral vehicles that may optionally be usedinclude fixed oils of vegetable origin, cottonseed oil, corn oil, sesameoil and peanut oil.

Antimicrobial agents in bacteriostatic or fungistatic concentrations maybe added to parenteral preparations, particularly when the preparationsare packaged in multiple-dose containers and thus designed to be storedand multiple aliquots to be removed. Examples of antimicrobial agentsthat may be used include phenols or cresols, mercurials, benzyl alcohol,chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters,thimerosal, benzalkonium chloride and benzethonium chloride.

Examples of isotonic agents that may be used include sodium chloride anddextrose. Examples of buffers that may be used include phosphate andcitrate. Examples of antioxidants that may be used include sodiumbisulfate. Examples of local anesthetics that may be used includeprocaine hydrochloride. Examples of suspending and dispersing agentsthat may be used include sodium carboxymethylcellulose, hydroxypropylmethylcellulose and polyvinylpyrrolidone. Examples of emulsifying agentsthat may be used include Polysorbate 80 (TWEEN 80). A sequestering orchelating agent of metal ions includes EDTA.

Pharmaceutical carriers may also optionally include ethyl alcohol,polyethylene glycol and propylene glycol for water miscible vehicles andsodium hydroxide, hydrochloric acid, citric acid or lactic acid for pHadjustment.

The concentration of an activator in the parenteral formulation may beadjusted so that an injection administers a pharmaceutically effectiveamount sufficient to produce the desired pharmacological effect. Theexact concentration of an activator and/or dosage to be used willultimately depend on the age, weight and condition of the patient oranimal as is known in the art.

Unit-dose parenteral preparations may be packaged in an ampoule, a vialor a syringe with a needle. All preparations for parenteraladministration should be sterile, as is known and practiced in the art.

Injectables may be designed for local and systemic administration.Typically a therapeutically effective dosage is formulated to contain aconcentration of at least about 0.1% w/w up to about 90% w/w or more,preferably more than 1% w/w of the glucokinase activator to the treatedtissue(s). The activator may be administered at once, or may be dividedinto a number of smaller doses to be administered at intervals of time.It is understood that the precise dosage and duration of treatment willbe a function of the location of where the composition is parenterallyadministered, the carrier and other variables that may be determinedempirically using known testing protocols or by extrapolation from invivo or in vitro test data. It is to be noted that concentrations anddosage values may also vary with the age of the individual treated. Itis to be further understood that for any particular subject, specificdosage regimens may need to be adjusted over time according to theindividual need and the professional judgment of the personadministering or supervising the administration of the formulations.Hence, the concentration ranges set forth herein are intended to beexemplary and are not intended to limit the scope or practice of theclaimed formulations.

The glucokinase activator may optionally be suspended in micronized orother suitable form or may be derivatized to produce a more solubleactive product or to produce a prodrug. The form of the resultingmixture depends upon a number of factors, including the intended mode ofadministration and the solubility of the compound in the selectedcarrier or vehicle. The effective concentration is sufficient forameliorating the symptoms of the disease state and may be empiricallydetermined.

Lyophilized Powders

The compounds of the present invention may also be prepared aslyophilized powders, which can be reconstituted for administration assolutions, emulsions and other mixtures. The lyophilized powders mayalso be formulated as solids or gels.

Sterile, lyophilized powder may be prepared by dissolving the compoundin a sodium phosphate buffer solution containing dextrose or othersuitable excipient. Subsequent sterile filtration of the solutionfollowed by lyophilization under standard conditions known to those ofskill in the art provides the desired formulation. Briefly, thelyophilized powder may optionally be prepared by dissolving dextrose,sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose orother suitable agent, about 1-20%, preferably about 5 to 15%, in asuitable buffer, such as citrate, sodium or potassium phosphate or othersuch buffer known to those of skill in the art at, typically, aboutneutral pH. Then, a glucokinase activator is added to the resultingmixture, preferably above room temperature, more preferably at about30-35° C., and stirred until it dissolves. The resulting mixture isdiluted by adding more buffer to a desired concentration. The resultingmixture is sterile filtered or treated to remove particulates and toinsure sterility, and apportioned into vials for lyophilization. Eachvial may contain a single dosage or multiple dosages of the activator.

Topical Administration

The compounds of the present invention may also be administered astopical mixtures. Topical mixtures may be used for local and systemicadministration. The resulting mixture may be a solution, suspension,emulsions or the like and are formulated as creams, gels, ointments,emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes,foams, aerosols, irrigations, sprays, suppositories, bandages, dermalpatches or any other formulations suitable for topical administration.

The glucokinase activators may be formulated as aerosols for topicalapplication, such as by inhalation (see, U.S. Pat. Nos. 4,044,126,4,414,209, and 4,364,923, which describe aerosols for delivery of asteroid useful for treatment of inflammatory diseases, particularlyasthma). These formulations for administration to the respiratory tractcan be in the form of an aerosol or solution for a nebulizer, or as amicrofine powder for insufflation, alone or in combination with an inertcarrier such as lactose. In such a case, the particles of theformulation will typically have diameters of less than 50 microns,preferably less than 10 microns.

The activators may also be formulated for local or topical application,such as for topical application to the skin and mucous membranes, suchas in the eye, in the form of gels, creams, and lotions and forapplication to the eye or for intracisternal or intraspinal application.Topical administration is contemplated for transdermal delivery and alsofor administration to the eyes or mucosa, or for inhalation therapies.Nasal solutions of the glucokinase activator alone or in combinationwith other pharmaceutically acceptable excipients can also beadministered.

Formulations for Other Routes of Administration

Depending upon the disease state being treated, other routes ofadministration, such as topical application, transdermal patches, andrectal administration, may also be used. For example, pharmaceuticaldosage forms for rectal administration are rectal suppositories,capsules and tablets for systemic effect. Rectal suppositories are usedherein mean solid bodies for insertion into the rectum that melt orsoften at body temperature releasing one or more pharmacologically ortherapeutically active ingredients. Pharmaceutically acceptablesubstances utilized in rectal suppositories are bases or vehicles andagents to raise the melting point. Examples of bases include cocoabutter (theobroma oil), glycerin-gelatin, carbowax, (polyoxyethyleneglycol) and appropriate mixtures of mono-, di- and triglycerides offatty acids. Combinations of the various bases may be used. Agents toraise the melting point of suppositories include spermaceti and wax.Rectal suppositories may be prepared either by the compressed method orby molding. The typical weight of a rectal suppository is about 2 to 3gm. Tablets and capsules for rectal administration may be manufacturedusing the same pharmaceutically acceptable substance and by the samemethods as for formulations for oral administration.

Examples of Formulations

The following are particular examples of oral, intravenous and tabletformulations that may optionally be used with compounds of the presentinvention. It is noted that these formulations may be varied dependingon the particular compound being used and the indication for which theformulation is going to be used.

Oral Formulation

Compound of the Present Invention 10-100 mg Citric Acid Monohydrate 105mg Sodium Hydroxide 18 mg Flavoring Water q.s. to 100 mL

Intravenous Formulation

Compound of the Present Invention 0.1-10 mg Dextrose Monohydrate q.s. tomake isotonic Citric Acid Monohydrate 1.05 mg Sodium Hydroxide 0.18 mgWater for Injection q.s. to 1.0 mL

Tablet Formulation

Compound of the Present Invention  1% Microcrystalline Cellulose 73%Stearic Acid 25% Colloidal Silica   1%.Kits Comprising Glucokinase Activators

The invention is also directed to kits and other articles of manufacturefor treating diseases associated with glucokinase. It is noted thatdiseases are intended to cover all conditions for which increasingglucokinase activity (e.g., upregulation of glucokinase) ameliorates thepathology and/or symptomology of the condition.

In one embodiment, a kit is provided that comprises a compositioncomprising at least one activator of the present invention incombination with instructions. The instructions may indicate the diseasestate for which the composition is to be administered, storageinformation, dosing information and/or instructions regarding how toadminister the composition. The kit may also comprise packagingmaterials. The packaging material may comprise a container for housingthe composition. The kit may also optionally comprise additionalcomponents, such as syringes for administration of the composition. Thekit may comprise the composition in single or multiple dose forms.

In another embodiment, an article of manufacture is provided thatcomprises a composition comprising at least one activator of the presentinvention in combination with packaging materials. The packagingmaterial may comprise a container for housing the composition. Thecontainer may optionally comprise a label indicating the disease statefor which the composition is to be administered, storage information,dosing information and/or instructions regarding how to administer thecomposition. The kit may also optionally comprise additional components,such as syringes for administration of the composition. The kit maycomprise the composition in single or multiple dose forms.

It is noted that the packaging material used in kits and articles ofmanufacture according to the present invention may form a plurality ofdivided containers such as a divided bottle or a divided foil packet.The container can be in any conventional shape or form as known in theart which is made of a pharmaceutically acceptable material, for examplea paper or cardboard box, a glass or plastic bottle or jar, are-sealable bag (for example, to hold a “refill” of tablets forplacement into a different container), or a blister pack with individualdoses for pressing out of the pack according to a therapeutic schedule.The container that is employed will depend on the exact dosage forminvolved, for example a conventional cardboard box would not generallybe used to hold a liquid suspension. It is feasible that more than onecontainer can be used together in a single package to market a singledosage form. For example, tablets may be contained in a bottle that isin turn contained within a box. Typically the kit includes directionsfor the administration of the separate components. The kit form isparticularly advantageous when the separate components are preferablyadministered in different dosage forms (e.g., oral, topical, transdermaland parenteral), are administered at different dosage intervals, or whentitration of the individual components of the combination is desired bythe prescribing physician.

One particular example of a kit according to the present invention is aso-called blister pack. Blister packs are well known in the packagingindustry and are being widely used for the packaging of pharmaceuticalunit dosage forms (tablets, capsules, and the like). Blister packsgenerally consist of a sheet of relatively stiff material covered with afoil of a preferably transparent plastic material. During the packagingprocess recesses are formed in the plastic foil. The recesses have thesize and shape of individual tablets or capsules to be packed or mayhave the size and shape to accommodate multiple tablets and/or capsulesto be packed. Next, the tablets or capsules are placed in the recessesaccordingly and the sheet of relatively stiff material is sealed againstthe plastic foil at the face of the foil which is opposite from thedirection in which the recesses were formed. As a result, the tablets orcapsules are individually sealed or collectively sealed, as desired, inthe recesses between the plastic foil and the sheet. Preferably thestrength of the sheet is such that the tablets or capsules can beremoved from the blister pack by manually applying pressure on therecesses whereby an opening is formed in the sheet at the place of therecess. The tablet or capsule can then be removed via said opening.

Another specific embodiment of a kit is a dispenser designed to dispensethe daily doses one at a time in the order of their intended use.Preferably, the dispenser is equipped with a memory-aid, so as tofurther facilitate compliance with the regimen. An example of such amemory-aid is a mechanical counter that indicates the number of dailydoses that has been dispensed. Another example of such a memory-aid is abattery-powered micro-chip memory coupled with a liquid crystal readout,or audible reminder signal which, for example, reads out the date thatthe last daily dose has been taken and/or reminds one when the next doseis to be taken.

Dosage, Host and Safety

The compounds of the present invention are stable and can be usedsafely. In particular, the compounds of the present invention are usefulas GK activators for a variety of subjects (e.g., humans, non-humanmammals and non-mammals). The optimal dose may vary depending upon suchconditions as, for example, the type of subject, the body weight of thesubject, the route of administration, and specific properties of theparticular compound being used. In general, the daily dose for oraladministration to an adult (body weight of about 60 kg) is about 1 to1000 mg, about 3 to 300 mg, or about 10 to 200 mg. It will beappreciated that the daily dose can be given in a single administrationor in multiple (e.g., 2 or 3) portions a day.

Combination Therapies

A wide variety of therapeutic agents may have a therapeutic additive orsynergistic effect with GK activators according to the presentinvention. In particular, the present invention also relates to the useof the GK activators of the present invention in combination with one ormore other antidiabetic compounds. Examples of such other antidiabeticcompounds include, but are not limited to S9 proteases, like dipeptidylpeptidase IV (DPP-IV) inhibitors; insulin signaling pathway modulators,like protein tyrosine phosphatase (PTPase) inhibitors, andglutamine-fructose-6-phosphate amidotransferase (GFAT) inhibitors;compounds influencing a dysregulated hepatic glucose production, likeglucose-6-phosphatase (G6 Pase) inhibitors, fructose-1,6-bisphosphatase(F-1,6-BPase) inhibitors, glycogen phosphorylase (GP) inhibitors,glucagon receptor antagonists and phosphoenolpyruvate carboxykinase(PEPCK) inhibitors; pyruvate dehydrogenase kinase (PDHK) inhibitors;insulin sensitivity enhancers (insulin sensitizers); insulin secretionenhancers (insulin secretagogues); alpha-glucosidase inhibitors;inhibitors of gastric emptying; other glucokinase (GK) activators; GLP-1receptor agonists; UCP modulators; RXR modulators; GSK-3 inhibitors;PPAR modulators; metformin; insulin; and α₂-adrenergic antagonists. Thecompound of the present invention may be administered with such at leastone other antidiabetic compound either simultaneously as a single dose,at the same time as separate doses, or sequentially (i.e., where one isadministered before or after the other is administered).

In the case of combination therapy with compounds of the presentinvention, the other antidiabetic compound may be administered (e.g.,route and dosage form) in a manner known per se for such compound.Compounds of the present invention and the other antidiabetic compoundmay be administered sequentially (i.e., at separate times) or at thesame time, either one after the other separately in two separate doseforms or in one combined, single dose form. In one particularembodiment, the other antidiabetic compound is administered withcompounds of the present invention as a single, combined dosage form.The dose of the antidiabetic compound may be selected from the rangeknown to be clinically employed for such compound. Any of thetherapeutic compounds of diabetic complications, antihyperlipemiccompounds or antiobestic compounds can be used in combination withcompounds of the present invention in the same manner as the aboveantidiabetic compounds.

EXAMPLES Preparation of Glucokinase Activators

Various methods may be developed for synthesizing compounds according tothe present invention. Representative methods for synthesizing thesecompounds are provided in the Examples. It is noted, however, that thecompounds of the present invention may also be synthesized by othersynthetic routes that others may devise.

It will be readily recognized that certain compounds according to thepresent invention have atoms with linkages to other atoms that confer aparticular stereochemistry to the compound (e.g., chiral centers). It isrecognized that synthesis of compounds according to the presentinvention may result in the creation of mixtures of differentstereoisomers (i.e., enantiomers and diastereomers). Unless a particularstereochemistry is specified, recitation of a compound is intended toencompass all of the different possible stereoisomers.

Various methods for separating mixtures of different stereoisomers areknown in the art. For example, a racemic mixture of a compound may bereacted with an optically active resolving agent to form a pair ofdiastereoisomeric compounds. The diastereomers may then be separated inorder to recover the optically pure enantiomers. Dissociable complexesmay also be used to resolve enantiomers (e.g., crystallinediastereoisomeric salts). Diastereomers typically have sufficientlydistinct physical properties (e.g., melting points, boiling points,solubilities, reactivity, etc.) and can be readily separated by takingadvantage of these dissimilarities. For example, diastereomers cantypically be separated by chromatography or by separation/resolutiontechniques based upon differences in solubility. A more detaileddescription of techniques that can be used to resolve stereoisomers ofcompounds from their racemic mixture can be found in Jean Jacques AndreCollet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, JohnWiley & Sons, Inc. (1981).

Compounds according to the present invention can also be prepared as apharmaceutically acceptable acid addition salt by reacting the free baseform of the compound with a pharmaceutically acceptable inorganic ororganic acid. Alternatively, a pharmaceutically acceptable base additionsalt of a compound can be prepared by reacting the free acid form of thecompound with a pharmaceutically acceptable inorganic or organic base.Inorganic and organic acids and bases suitable for the preparation ofthe pharmaceutically acceptable salts of compounds are set forth in thedefinitions section of this Application. Alternatively, the salt formsof the compounds can be prepared using salts of the starting materialsor intermediates.

The free acid or free base forms of the compounds can be prepared fromthe corresponding base addition salt or acid addition salt form. Forexample, a compound in an acid addition salt form can be converted tothe corresponding free base by treating with a suitable base (e.g.,ammonium hydroxide solution, sodium hydroxide, and the like). A compoundin a base addition salt form can be converted to the corresponding freeacid by treating with a suitable acid (e.g., hydrochloric acid, etc).

The N-oxides of compounds according to the present invention can beprepared by methods known to those of ordinary skill in the art. Forexample, N-oxides can be prepared by treating an unoxidized form of thecompound with an oxidizing agent (e.g., trifluoroperacetic acid,permaleic acid, perbenzoic acid, peracetic acid,meta-chloroperoxybenzoic acid, or the like) in a suitable inert organicsolvent (e.g., a halogenated hydrocarbon such as dichloromethane) atapproximately 0° C. Alternatively, the N-oxides of the compounds can beprepared from the N-oxide of an appropriate starting material.

Compounds in an unoxidized form can be prepared from N-oxides ofcompounds by treating with a reducing agent (e.g., sulfur, sulfurdioxide, triphenyl phosphine, lithium borohydride, sodium borohydride,phosphorus trichloride, tribromide, or the like) in an suitable inertorganic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or thelike) at 0 to 80° C.

Prodrug derivatives of the compounds can be prepared by methods known tothose of ordinary skill in the art (e.g., for further details seeSaulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol.4, p. 1985). For example, appropriate prodrugs can be prepared byreacting a non-derivatized compound with a suitable carbamylating agent(e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, orthe like).

Protected derivatives of the compounds can be made by methods known tothose of ordinary skill in the art. A detailed description of thetechniques applicable to the creation of protecting groups and theirremoval can be found in T. W. Greene, Protecting Groups in OrganicSynthesis, 3^(rd) edition, John Wiley & Sons, Inc. 1999.

Compounds according to the present invention may be convenientlyprepared, or formed during the process of the invention, as solvates(e.g., hydrates). Hydrates of compounds of the present invention may beconveniently prepared by recrystallization from an aqueous/organicsolvent mixture, using organic solvents such as dioxin, tetrahydrofuranor methanol.

Compounds according to the present invention can also be prepared astheir individual stereoisomers by reacting a racemic mixture of thecompound with an optically active resolving agent to form a pair ofdiastereoisomeric compounds, separating the diastereomers and recoveringthe optically pure enantiomer. While resolution of enantiomers can becarried out using covalent diastereomeric derivatives of compounds,dissociable complexes are preferred (e.g., crystalline diastereoisomericsalts). Diastereomers have distinct physical properties (e.g., meltingpoints, boiling points, solubilities, reactivity, etc.) and can bereadily separated by taking advantage of these dissimilarities. Thediastereomers can be separated by chromatography or, preferably, byseparation/resolution techniques based upon differences in solubility.The optically pure enantiomer is then recovered, along with theresolving agent, by any practical means that would not result inracemization. A more detailed description of the techniques applicableto the resolution of stereoisomers of compounds from their racemicmixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen,Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).

As used herein the symbols and conventions used in these processes,schemes and examples are consistent with those used in the contemporaryscientific literature, for example, the Journal of the American ChemicalSociety or the Journal of Biological Chemistry. Standard single-letteror three-letter abbreviations are generally used to designate amino acidresidues, which are assumed to be in the L-configuration unlessotherwise noted. Unless otherwise noted, all starting materials wereobtained from commercial suppliers and used without furtherpurification. Specifically, the following abbreviations may be used inthe examples and throughout the specification:

μL (microliters) Ac (acetyl) atm (atmosphere) ATP (AdenosineTriphophatase) BOC (tert-butyloxycarbonyl) BOP(bis(2-oxo-3-oxazolidinyl)- phosphinic chloride) BSA (Bovine SerumAlbumin) CBZ (benzyloxycarbonyl) CDI (1,1-carbonyldiimidazole) DCC(dicyclohexylcarbodiimide) DCE (dichloroethane) DCM (dichloromethane)DMAP (4-dimethylaminopyridine) DME (1,2-dimethoxyethane) DMF(N,N-dimethylformamide) DMPU (N,N′-dimethylpropyleneurea) DMSO(dimethylsulfoxide) EDCI (ethylcarbodiimide hydrochloride) EDTA(Ethylenediaminetetraacetic Et (ethyl) acid) Et₂O (diethyl ether) EtOAc(ethyl acetate) FMOC (9-fluorenylmethoxy- g (grams) carbonyl) h (hours)HOAc or AcOH (acetic acid) HOBT (1-hydroxybenzotriazole) HOSu(N-hydroxysuccinimide) HPLC (high pressure liquid Hz (Hertz)chromatography) i.v. (intravenous) IBCF (isobutyl chloroformate) i-PrOH(isopropanol) L (liters) M (molar) mCPBA (meta-chloroperbenzoic acid) Me(methyl) MeOH (methanol) mg (milligrams) MHz (megahertz) min (minutes)mL (milliliters) mM (millimolar) mmol (millimoles) mol (moles) MOPS(Morpholinepropanesulfonic acid) mp (melting point) NaOAc (sodiumacetate) OMe (methoxy) psi (pounds per square inch) RP (reverse phase)RT (ambient temperature) SPA (Scintillation Proximity TBAF(tetra-n-butylammonium Assay) fluoride) TBS (t-butyldimethylsilyl) tBu(tert-butyl) TEA (triethylamine) TFA (trifluoroacetic acid) TFAA(trifluoroacetic anhydride) THF (tetrahydrofuran) TIPS(triisopropylsilyl) TLC (thin layer chromatography) TMS (trimethylsilyl)TMSE (2-(trimethylsilyl)ethyl) Tr (retention time)

All references to ether or Et₂O are to diethyl ether; and brine refersto a saturated aqueous solution of NaCl. Unless otherwise indicated, alltemperatures are expressed in ° C. (degrees Centigrade). All reactionsare conducted under an inert atmosphere at RT unless otherwise noted.

¹H NMR spectra were recorded on a Bruker Avance 400. Chemical shifts areexpressed in parts per million (ppm). Coupling constants are in units ofHertz (Hz). Splitting patterns describe apparent multiplicities and aredesignated as s (singlet), d (doublet), t (triplet), q (quartet), m(multiplet), br (broad).

Low-resolution mass spectra (MS) and compound purity data were acquiredon a Waters ZQ LC/MS single quadrupole system equipped with electrosprayionization (ESI) source, UV detector (220 and 254 nm), and evaporativelight scattering detector (ELSD). Thin-layer chromatography wasperformed on 0.25 mm E. Merck silica gel plates (60E-254), visualizedwith UV light, 5% ethanolic phosphomolybdic acid, Ninhydrin orp-anisaldehyde solution. Flash column chromatography was performed onsilica gel (230-400 mesh, Merck).

The starting materials and reagents used in preparing these compoundsare either available from commercial suppliers such as the AldrichChemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma(St. Louis, Mo.), or may be prepared by methods well known to a personof ordinary skill in the art, following procedures described in suchstandard references as Fieser and Fieser's Reagents for OrganicSynthesis, vols. 1-17, John Wiley and Sons, New York, N.Y., 1991; Rodd'sChemistry of Carbon Compounds, vols. 1-5 and supps., Elsevier SciencePublishers, 1989; Organic Reactions, vols. 1-40, John Wiley and Sons,New York, N.Y., 1991; March J.: Advanced Organic Chemistry, 4th ed.,John Wiley and Sons, New York, N.Y.; and Larock: Comprehensive OrganicTransformations, VCH Publishers, New York, 1989.

The entire disclosures of all documents cited throughout thisapplication are incorporated herein by reference.

Synthetic Schemes for Compounds of the Present Invention

Compounds according to the present invention may be synthesizedaccording to the reaction schemes shown below. Other reaction schemescould be readily devised by those skilled in the art. It should also beappreciated that a variety of different solvents, temperatures and otherreaction conditions can be varied to optimize the yields of thereactions.

In the reactions described hereinafter it may be necessary to protectreactive functional groups, for example hydroxy, amino, imino, thio orcarboxy groups, where these are desired in the final product, to avoidtheir unwanted participation in the reactions. Conventional protectinggroups may be used in accordance with standard practice, for examplessee T. W. Greene and P. G. M. Wuts in “Protective Groups in OrganicChemistry” John Wiley and Sons, 1991.

Referring to Scheme 1, compound A is condensed with amino acid B to givecompound C. Compound C is coupled with amino heterocycle D to givecompound E.

Referring to Scheme 2, dimethyl 1,3-acetonedicarboxylate F is condensedwith triethyl orthoformate, and then cyclized with amino ester G to givecompound H. Decarboxylation in conc. HBr provides compound I, which isthen esterified and chlorinated to obtain compound J. Displacement ofthe chloride with nucleophile R₅—R_(a) (where R_(a) is a metal (e.g., Naor Li)) gives compound K. Compound K is treated with base (e.g., LiOH)to form acid L. Acid L is coupled with amino heterocycle D to obtaincompound M.

Referring to Scheme 3, butenoate ester N, where R_(b) is a (C₁₋₃)alkyl,is converted to aminopentadienoate O, which is then cyclized with anamino ester to obtain compound P. Compound P is treated with base (e.g.,LiOH) to form acid Q. Acid Q is coupled with amino heterocycle D toobtain compound R.

Referring to Scheme 4, 2-hydroxy-, 2-alkoxy- or 2-halo-pyridinederivative S is alkylated with ester T, where R_(b) is a (C₁₋₃)alkyl andR_(d) is a leaving group (e.g., halo), to obtain compound U. Compound Uis treated with base (e.g., LiOH) to form acid V. Acid V is coupled withamino heterocycle D to obtain compound W.

Referring to Scheme 5, 2-hydroxy-, 2-alkoxy- or 2-halo-pyridinederivative S is alkylated with ester X, R_(b) is a (C₁₋₃)alkyl and R_(d)is a leaving group (e.g., halo), to provide compound Y. An aldolcondensation followed by reduction yields compound Z. Compound Z istreated with base (e.g., LiOH) to form acid AA. Acid AA is coupled withamino heterocycle D to obtain compound BB.

Referring to Scheme 6, 2-hydroxy-, 2-alkoxy- or 2-halo-pyridinederivative S is alkylated with ester X, R_(b) is a (C₁₋₃)alkyl and R_(d)is a leaving group (e.g., halo), to provide compound Y. Alkylation ofthe unsubstituted alpha carbon of compound Y by R₂₁CH₂R_(e), where R_(e)is a leaving group (e.g., halo, (C₁₋₃)alkyl), provides compound Z.Compound Z is treated with base (e.g., LiOH) to form acid AA. Acid AA iscoupled with amino heterocycle D to obtain compound BB.

Chiral components can be separated and purified using any of a varietyof techniques known to those skilled in the art. For example, chiralcomponents can be purified using supercritical fluid chromatography(SFC). In one particular variation, chiral analytical SFC/MS analysesare conducted using a Berger analytical SFC system (AutoChem, Newark,Del.) which consists of a Berger SFC dual pump fluid control module witha Berger FCM 1100/1200 supercritical fluid pump and FCM 1200 modifierfluid pump, a Berger TCM 2000 oven, and an Alcott 718 autosampler. Theintegrated system can be controlled by BI-SFC Chemstation softwareversion 3.4. Detection can be accomplished with a Watrers ZQ 2000detector operated in positive mode with an ESI interface and a scanrange from 200-800 Da with 0.5 second per scan. Chromatographicseparations can be performed on a ChiralPak AD-H, ChiralPak AS-H,ChiralCel OD-H, or ChiralCel OJ-H column (5μ, 4.6×250 mm; ChiralTechnologies, Inc. West Chester, Pa.) with 10 to 40% methanol as themodifier and with or without ammonium acetate (10 mM). Any of a varietyof flow rates can be utilized including, for example, 1.5 or 3.5 mL/minwith an inlet pressure set at 100 bar. Additionally, a variety of sampleinjection conditions can be used including, for example, sampleinjections of either 5 or 10 μL in methanol at 0.1 mg/mL inconcentration.

In another variation, preparative chiral separations are performed usinga Berger MultiGram II SFC purification system. For example, samples canbe loaded onto a ChiralPak AD column (21×250 mm, 10μ). In particularvariations, the flow rate for separation can be 70 mL/min, the injectionvolume up to 2 mL, and the inlet pressure set at 130 bar. Stackedinjections can be applied to increase the efficiency.

In each of the above reaction procedures or schemes, the varioussubstituents may be selected from among the various substituentsotherwise taught herein.

Descriptions of the syntheses of particular compounds according to thepresent invention based on the above reaction scheme are set forthherein.

Examples of Glucokinase Activators

The present invention is further exemplified, but not limited by, thefollowing examples that describe the synthesis of particular compoundsaccording to the invention.

Method A

Compounds designated in Table 1 below as being prepared using Method Awere prepared using a procedure analogous to that described inconnection with Example 1.

Example 13-cyclohexyl-2-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamidetrifluoroacetic acid salt

4-Hydroxy-6-methyl-2-pyrone (1.10 g) was added in portions at roomtemperature to a solution of 2-amino-3-cyclohexylpropanoic acid (1.5 g)in 9 ml of 1N aqueous NaOH. The mixture was heated under refluxovernight, cooled and acidified with 9 ml of 1N hydrochloric acid. Thereaction mixture was then concentrated to half its volume and theprecipitate was filtered, washed with cold water and dried to givecompound 1A. ¹H NMR (400 MHz, MeOD) δ 0.8-1.93 (m, 13H), 2.30 (m, 1H),2.36 (s, 3H), 5.67 (s, 1H), 5.93 (d, J=4 Hz, 1H). [M+H] Calc'd forC₁₅H₂₁NO₄, 280.33. Found, 280.3.

To compound 1A (0.16 mg) in 3 ml of THF was added N-methylmorpholine(NMM, 0.09 ml) and the flask cooled to 0° C. To this reaction mixturewas added isobutylchloroformate (0.081 ml) dropwise. After 20 min,2-aminothiazole (0.057 mg) was added and the reaction was allowed towarm to room temperature and stirred overnight. The reaction mixture wasdiluted with ethyl acetate, and washed with water and brine, dried overNa₂SO₄, and concentrated in vacuo. Purification by HPLC afforded thetitle compound as a colorless solid (36 mg). ¹H NMR (400 MHz, MeOD) δ0.9-1.93 (m, 13H), 2.40 (m, 1H), 2.44 (s, 3H), 5.67 (d, J=4 Hz, 1H),6.02 (s, 1H), 7.11 (s, 1H), 7.40 (s, 1H). [M+H] Calc'd for C₁₈H₂₃N₃O₃S,362.4. Found, 362.5.

Method B

Compounds designated in Table 1 below as being prepared using Method Bwere prepared using a procedure analogous to that described inconnection with Example 2.

Example 23-cyclohexyl-2-(4-methoxy-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamidetrifluoroacetic acid salt

Compound 1A (0.36 g) in 13 ml of acetonitrile at 0° C. was treated withtrimethylsilyldiazomethane (1.93 ml of a 2M solution) and the reactionwas allowed to warm to room temperature and stirred overnight. Thereaction mixture was concentrated on a rotary evaporator and redissolvedin DMF (5 ml). To this solution was added K₂CO₃ and methyl iodide (3equiv each) and the reaction was stirred overnight at room temperature.The product was extracted into ethyl acetate, and washed with water andbrine, dried over Na₂SO₄, and concentrated in vacuo to yield compound2B. [M+H] Calc'd for C₁₇H₂₅NO₄, 308.38 Found, 308.4.

To a solution of compound 2B (0.131 g) in dioxane (4 ml) was added 1.27ml of a 1N LiOH solution and the reaction mixture stirred overnight atroom temperature. The reaction mixture was diluted with ethyl acetateand the separated aqueous layer was acidified with 1N hydrochloric acidto pH 2. The aqueous layer was extracted with ethyl acetate (2×), andwashed with water and brine, dried over Na₂SO₄, and concentrated invacuo to obtain the intermediate acid. [M+H] Calc'd for C₁₆H₂₃NO₄,294.36. Found, 294.4.

To the intermediate acid in DMF (3 ml) was added HBTU (0.33 g) and Et₃N(0.15 ml). After 20 min., 2-aminothiazole (0.065 g) was added and thereaction mixture stirred overnight at room temperature. The reactionmixture was diluted with ethyl acetate, and the mixture was washed withwater and brine, dried over Na₂SO₄, and concentrated in vacuo to yieldcompound 2. ¹H NMR (400 MHz, CDCl₃) δ 0.9-1.38 (m, 7H), 1.58-1.82 (m,5H), 2.39 (s, 3H), 2.46 (m, 1H), 3.76 (s, 3H), 5.81 (s, 1H), 5.84 (s,1H), 6.97 (d, J=4 Hz, 1H), 7.42 (d, J=4 Hz, 1H). [M+H] Calc'd forC₁₈H₂₃N₃O₃S, 376.49. Found, 376.4.

Method C

Compounds designated in Table 1 below as being prepared using Method Cwere prepared using a procedure analogous to that described inconnection with Example 3.

Example 33-cyclohexyl-2-(6-methyl-4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamidetrifluoroacetic acid salt

To a solution of compound 1A (2 g) in 30 ml of methanol was addedconcentrated HCl (2 ml) in one portion. The solution was refluxed for 3h, cooled to room temperature, concentrated, and poured on crushed ice.The solid obtained was filtered, washed with cold water and dried toyield the corresponding ester in quantitative yield.

To a rapidly stirring solution of the intermediate ester of compound 1A(0.53 g), Et₄NCl (1.19 g) and dry N,N-dimethylaniline (0.22 ml) inanhydrous acetonitrile (5 ml) was added POCl₃ (0.41 ml) at ambienttemperature under nitrogen. The reaction was placed in a preheated oilbath and refluxed at 100° C. for 15 min. The reaction mixture was thenevaporated on a rotary evaporator and the resulting oil was dissolved indichloromethane and poured onto crushed ice. The layers were separated,and the organic phase was washed with water, 5% NaHCO₃ and brine, driedover Na₂SO₄, and concentrated in vacuo to yield compound 3B. ¹H NMR (400MHz, CDCl₃) δ 0.8-1.7 (m, 13H), 2.27 (s, 3H), 2.35 (m, 1H), 3.64 (s,3H), 6.03 (d, J=4 Hz, 1H), 6.40 (d, J=4 Hz, 1H). [M+H] Calc'd forC₁₆H₂₂ClNO₃, 312.80. Found, 312.8.

To compound 3B (0.29 g) in 5 ml of DMSO was added sodium methylthiolate(0.066 g) and the solution was heated at 80° C. overnight. The reactionmixture was allowed to cool to room temperature, extracted into ethylacetate, washed with water and brine, dried over Na₂SO₄, andconcentrated in vacuo to obtain an oil. To the oil in 6 ml ofdichloromethane was added MCPBA (0.318 g) and the reaction stirred atroom temperature for 3 h. The excess MCPBA was quenched with aqueoussodium sulfite, and the organic layer was washed with water, 5% NaHCO₃and brine, dried over Na₂SO₄, and concentrated in vacuo to yieldcompound 3C. [M+H] Calc'd for C₁₇H₂₅NO₅S, 356.50. Found, 356.5

To a solution of compound 3C (0.131 g) in dioxane (4 ml) was added 1.27ml of a 1N LiOH solution and the reaction mixture stirred overnight atroom temperature. The reaction mixture was diluted with ethyl acetate,and the separated aqueous layer was acidified with 1N hydrochloric acidto pH 2. The aqueous layer was extracted with ethyl acetate (2×), andwashed with water and brine, dried over Na₂SO₄, and concentrated invacuo to obtain the intermediate acid. [M+H] Calc'd for C₁₆H₂₃NO₅S,342.42. Found, 342.5

To the intermediate acid in DMF (3 ml) was added HBTU (0.33 g) and Et₃N(0.15 ml). After 20 min., 2-aminothiazole (0.065 g) was added and thereaction mixture stirred overnight at room temperature. The reactionmixture was extracted into ethyl acetate, and the organic layer waswashed with water and brine, dried over Na₂SO₄, and concentrated invacuo. Purification by HPLC afforded the title compound (3) as acolorless solid. ¹H NMR (400 MHz, CDCl₃) δ 0.9-1.35 (m, 7H), 1.60-1.82(m, 5H), 2.47 (m, 1H), 2.52 (s, 3H), 3.08 (s, 3H), 5.0 (bs, 1H), 6.45(d, J=4 Hz, 1H), 6.99 (s, 1H), 7.00 (s, 1H), 7.42 (d, J=4 Hz, 1H). [M+H]Calc'd for C₁₉H₂₅N₃O₄S₂, 424.5. Found, 424.5.

Compound 3 was separated into its enantiomers under SFC conditions,using a chiral column (ChiralPak OJ-H) with mobile Phase A: liquid CO₂and mobile Phase B: methanol at a flow rate of 20 min/ml. [M+H] Calc'dfor C₁₉H₂₅N₃O₄S₂, 424.5. Found, 424.5

Example 43-cyclohexyl-2-(4-(ethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamidetrifluoroacetic acid salt

The title compound was synthesized using an analogous procedure to thatdescribed in connection with Example 3, except that sodiumethanethiolate was used. ¹H NMR (400 MHz, CDCl₃) δ 0.95-1.30 (m, 5H),1.28 (t, J=4 Hz, 3H), 1.4-1.90 (m, 7H), 2.59 (s, 3H), 2.73 (m, 1H), 3.10(q, J=4 Hz, 2H), 4.8 (bs, 1H), 6.54 (d, J=4 Hz, 1H), 6.90 (d, J=4 Hz,1H), 7.10 (d, J=4 Hz, 1H), 7.43 (d, J=4 Hz, 1H). [M+H] Calc'd forC₂₀H₂₇N₃O₄S₂, 438.5. Found, 438.5.

Example 53-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamidetrifluoroacetic acid salt

The title compound was synthesized using an analogous procedure to thatdescribed in connection with Example 3, except that sodiumcyclopentylthiolate was used. ¹H NMR (400 MHz, CDCl₃) δ 0.90-1.35 (m,5H), 1.45-2.20 (m, 16H), 2.58 (s, 3H), 2.71 (m, 1H), 3.45 (m, 1H), 6.54(d, J=4 Hz, 1H), 6.88 (d, J=4 Hz, 1H), 7.10 (d, J=4 Hz, 1H), 7.41 (d,J=4 Hz, 1H). [M+H] Calc'd for C₂₃H₃₁N₃O₄S₂, 478.6. Found, 478.6.

Example 66-(3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamido)nicotinamidetrifluoroacetic acid salt

The title compound was synthesized using an analogous procedure to thatdescribed in connection with Example 3, except that sodiumcyclopentylthiolate was used. ¹H NMR (400 MHz, CDCl₃) δ 0.90-1.4 (m,5H), 1.6-2.20 (m, 16H), 2.48 (m, 1H), 2.59 (s, 3H), 3.57 (m, 1H), 6.56(bs, 1H), 6.96 (bs, 1H), 8.26 (bs, 2H), 8.77 (bs, 1H). [M+H] Calc'd forC₂₆H₃₄N₄O₅S, 515.6. Found 514.6.

Example 72-(6-methyl-4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazol-2-yl)propanamidetrifluoroacetic acid salt

The title compound was synthesized using an analogous procedure to thatdescribed in connection with Example 3, except that2-amino-3-(4-tetrahydropyranyl)-propionic acid was used in place of2-amino-3-cyclohexylpropanoic acid in the first step. ¹H NMR (400 MHz,CDCl₃) δ 1.3-1.9 (m, 7H), 2.61 (s, 3H), 2.87 (m, 1H), 3.04 (s, 3H), 3.45(m, 2H), 4.0 (m, 2H), 4.89 (bs, 1H), 6.61 (s, 1H), 6.96 (s, 1H), 7.14(d, J=4 Hz, 1H), 7.47 (d, J=4 Hz, 1H), [M+H] Calc'd for C₁₈H₂₃N₃O₅S,426.5. Found 426.5.

Method D

Compounds designated in Table 1 below as being prepared using Method Dwere prepared using a procedure analogous to that described inconnection with Example 8.

Example 83-cyclohexyl-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamidetrifluoroacetic acid salt

To dimethyl 1,3-acetonedicarboxylate (0.87 g) was added triethylorthoformate (0.741 g) followed by acetic anhydride (0.969 g). Theresulting solution was stirred for 1 h at 135° C. The reaction mixturewas cooled to room temperature and concentrated under reduced pressure.To the resulting residue at 0° C. was added methyl2-amino-3-cyclohexylpropanoate in methanol (30 ml) and the solution wasstirred at room temperature overnight. The reaction mixture wasconcentrated under reduced pressure, diluted with ethyl acetate, washedwith water and brine, dried over Na₂SO₄, and concentrated in vacuo toyield compound 8A. [M+H] Calc'd for C₁₇H₂₃NO₆, 338.37. Found, 338.4.

Compound 8A (1.0 g) was dissolved in 30 ml of 48% concentrated HBr andthe solution was refluxed at 170° C. for 2 days. The reaction mixturewas concentrated under reduced pressure, diluted with ethyl acetate,washed with water, saturated bicarbonate solution and brine, dried overNa₂SO₄, and concentrated in vacuo to yield compound 8B. [M+H] Calc'd forC₁₄H₁₉NO₄, 266.3. Found, 266.3

The title compound was synthesized using compound 8B in an analogousprocedure to that described in connection with Example 3. ¹H NMR (400MHz, CDCl₃) δ 0.90-1.25 (m, 5H), 1.59-2.18 (m, 16H), 3.51 (m, 1H), 6.18(t, J=8 Hz, 1H), 6.96 (dd, J=4, 8 Hz, 2H), 7.04 (d, J=4 Hz, 1H), 7.59(d, J=3 Hz, 1H), 7.62 (d, J=4 Hz, 1H), 7.95 (d, J=8 Hz, 1H), [M+H]Calc'd for C₂₂H₂₉N₃O₄S₂, 464.6. Found 464.6.

Method E

Compounds designated in Table 1 below as being prepared using Method Ewere prepared using a procedure analogous to that described inconnection with Example 9.

Example 93-(2-chloro-5-fluorophenyl)-N-(5-chlorothiazol-2-yl)-2-(4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)propanamide

4-bromo-2-chloropyridine (5.0 g, 26 mmole), NiBr (0.567 g, 2.6 mmole),2,2′-bipyridine (0.406 g, 2.6 mmole), Zinc dust (3.4 g, 52 mmole) and1,2-dimethyldisulfane (1.2 g, 13 mmole) were added to a solution of DMF(25 mL) and the mixture was heated under N₂ for 18 h at 100° C. Thesolvent was removed from the crude reaction mixture under vacuum and theorange gum was treated with MeOH. The resulting ppt was filtered anddiscarded. The filtrate was purified with silica column chromatographyusing 5% MeOH in CH₂Cl₂; compound 9A was obtained as clear oil (1.1 g,27% yield); [M+H] Calc'd for C₆H₇ClNS, 159.99. Found 160.1.

Compound 9A (2.0 g, 12.5 mmole) was added to a microwave vial with 6 NHCl (4 mL) and the mixture was heated at 200° C. for 1 h. The solventwas removed under vacuum and MeOH was added. The product 9B was isolatedwith preparative HPLC to afford a tan solid (0.75 g, 42% yield). ¹H NMR(400 MHz, CDCl₃) δ 2.48 (s, 3H) 6.36-6.43 (m, 2H) 7.30 (d, J=7.33 Hz,1H); [M+H] Calc'd for C₆H₈NOS, 142.02. Found 142.1.

Compound 9B (0.228 g, 1.61 mmole) was dissolved in DMF (5 mL), thesolution was chilled to 0° C. and NaH (0.043 g, 1.77 mmole) was added.When the reaction subsided, NaI (0.265 g, 1.77 mmole) was added alongwith tert-butyl 2-bromoacetate (0.345 g, 1.77 mmole) and the mixture wasallowed to warm to RT over 3 h. Subsequently the solvent was removedunder vacuum and the crude residue was subjected to columnchromatography eluted with 1:1 EtOAc/Hexanes followed by 100% EtOAc toafford product 9C as a white solid (0.14 g, 34% yield). [M+H] Calc'd forC₁₂H₁₈NO₃S, 256.09. Found 256.1.

Compound 9C (0.140 g, 0.55 mmole) was dissolved in THF (10 mL) andcooled to −78° C. A solution of 1.8 M LDA (0.455 mL, 0.82 mmole) wasadded and the resultant orange soln. was stirred for 15 min. To thismixture 2-(bromomethyl)-1-chloro-4-fluorobenzene (0.184 g, 0.82 mmole)was added and the reaction was allowed to warm to RT overnight. Thecrude reaction mixture was partitioned between EtOAc and H₂O, theorganic layer was dried over Na₂SO₄ and the solvent was removed undervacuum. The crude residue was subjected to column chromatography elutedwith a Hexanes/EtOAc gradient to afford product 9D as a white solid(0.161 g, 74% yield). [M⁺-C₄H₉] Calc'd for C₁₅H₁₄ClFNO₃S, 342.03. Found342.1.

Compound 9D (0.161 g, 0.41 mmole) was dissolved in CH₂Cl₂ (10 mL) thesoln. was cooled to 0° C. and mCPBA (0.175 g, 1.01 mmole) was added. Thecooling bath was removed after 20 min and the reaction mixture wasstirred for an additional 2 h.

LC/MS indicated conversion to the desired sulfone; the reaction waswashed with NaHCO₃ (saturated) and the organic layer was dried overNa₂SO₄. The crude residue was subjected to column chromatographyaffording the product (0.140 g) as an oil. This material was thentreated with a 50% soln of TFA in CH₂Cl₂ (4 mL) for 15 min. The solventwas removed under vacuum, small amounts of MeOH were added and removedunder vacuum to purge residual TFA (3×). MeOH was then added followed bytrimethylsilyldiazomethane until a yellow color persisted. The reactionwas quenched with AcOH and the solvent was removed under vacuum toafford crude 9E. [M+H] Calc'd for C₁₆Hl₆ClFNO₅S, 388.03. Found 388.0.

To 4 mL of chilled DCE (0° C.) was added 1M (CH₃)₃Al (0.8 mL) and themixture was stirred for 5 min. 5-chlorothiazol-2-amine hydrochloride(0.069 g, 0.40 mmole) was added and the reaction mixture was allowed towarm to RT over 40 min. A soln. of compound 9E (0.052 g, 0.134 mmole) inDCE (3 mL) was added and the reaction mixture was heated for 2 h at 110°C. The reaction was quenched with 1N HCl and extracted with CH₂Cl₂. Theorganics were dried over Na₂SO₄ and the solvent was removed undervacuum. Preparative HPLC of the crude residue afforded compound 9 as atan solid (0.023 g, 35% yield). ¹H NMR (400 MHz, MeOD) δ ppm 3.15 (s,3H) 3.49-3.67 (m, 1H) 3.67-3.81 (m, 1H) 5.86 (dd, J=9.35, 6.06 Hz, 1H)6.71 (dd, J=7.20, 1.89 Hz, 1H) 6.94-7.10 (m, 3H) 7.31 (s, 1H) 7.39 (dd,J=8.72, 5.18 Hz, 1H) 7.89 (d, J=7.33 Hz, 1H); [M+H] Calc'd forC₁₈H₁₅C₁₂FN₃O₄S₂, 489.98. Found 489.8.

Method F

Compounds designated in Table 1 below as being prepared using Method Fwere prepared from Example 61 by a Suzuki coupling.

Method G

Compounds designated in Table 1 below as being prepared using Method Gwere prepared using a procedure analogous to that described inconnection with Example 77.

Example 772-(3-chloro-4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-cyclohexylpropanamide

To 4-chloro-6-methyl-3-nitropyridin-2(1H)-one (1 g, 5.3 mmol) in 10 mlof DMF at 0° C. was added NaH (0.133 g, 5.56 mmol). After 10 minutes,LiBr (0.9 g, 10.6 mmol) was added and the reaction was allowed to stirat room temperature for 15 minutes followed by the addition of methyl2-bromo-3-cyclohexylpropanoate in 3 ml of DMF. The reaction was heatedat 65° C. overnight. The reaction mixture was extracted into ethylacetate, and the organic layer was washed with water and brine, driedover Na₂SO₄, and concentrated in vacuo to yield an oil which waspurified with silica chromatography using 75% EtOAc in hexanes to obtaincompound 77A as an oil (1.32 g, 70% yield). [M+H] Calc'd C₁₆H₂₁ClN₂O₅,356.80. Found, 356.9.

Compound 77A (0.38 g, 1.14 mmol) was dissolved in 5 ml of DMF and tothis was added sodium cyclopropanesulfinate (0.13 g, 1.09 mmol). Thereaction mixture was heated at overnight at 80° C. The reaction mixturewas extracted into ethyl acetate, and the organic layer was washed withwater and brine, dried over Na₂SO₄, and concentrated in vacuo to yieldcompound 77B as an oil in quantitative yield. [M+H] Calc'd C₁₉H₂₆N₂O₇S,427.48. Found 427.6.

To compound 77B (0.44 g, 1.04 mmol) in 6 ml of EtOH was added acatalytic amount of Pd/C and the reaction mixture degassed and flushedwith hydrogen gas. The reaction was stirred under hydrogen overnight.The Pd/C was filtered through celite and the filtrate was concentratedto obtain compound 77C as an oil in quantitative yield. [M+H] Calc'dC₁₉H₂₈N₂O₇S, 429.48. Found 429.6.

To t-butyl nitrite (0.160 g, 1.56 mmol) and cupric chloride (0.167 g,1.24 mmol) in acetonitrile was added 77 C (0.41 g, 1.04 mmol) at roomtemperature and the solution was heated at 65° C. overnight. Thereaction mixture was extracted into ethyl acetate, and the organic layerwas washed with water and brine, dried over Na₂SO₄, and concentrated invacuo to yield an oil which was purified with silica chromatographyusing 25% EtOAc in hexanes to obtain compound 77D as an oil (0.06 g, 14%yield). [M+H] Calc'd C₁₉H₂₆ClNO₅S, 416.93. Found, 417.0.

Compound 77 was obtained by treating compound 77D with5-chloro-2-aminothiazole in the presence of (CH₃)₃Al using the proceduredescribed in connection with Example 9 (Method E)

Method H

Compounds designated in Table 1 below as being prepared using Method Hwere prepared using a procedure analogous to that described inconnection with Example 79.

Example 793-cyclohexyl-2-(6-methyl-4-morpholino-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide

Compound 79A was synthesized using the procedure described in connectionwith Example 9 (Method C). Compound 79A (100 mg, 0.24 mmol) andmorpholine (61.0 mg, 0.71 mmol) in DMF (3 ml) was heated at 140° C.overnight. The product was purified by HPLC to yield compound 7986.7 mg.[M+H] Calc'd for C₂₂H₃₀N₄O₃S, 431.57. ¹H NMR (400 MHz, MeOD). δ ppm 0.96(m, 3H) 1.21 (m, 5H) 1.66 (m, 5H) 1.87 (m, 2H) 2.24 (m, 1H) 2.37 m, 4H),3.76 (m, 5H) 5.58 (m, 1H) 6.16n (s, 1H) 6.64 (d, J=4 Hz, 1H) 7.02 (d,J=4 Hz, 1H).

Method I

Compounds designated in Table 1 below as being prepared using Method Iwere prepared using a procedure analogous to that described inconnection with Example 137.

Example 137N-(5-chlorothiazol-2-yl)-2-(4-(3-hydroxyprop-1-ynyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide

Compound 137A was synthesized using the procedure described inconnection with Example 1 (Method A). Compound 137A (0.51 g, 1.75 mmol)was dissolved in methylene chloride (5 ml) and to this was addedtriethyl amine (0.365 ml, 2.625 mmol). The reaction mixture was cooledto 0° C. Tf₂O (0.353 ml, 2.10 mmol) was added slowly dropwise and thereaction mixture stirred for 1 h. Solvent removed in vacuo. The residuewas dissolved in DMF (2 ml) and transferred to a microwave vail.Propargyl alcohol (0.173 ml, 1.93 mmol), PdCl₂(PPh₃)₂ (8.3 mg, 0.035mmol), iPrNEt₃ (0.355 ml, 2.04 mmol) were added and the mixture heatedin microwave at 100° C. for 15 min. The reaction mixture was dilutedwith ethyl acetate, filtered through celite and concentrated to yieldcompound 137B. [M+H] Calc'd C₁₈H₂₄NO₅, 334.16. Found 334.21. The titlecompound (137) was synthesized using the procedure described inconnection with Example 9 (Method E).

Method J

Compounds designated in Table 1 below as being prepared using Method Jwere prepared using a procedure analogous to that described inconnection with Example 151.

Example 1512-(4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide

Compound 151A was synthesized as reported in Tetrahedron 62, 2006,6945-6954. Compound 151B was synthesized using the procedure describedin connection with Example 77 (Method G). Compound 151C was synthesizedusing the procedure described in connection with Example 3 (Method C)and the title compound (151) was synthesized using the proceduredescribed in connection with Example 9 (Method E).

Method K

Compounds designated in Table 1 below as being prepared using Method Kwere prepared using a procedure analogous to that described inconnection with Example 172.

Example 172N-(5-chlorothiazol-2-yl)-2-(4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide

Compound 172A was synthesized using the procedure described inconnection with Example 1 (Method A).

To the mixture of 172A (1.28 g, 4.08 mmol) and cyclopropylsulfinic acidsodium salt (1.08 g, 8.50 mmol) was added dry N-Methyl-2-pyrrolidone(NMP) (5.8 ml). The reaction was placed in microwave and heated for 45minutes at 180° C. The reaction was cooled, diluted with EtOAc andfiltered through celite. To the filtrate was added 1NHCl. And the layerswere separated and the organic phase was washed with brine, dried overNa₂SO₄, and concentrated in vacuo to yield compound 172B.

To 5-chlorothiazol-2-amine hydrochloride (0.545 g, 3.19 mmole) in DCE (4ml) was added 2M (CH₃)₃Al (1.59 mL, 3.18 mmol) dropwise at 0° C. underN₂ for 15 minutes. Then the solution of compound 1B (0.204 g, 0.531mmole) in 4 ml of DCE was added to the reaction mixture dropwise. Afteraddition, the ice bath was removed, the reaction was stirred at roomtemperature for 0.5 hour, and then it was heated in a microwave at 110°C. for 1 hr. The reaction was quenched with 1N HCl and extracted withCH₂Cl₂. The organics were dried over Na₂SO₄ and the solvent was removedunder vacuum. Preparative HPLC of the crude residue afforded compound172. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.10-1.22 (m, 2H) 1.29-1.46(m, 4H) 1.59-1.88 (m, 2H) 2.36-2.61 (m, 4H) 2.66 (d, J=3.79 Hz, 1H) 3.40(td, J=11.24, 5.81 Hz, 2H) 3.97 (d, J=11.12 Hz, 5H) 6.53 (br. s., 1H)6.95 (br. s., 1H) 7.24 (s, 1H).

Method L

Compounds designated in Table 1 below as being prepared using Method Lwere prepared using a procedure analogous to that described inconnection with Example 174.

Example 174N-(5-chlorothiazol-2-yl)-3-cyclohexyl-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4-ylsulfonyl)pyridin-1(2H)-yl)propanamide

Compound 174A was synthesized using the procedure described inconnection with compound 3. To a solution of compound 174A (1.315 g,3.85 mmol) in DMF (14 ml) was added a solution of sodium sulfhydrate(323.0 mg, 5.77 mmol) in H₂O (3 ml). The reaction mixture was subjectedto microwave heating at 100° C. for 30 minutes. The reaction solutionwas diluted with water and extracted with ethylacetate, dried overmagnesium sulfate, concentrated under high vacuum to yield compound 174B1.043 g. To a solution of compound 174B (500.0 mg, 1.69 mmol) in DMF (8ml) was added sodium hydride at 0° C., followed by a solution of4-iodotetrahydro-2H-pyran. The mixture was heated under nitrogen at 80°C. overnight. The reaction solution was diluted with water and extractedwith ethylacetate, dried over magnesium sulfate, and concentrated underhigh vacuum to yield compound 174C (273 mg). Compound 174C was oxidizedwith m-chloroperoxybenzoic acid to yield compound 174D. Compound 174 wasgenerated using the procedure described in connection with compound 9.[M+H] Calc'd for C₂₂H₂₈ClN₃O₅S₂, 515.06. Found 515. ¹H NMR (400 MHz,MeOD). δ ppm 1.04 (m, 1H) 1.28 (m, 1H) 1.59 (m, 5H) 1.84 (m, 6H) 2.12(m, 1H) 2.60 (m, 4H) 3.41 (m, 2H) 3.54 (m, 1H) 4.03 (m, 2H) 5.29 (m, 1H)6.69 (s, 1H) 6.82 (s, 1H) 7.29 (s, 1H).

The above reaction schemes and variations thereof have been used toprepare the following compounds listed in Table 1.

TABLE 1 Ex. Structure Method LCMS ([M + H]) NMR data 1

  3-cyclohexyl-2-(4-hydroxy-6- methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide A calc'd for C₁₅H₂₁NO₄, 280.33; found 280.3¹H NMR (400 MeOD) δ 0.8-1.93 (m, 13 H) 2.30 (m, 1 H), 2.36 (s, 3 H),5.67 (s, 1 H), 5.93 2

  3-cyclohexyl-2-(4-methoxy-6- methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide B calc'd for C₁₈H₂₃N₃O₃S 376.49; found376.4. ¹H NMR (400 MHz, CDCl₃) δ 0.9-1.38 (m, 7 H), 1.58-1.82 (m, 5 H),2.39 (s, 3 H), 2.46 (m, 1 H), 3.76 (s, 3H), 5.81 (s, 1 H), 5.84 (s, 1H), 6.97 (d, J = 4 Hz, 1 H), 7.42 (d, J = 4 Hz, 1 H). 3

  3-cyclohexyl-2-(6-methyl-4- (methylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol-2- yl)propanamide C calc'd for C₁₆H₂₂ClNO₃, 312.80found, 312.8 ¹H NMR (400 MHz, CDCl₃) δ 0.8-1.7 (m, 13 H), 2.27 (s, 3 H),2.35 (m, 1H), 3.64 (s, 3 H), 6.03 (d, J = 4 Hz, 1 H), 6.40 (d, J = 4 Hz,1 H). [M + H] 4

  3-cyclohexyl-2-(4- (ethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide C calc'd forC₂₀H₂₇N₃O₄S₂ 438.5; found 438.5 ¹HNMR (400 MHz, CDCl₃) δ 0.95-1.30 (m, 5H), 1.28 (t, J = 4 Hz, 3 H), 1.4-1.90 (m, 7 H), 2.59 (s, 3 H), 2.73 (m,1 H), 3.10 (q, J = 4 Hz, 2 H), 4.8 (bs, 1 H), 6.54 (d, J = 4 Hz, 1 H),6.90 (d, J = 4 Hz, 1 H), 7.10 (d, J = 4 Hz, 1 H), 7.43 (d, J = 4 Hz, 1H). 5

  3-cyclohexyl-2-(4- (cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N- (thiazol-2-yl)propanamide C calc'd forC₂₃H₃₁N₃O₄S₂ 478.6; found, 478.6 ¹H NMR (400 MHz, CDCl₃) δ 0.90-1.35 (m,5 H), 1.45-2.20 (m, 16 H), 2.58 (s, 3 H), 2.71 (m, 1 H), 3.45 (m, 1 H),6.54 (d, J = 4 Hz, 1 H), 6.88 (d, J = 4 Hz, 1 H), 7.10 (d, J = 4 Hz, 1H), 7.41 (d, J = 4 Hz, 1 H). 6

  6-(3-cyclohexyl-2-(4- (cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)- yl)propanamido)nicotinamide C calc'd for C₂₆H₃₄N₄O₅S515.6; found 514.6 ¹H NMR (400 MHz, CDCl₃) δ 0.90-1.4 (m, 5 H), 1.6-2.20(m, 16 H), 2.48 (m, 1 H), 2.59 (s, 3 H), 3.57 (m, 1 H), 6.56 (bs, 1 H),6.96 (bs, 1 H), 8.26 (bs, 2 H), 8.77 (bs, 1 H). 7

  2-(6-methyl-4-(methylsulfonyl)- 2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N- (thiazol-2-yl)propanamide C calc'd forC₁₈H₂₃N₃O₅S 426.5; found 426.5 ¹H NMR (400 MHz, CDCl₃) δ 1.3-1.9 (m, 7H), 2.61 (s, 3 H), 2.87 (m, 1 H), 3.04 (s, 3 H), 3.45 (m, 2 H), 4.0 (m,2 H), 4.89 (bs, 1 H), 6.61 (s, 1 H), 6.96 (s, 1 H), 7.14 (d, J = 4 Hz, 1H), 7.47 (d, J = 4 Hz, 1 H). 8

  3-cyclohexyl-2-(4- (cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide D calc'd forC₂₂H₂₉N₃O₄S₂ 464.16; found 464.0 ¹H NMR (400 MHz, CDCl₃) δ 0.90-1.25 (m,5 H), 1.59-2.18 (m, 16 H), 3.51 (m, 1 H), 6.18 (t, J = 8 Hz, 1 H), 6.96(dd, J = 4, 8 Hz, 2 H), 7.04 (d, J = 4 Hz, 1 H), 7.59 (d, J = 3 Hz, 1H),7.62 (d, J = 4 Hz, 1H), 7.95 (d, J = 8 Hz, 1 H) 9

  3-(2-chloro-5-fluorophenyl)-N- (5-chlorothiazol-2-yl)-2-(4-(methylsulfonyl)-2-oxopyridin- 1(2H)-yl)propanamide E calc'd forC₁₈H₁₅C₁₂FN₃O₄S₂, 489.98; found 489.8. ¹H NMR (400 MHz, MeOD) δ ppm 3.15(s, 3 H) 3.49-3.67 (m, 1 H) 3.67-3.81 (m, 1 H) 5.86 (dd, J = 9.35, 6.06Hz, 1 H) 6.71 (dd, J = 7.20, 1.89 Hz, 1 H) 6.94-7.10 (m, 3 H) 7.31 (s, 1H) 7.39 (dd, J = 8.72, 5.18 Hz, 1 H) 7.89 (d, J = 7.33 Hz, 1 H) 10

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)-3-p- tolylpropanamide C calc'd for C₂₄H₂₇N₃O₄S₂ 486.14;found 486.02 ¹H NMR (400 MHz, CDCl₃) δ 1.62-2.09 (m, 11 H), 2.30 (s,3H), 3.45 (m, 1 H), 3.62 (m, 1H), 3.74 (m, 1 H), 5.0 (bs, 1H), 6.24 (s,1 H), 6.92 (d, J = 8 Hz, 2 H), 6.97 (s, 1 H), 7.02 (m, 3 H), 7.41 (d, J= 3 Hz, 1 H) 11

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-4-methyl-N-(thiazol-2- yl)pentanamide C calc'd for C₂₀H₂₇N₃O₄S₂ 438.14;found 437.98 ¹H NMR (400 MHz, CDC1₃) δ 0.97 (d, J = 4 Hz, 3 H), 1.01 (d,J = 4 Hz, 3 H), 1.59-2.16 (m, 10 H), 2.52 (m, 1H), 2.58 (s, 3H), 3.48(m, 1 H), 4.89 (bs, 1H), 6.52 (s, 1 H), 6.94 (s, 1 H), 7.06 (s, 1 H),7.44 (s, 1 H). 12

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-cyclopropyl-N-(thiazol-2- yl)propanamide C calc'd for C₂₀H₂₅N₃O₄S₂436.13; found 436.0 ¹H NMR (400 MHz, MeOD) δ 0.18 (m, 1 H), 0.39 (m, 1H), 0.71 (m, 2 H), 0.82 (m, 1 H), 1.90 (m, 2 H), 2.04 (m, 2 H), 2.22 (m,4 H), 2,42 (m, 1 H), 2.56 (m, 1 H), 2.89 (s, 3H), 3.81 (q, J = 8 Hz, 1H), 5.41 (bs, 1H), 6.83 (s, 1 H), 7.10 (s, 1 H), 7.39 (s, 1 H), 7.71 (s,1 H) 13

  (S)-3-cyclohexyl-2-(4- (cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide C calc'd forC₂₂H₂₉N₃O₄S₂ 464.16; found 464.10 14

  3-cyclopentyl-2-(4- (cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N- (thiazol-2-yl)propanamide C calc'd forC₂₂H₂₉N₃O₄S₂ 464.16; found 464.10 ¹H NMR (400 MHz, CDC1₃) δ 1.06-1.26(m, 2 H), 1.47-2.15 (m, 16 H), 2.53 (m, 1 H), 2.57 (s, 3 H), 3.48 (q, J= 8 Hz, 1 H), 4.90 (bs, 1 H), 6.51 (s, 1 H), 6.96 (s, 1 H), 7.03 (d, J =4 Hz, 1 H), 7.44 (d, J = 4 Hz, 1 H) 15

  N-(5-chlorothiazol-2-yl)-2-(4- (methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(thiophen-3- yl)propanamide E calc'd for C₁₆H₁₅ClN₃O₄S₃443.98; found 443.8 ¹H NMR (400 MHz, MeOD) δ ppm 3.13 (s, 3 H) 3.48 (d,J = 9.85 Hz, 2 H) 6.00 (dd, J = 10.23, 5.94 Hz, 1 H) 6.71 (dd, J = 7.45,1.89 Hz, 1 H) 6.95 (dd, J = 5.05, 1.01 Hz, 1 H) 6.99 (d, J = 2.02 Hz, 1H) 7.10 (s, 1 H) 7.29 (d, J = 7.83 Hz, 1 H) 7.29 (s, 1 H) 7.76 (s, 1 H)8.01 (d, J = 7.58 Hz, 1 H) 16

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N- (thiazol-2-yl)propanamide C calc'd forC₂₂H₂₉N₃O₅S₂ 480.15; found 480.10 ¹H NMR (400 MHz, CDC1₃) δ 1.30-1.45(m, 3 H), 1.6-2.15 (m, 12 H), 2.50 (s, 3 H), 2.65 (m, 1 H), 3.25 (bs, 2H), 3.38 (m, 2 H), 3.55 (m, 1 H), 3.96 (m, 2H), 6.51 (s, 1 H), 6.98 (s,1 H), 7.02 (s, 1 H), 7.41 (s, 1H) 17

  N-(5-chlorothiazol-2-yl)-3-(2,6- dichlorophenyl)-2-(4-(methylsulfonyl)-2-oxopyridin- 1(2H)-yl)propanamide E calc'd forC1₈H1₅C1₃N₃O₄S₂ 505.95; found 506.0 ¹H NMR (400 MHz, CDC1₃) δ ppm 3.06(s, 3 H) 3.72 (dd, 1 H) 3.89 (dd, J = 14.15, 6.32 Hz, 1 H) 5.85 (br. s.,1 H) 6.64 (dd, J = 7.07, 1.77 Hz, 1 H) 7.11- 7.21 (m, 3H) 7.25 (s, 2 H)7.73 (br. s., 1 H) 18

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)hexanamide C calc'd for C₂₀H₂₇N₃O₄S₂ 438.14; found438.10 ¹H NMR (400 MHz, CDC1₃) δ 0.91 (t, J = 8 Hz, 3 1H), 1.09-2.16 (m,14 H), 2.44 (m, 1H), 2.55 (s, 3H), 3.48 (m, 1 H), 4.89 (bs, 1H), 6.51(s, 1 H), 6.95 (s, 1 H), 7.04 (d, J = 4 Hz, 1 H), 7.44 (s, 1 H). 19

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-5-methyl-N-(thiazol-2- yl)hexanamide C calc'd for C₂₁H₂₉N₃O₄S₂ 452.16;found 452.10 ¹H NMR (400 MHz, CDC1₃) δ 0.90 (d, J = 8 Hz, 3 H), 0.93 (d,J = 8 Hz, 3 H), 1.26-2.36 (m, 13 H), 2.48 (m, 1H), 2.55 (s, 3H), 3.55(m, 1 H), 4.89 (bs, 1 H), 6.54 (s, 1 H), 6.95 (s, 1 H), 7.08 (s, 1 H),7.47 (s, 1 H). 20

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-(3-methoxyphenyl)-N-(thiazol- 2-yl)propanamide C calc'd forC₂₄H₂₇N₃O₅S₂, 502; found, 502 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.60(s, 3 H) 1.77-1.87 (m, 2 H) 1.87-1.98 (m, 2 H) 1.98-2.11 (m, 4 H)3.40-3.50 (m, 1 H) 3.55- 3.64 (m, 1 H) 3.71 (s, 3 H) 3.76-3.91 (m, 1 H)4.93- 5.06 (m, 1 H) 6.26 (br. s., 1 H) 6.55 (br. s., 1 H) 6.65 (d, J =7.58 Hz, 1 H) 6.77 (dd, J = 8.21, 2.65 Hz, 1 H) 7.01 (d, J = 2.78 Hz,2H) 7.16 (t, J = 7.96 Hz, 1 H) 7.44 (d, J = 3.54 Hz, 1 H) 21

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-(furan-2-yl)-N-(thiazol-2- yl)propanamide C calc'd for C₂₁H₂₃N₃O₅S₂462.11; found 462.0 ¹H NMR (400 MHz, CDCl₃) δ 1.59-2.11 (m, 9 H), 2.16(s, 3H), 3.45 (m, 1 H), 3.76 (m, 2H), 5.10 (bs, 1 H), 6.00 (d, J = 4 Hz,1 H), 6.26 (m, 1 H), 6.36 (s, 1 H), 6.94 (s, 2 H), 7.06 (d, J = 4 Hz, 1H), 7.31 (s, 1 H), 7.41 (d, J = 4 Hz, 1 H) 22

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide E calc'dfor C₁₇H₂₁ClN₃O₅S₂ 446.05; found 446.12 ¹H NMR (400 MHz, CDCl₃) δ ppm1.39 (br. s., 1 H) 1.42 (d, J = 3.54 Hz, 2 H) 1.63 (d, J = 12.13 Hz, 1H) 1.71 (br. s., 1 H) 1.86- 2.09 (m, 1 H) 2.13-2.36 (m, 1 H) 3.10 (s, 3H) 3.21- 3.44 (m, 2 H) 3.97 (d, J = 11.62 Hz, 2 H) 5.93 (dd, J = 8.84,6.32 Hz, 1 H) 6.75 (dd, J = 7.20, 1.89 Hz, 1 H) 7.34 (s, 1 H) 7.40 (d, J= 2.02 Hz, 1 H) 7.76 (d, J = 7.33 Hz, 1 H) 23

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(methylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide E calc'dfor C₁₇H₂₁ClN₃O₅S₂ 446.05; found 446.12 24

  N-(5-chlorothiazol-2-yl)-3-(3,5- dimethylphenyl)-2-(4-(methylsulfonyl)-2-oxopyridin- 1(2H)-yl)propanamide E calc'd forC₂₀H₂₁ClN₃O₄S₂ 466.06; found 466.1 ¹H NMR (400 MHz, CDCl₃) δ ppm 2.21(s, 6 H) 3.04 (s, 3 H) 3.18-3.35 (m, 2 H) 3.44-3.62 (m, 1 H) 5.48 (br.s., 1 H) 6.57 (d, J = 6.82 Hz, 1 H) 6.71 (s, 2H) 6.86 (s, 1 H) 7.18 (s,1 H) 7.48 (d, J = 7.83 Hz, 1 H) 25

  N-(5-chlorothiazol-2-yl)-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-4,4- dimethylpentanamide C calc'd forC₁₉H₂₅ClN₃O₄S₂ 458.09; found 458.0 ¹H NMR (400 MHz, CDCl₃) δ ppm 0.96(s, 9 H) 1.08-1.19 (m, 2 H) 1.22-1.29 (m, 2 H) 1.36- 1.41 (m, 1 H)2.42-2.52 (m, 1 H) 2.64 (s, 3 H) 2.73- 2.83 (m, 1 H) 4.88 (br. s., 1 H)6.54 (br. s., 1 H) 6.93 (br. s., 1 H) 7.28 (br. s., 2 H) 26

  N-(5-chlorothiazol-2-yl)-2-(4- (methylsulfonyl)-2-oxopyridin-1(2H)-yl)hex-4-ynamide E calc'd for C₁₅H₁₅ClN₃O₄S₂ 400.01; found 400.1¹H NMR (400 MHz, CDCl₃) δ ppm 1.16-1.36 (m, 1 H) 1.26 (s, 0 H) 1.72 (s,3 H) 2.05 (s, 0 H) 2.89- 3.06 (m, 2 H) 3.09 (s, 3 H) 6.05 (t, J = 7.58Hz, 1 H) 6.74 (d, J = 7.33 Hz, 1 H) 7.39 (s, 1 H) 7.53 (s, 1 H) 7.93 (d,J = 7.33 Hz, 1 H) 27

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-(4-methoxyphenyl)-N-(thiazol- 2-yl)propanamide C calc'd forC₂₄H₂₇N₃O₅S₂, 502; found, 502 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.54- 1.73(m, 4H) 1.76-1.87 (m, 4H) 1.89 (s, 3 H) 3.26- 3.35 (m, 1 H) 3.44-3.54(m, 1 H) 3.67 (s, 3 H) 3.79- 3.91 (m, 1 H) 5.30-5.40 (m, 1 H) 6.34 (d, J= 1.77 Hz, 1 H) 6.68 (s, 1 H) 6.73 (d, J = 8.34 Hz, 2 H) 6.91 (d, J =8.34 Hz, 2 H) 7.21 (d, J = 3.54 Hz, 1 H) 7.44 (d, J = 3.54 Hz, 1 H) 28

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-(4-hydroxyphenyl)-N-(thiazol- 2-yl)propanamide C calc'd forC₂₃H₂₅N₃O₅S₂, 488; found, 488 ¹H NMR (400 MHz, MeOD) δ ppm 1.64-1.86 (m,4 H) 1.87-1.99 (m, 4 H) 2.01 (s, 3 H) 3.45-3.54 (m, 1 H) 3.55-3.64 (m, 1H) 3.69-3.81 (m, 1 H) 5.42 (dd, J = 10.48, 3.92 Hz, 1 H) 6.48 (d, J =1.26 Hz, 1 H) 6.60-6.66 (m, 2 H) 6.81-6.87 (m, 2 H) 6.91 (d, J = 1.77Hz, 1 H) 7.39 (d, J = 4.04 Hz, 1 H) 7.60 (d, J = 4.04 Hz, 1 H) 29

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide E calc'dfor C₁₉H₂₃ClN₃O₅S₂ 472.07; found 472.1 ¹H NMR (400 MHz, MeOD) δ ppm1.14-1.20 (m, 2 H) 1.22-1.42 (m, 7 H) 1.60 (d, J = 1.77 Hz, 1 H) 1.69(d, J = 9.60 Hz, 1 H) 1.99-2.24 (m, 2 H) 2.67-2.86 (m, 1 H) 3.87 (br.s., 2 H) 5.94 (dd, J = 10.61, 5.31 Hz, 1 H) 6.80 (dd, J = 7.33, 2.02 Hz,1 H) 7.00 (d, J = 2.02 Hz, 1 H) 7.33 (s, 1 H) 8.08 (d, J = 7.33 Hz, 1 H)30

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide E calc'dfor C₁₉H₂₃ClN₃O₅S₂ 472.07; found 472.1 31

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₁H₂₆ClN₃O₅S₂ 500.10; found 500.00 ¹H NMR (400 MHz, CDCl₃) δ1.30-2.24 (m, 15 H), 3.33 (m, 2 H), 3.50 (m, 1 H), 3.92 (m, 2 H), 6.35(t, J = 8 Hz, 1 H), 6.74 (dd, J = 4, 8 Hz, 1 H), 7.99 (d, J = 4 Hz, 1H), 8.04 (d, J = 8 Hz, 1 H) 32

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₁H₂₆ClN₃O₅S₂ 500.10; found 500.00 33

  (R)-2-(4-(cyclopentylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₁H₂₆FN₃O₅S₂ 484.58; found 484.50 ¹H NMR (400 MHz, CDCl₃) δ1.20-2.24 (m, 15 H), 3.34 (m, 2 H), 3.50 (m, 1 H), 3.92 (m, 2 H), 6.29(t, J = 8 Hz, 1 H), 6.74 (dd, J = 4, 8 Hz, 1 H), 7.90 (d, J = 4 Hz, 1H), 8.02 (d, J = 8 Hz, 1 H) 34

  (S)-2-(4-(cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₁H₂₆FN₃O₅S₂ 484.58; found 484.5 35

  (S)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide E calc'dfor C₁₉H₂₃FN₃O₅S₂ 456.10; found 456.1 ¹H NMR (400 MHz, CHLOROFORM-d) δppm 1.04-1.54 (m, 8 H) 1.59- 1.82 (m, 2H) 2.01 (s, 1 H) 2.22 (d, J =7.07 Hz, 1 H) 2.50 (dd, J = 12.51, 3.16 Hz, 1 H) 3.22-3.44 (m, 2 H)3.84-4.07 (m, 2 H) 6.08 (t, J = 7.71 Hz, 1 H) 6.74 (dd, J = 7.20, 1.64Hz, 1 H) 7.12 (br. s., 1 H) 7.53 (s, 1 H) 7.85 (d, J = 7.33 Hz, 1 H) 36

  (R)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide E calc'dfor C₁₉H₂₃FN₃O₅S₂ 456.10; found 456.1 37

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideD calc'd for C₂₂H₂₈ClN₃O₅S₂ 514.12; found 514.10 38

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideD calc'd for C₂₂H₂₈ClN₃O₅S₂ 514.12; found 514.10 39

  (R)-2-(4-(cyclopentylsulfonyl)- 6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Dcalc'd for C₂₂H₂₈FN₃O₅S₂ 498.15; found 498.1 ¹H NMR (400 MHz, CDCl₃) δ1.30-2.24 (m, 14 H), 2.53 (s, 3 H), 2.57 (m, 1 H), 3.35 ( m, 2 H), 3.49(m, 1 H), 3.94 (m, 2 H), 4.92 (bs, 1 H), 6.50 (s, 1 H), 7.0 (s, 1 H),7.02 (d, J = 4 Hz, 1 H) 40

  (S)-2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Dcalc'd for C₂₂H₂₈FN₃O₅S₂ 498.15; found 498.1 41

  (R)-N-(5-chloropyridin-2-yl)-2- (4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₃H₂₈ClN₃O₅S 494.14; found 494.10 ¹H NMR (400 MHz, CDCl₃) δ1.18-2.20 (m, 15 H), 3.36 ( m, 2 H), 3.57 (m, 1 H), 3.95 (m, 2 H), 5.99(t, J = 4 Hz, 1 H), 6.71 (d, J = 8 Hz, 1 H), 7.68 (d, J = 8 Hz, 1 H),7.97 (d, J = 8 Hz, 1 H), 8.09 (d, J = 8 Hz, 1 H), 8.28 (s, 1 H) 42

  (S)-N-(5-chloropyridin-2-yl)-2- (4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₃H₂₈ClN₃O₅S 494.14; found 494.10 43

  N-(5-fluorothiazol-2-yl)-4,4- dimethyl-2-(6-methyl-2-oxo-4-tosylpyridin-1(2H)- yl)pentanamide C calc'd for C₂₃H₂₇FN₃O₄S₂ 492.13;found 492.2 ¹H NMR (400 MHz, CDCl₃) δ ppm 0.93 (s, 9 H) 2.44 (s, 3 H)2.57 (br. s., 3 H) 2.79 (d, J = 15.41 Hz, 2 H) 4.77 (br. s., 1 H) 6.50(br. s., 1 H) 6.89 (br. s., 1 H) 7.02 (d, J = 2.02 Hz, 1 H) 7.35 (m, J =8.34 Hz, 2 H) 7.81 (m, J = 8.08 Hz, 2 H) 44

  (R)-methyl 2-(2-(4- (cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)thiazole-5- carboxylate C calc'dfor C₂₃H₂₉N₃O₇S₂ 524.14; found 524.10 ¹H NMR (400 MHz, CDCl₃) δ1.20-2.26 (m, 15 H), 3.33 (m, 2 H), 3.51 (m, 1 H), 3.88 (s, 3 H), 3.92(m, 2H), 6.42 (t, J = 8 Hz, 1 H), 6.77 (d, J = 8 Hz, 1 H), 8.03 (s, 1H), 8.06 (d, J = 8 Hz, 1 H), 8.17 (s, 1 H) 45

  (S)-methyl 2-(2-(4- (cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)thiazole-5- carboxylate C calc'dfor C₂₃H₂₉N₃O₇S₂ 524.14; found 524.10 46

  (S)-6-(2-(4- (cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)nicotinamide C 47

  (R)-6-(2-(4- (cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)nicotinamide C calc'd forC₂₄H₃₀N₄O₆S 503.19; found 503.10 ¹H NMR (400 MHz, CDCl₃) δ 1.35-2.22 (m,15 H), 3.36 (m, 2 H), 3.62 (m, 1 H), 3.95 (m, 2 H), 5.95 (m, 1 H), 6.74(d, J = 4 Hz, 1 H), 7.12 (d, J = 8 Hz, 1 H), 7.95 (d, J = 8 Hz, 1 H),8.08 (d, J = 8 Hz, 1 H), 8.30 (d, J = 8 Hz, 1 H), 8.82 (s, 1 H) 48

  (R)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₃H₂₇N₄O₆S₂ 519.14; found 519.3 1H NMR (400MHz, CHLOROFORM-d) δ ppm 0.97-1.17 (m, 2 H) 1.18- 1.46 (m, 5H) 1.46-1.60(m, 1 H) 1.68-1.81 (m, 2 H) 1.88-1.99 (m, 1 H) 2.18-2.33 (m, 1 H) 2.45(br. s., 1 H) 3.25-3.42 (m, 2 H) 3.85-3.96 (m, 2 H) 3.98 (s, 3 H) 6.51(br. s., 1 H) 6.76 (br. s., 1 H) 6.82 (d, J = 8.34 Hz, 1 H) 8.09- 8.34(m, 3 H) 49

  (S)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₃H₂₇N₄O₆S₂ 519.14; found 519.3 1H NMR (400MHz, CHLOROFORM-d) δ ppm 0.97-1.17 (m, 2 H) 1.18- 1.46 (m, 5H) 1.46-1.60(m, 1 H) 1.68-1.81 (m, 2 H) 1.88-1.99 (m, 1 H) 2.18-2.33 (m, 1 H) 2.45(br. s., 1 H) 3.25-3.42 (m, 2 H) 3.85-3.96 (m, 2 H) 3.98 (s, 3 H) 6.51(br. s., 1 H) 6.76 (br. s., 1 H) 6.82 (d, J = 8.34 Hz, 1 H) 8.09- 8.34(m, 3 H) 50

  N-(5-fluorothiazol-2-yl)-2-(2- oxo-4-(pyridin-2-ylsulfonyl)pyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C₂₁H₂₂FN₄O₅S₂ 493.09; found 493.18 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.13-1.35 (m, 3 H) 1.35- 1.44 (m, 1 H) 1.53-1.76 (m,2 H) 1.90 (ddd, J = 14.02, 8.21, 5.81 Hz, 1 H) 2.19 (dt, J = 14.08, 6.98Hz, 1 H) 3.18-3.42 (m, 1 H) 3.79-3.99 (m, 2 H) 5.93 (t, J = 7.71 Hz, 1H) 6.87 (dd, J = 7.33, 2.02 Hz, 1 H) 7.09 (d, J = 2.53 Hz, 1 H) 7.53 (d,J = 2.02 Hz, 1 H) 7.57 (dd, J = 12.50, 1.14 Hz, 1 H) 7.72 (d, J = 7.33Hz, 1 H) 7.99 (td, J = 7.77, 1.64 Hz, 1 H) 8.19 (d, J = 7.83 Hz, 1 H)8.73 (d, J = 4.55 Hz, 1 H) 51

  (R)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N- (thiazolo[5,4-b]pyridin-2- yl)propanamideE calc'd for C₂₂H₂₅N₄O₅S₂ 489.12, found 489.28 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 0.66-0.95 (m, 1 H) 1.00- 1.18 (m, 2 H) 1.18-1.36 (m,2 H) 1.36-1.49 (m, 3 H) 1.76-1.83 (m, 2 H) 1.91-2.05 (m, 1 H) 2.25- 2.36(m, 1 H) 2.42-2.51 (m, 1 H) 3.30-3.42 (m, 2 H) 3.95 (dd, J = 11.49, 2.91Hz, 2 H) 6.51 (t, J = 7.71 Hz, 1 H) 6.79 (dd, J = 7.33, 2.02 Hz, 1 H)7.41 (dd, J = 8.21, 4.67 Hz, 1 H) 8.12 (d, J = 7.33 Hz, 1 H) 8.20 (d, J= 1.26 Hz, 1 H) 8.31 (dd, J = 8.34, 1.26 Hz, 1 H) 8.51 (d, J = 3.79 Hz,1 H) 52

  (S)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N- (thiazolo[5,4-b]pyridin-2- yl)propanamideE calc'd for C₂₂H₂₅N₄O₅S₂ 489.12, found 489.28 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 0.66-0.95 (m, 1 H) 1.00- 1.18 (m, 2 H) 1.18-1.36 (m,2H) 1.36-1.49 (m, 3 H) 1.76-1.83 (m, 2 H) 1.91-2.05 (m, 1 H) 2.25- 2.36(m, 1 H) 2.42-2.51 (m, 1 H) 3.30-3.42 (m, 2 H) 3.95 (dd, J = 11.49, 2.91Hz, 2H) 6.51 (t, J = 7.71 Hz, 1 H) 6.79 (dd, J = 7.33, 2.02 Hz, 1 H)7.41 (dd, J = 8.21, 4.67 Hz, 1 H) 8.12 (d, J = 7.33 Hz, 1 H) 8.20 (d, J= 1.26 Hz, 1 H) 8.31 (dd, J = 8.34, 1.26 Hz, 1 H) 8.51 (d, J = 3.79 Hz,1 H) 53

  3-(2-(2-(4-(methylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)thiazol-5- yl)propanoic acid Ecalc'd for C₂₀H₂₆N₃O₇S₂, 484.11, found 489.27 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 0.76-1.54 (m, 6 H) 1.65- 1.72 (m, 1 H) 1.73-1.81 (m,1 H) 2.12-2.28 (m, 2 H) 2.69 (t, J = 7.07 Hz, 2 H) 3.12 (t, J = 7.07 Hz,2 H) 3.27 (s, 3 H) 3.91-4.01 (m, 2 H) 6.03 (dd. J = 10.23, 5.68 Hz, 1 H)6.89 (dd, J = 7.33, 2.02 Hz, 1 H) 7.13 (d, J = 2.02 Hz, 1 H) 7.25 (s, 1H) 8.16 (d, J = 7.33 Hz, 1 H) 54

  N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2- oxopyridin-1(2H)- yl)propanamide D calc'dfor C₂₃H₂₆ClN₃O₅S₂ 524.10; found 524.10 ¹H NMR (400 MHz, CDCl₃) δ0.92-1.83 (m, 15 H), 2.53 (s, 3 H), 2.57 (s, 3 H), 2.65 (m, 1 H), 4.88(bs, 1 H), 6.53 (d, J = 3 Hz, 1 H), 6.58 (d, J = 4 Hz, 1 H), 6.88 (d, J= 3 Hz, 1 H), 7.26 (s, 1 H), 7.31 (d, J = 3 Hz, 1 H). 55

  2-(4-(benzyloxy)-2-oxopyridin- 1(2H)-yl)-N-(5-methylthiazol-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide J calc'd for C₂₄H₂₈N₃O₄S454.17; found 454.20 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.31-1.50 (m,3 H) 1.58 (d, J = 11.62 Hz, 1 H) 1.75 (d, J = 1.12 Hz, 1 H) 1.92- 2.06(m, 1 H) 2.18-2.30 (m, 1 H) 2.44 (s, 3 H) 3.27- 3.38 (m, 2 H) 3.94 (t, J= 12.38 Hz, 2 H) 5.01 (s, 2 H) 5.73 (dd, J = 9.98, 5.18 Hz, 1 H)6.09-6.20 (m, 2 H) 7.14 (br. s., 1 H) 7.32 (d, J = 7.58 Hz, 1 H) 7.35-7.45 (m, 5 H) . 56

  (R)-N-(5-cyanothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₂H₂₆N₄O₅S₂ 491.12; found 491.10 ¹H NMR (400 MHz, CDCl₃) δ1.26-2.16 (m, 15 H), 3.36 (m, 2H), 3.59 (m, 1 H), 3.95 (m, 2 H), 5.98(dd, J = 4, 8 Hz, 1 H), 6.72 (dd, J = 4, 8 Hz, 1 H), 7.12 (d, J = 4 Hz,1 H), 7.92 (d, J = 8 Hz, 1 H) 57

  (S)-N-(5-cyanothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide D calc'dfor C₂₂H₂₆N₄O₅S₂ 491.13; found 491.10 58

  (R)-2-(4-(cyclopentylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide D calc'd for C₂₅H₃₀N₄O₆S₂ 547.16; found 547.10 ¹H NMR(400 MHz, d- DMSO) δ 1.25-2.24 (m, 15 H), 3.26 ( m, 2 H), 3.85 (m, 1 H),3.86 (m, 2 H), 3.95 (s, 3H), 5.99 (dd, J = 4, 12 Hz, 1 H), 6.77 (d, J =8 Hz, 1 H), 6.90 (d, J = 12 Hz), 6.97 (s, 1 H), 8.01 (d, J = 8 Hz, 1 H),8.12 (d, J = 8 HZ, 1 H) 59

  (S)-2-(4-(cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide D calc'd for C₂₅H₃₀N₄O₆S₂ 547.16; found 547.10 60

  N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2-ylsulfonyl)pyridin- 1(2H)-yl)propanamide D calc'd forC₂₂H₂₄ClN₃O₄S₃ 527.09; found 527.09 ¹H NMR (400 MHz, MeOD). δ ppm 0.99(M, 2H) 1.20 (m, 3H) 1.36 (m, 1H) 1.69 (m, 5H) 1.76 (m, 1H) 2.49 (m,4H), 5.21 (m, 1H) 6.72 (s, 1H) 6.88 (s, 1H) 7.26 (m, 2H) 7.89 (d, J = 4Hz, 1H) 8.03 (d, J = 8 Hz, 1H) 61

  (S)-2-(4-bromo-6-methyl-2- oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2- yl)propanamide C calc'd for C₁₈H₂₂BrN₃O₂S425.36; found 425.36 ¹H NMR (400 MHz, MeOD). δ ppm 1.02 (m, 2H) 1.24 (m,3H) 1.37 (m, 1H) 1.73 (m, 5H) 1.86 (m, 1H) 2.49 (m, 4H) 5.24 (m, 1H)6.57 (s, 1H) 6.63 (s, 1H) 7.12 (d, J = 4 Hz, 1H) 7.42 (d, J = 0 Hz, 1H)62

  (S)-N-(5-methoxythiazolo[5,4- b]pyridin-2-yl)-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide D calc'd for C₂₆H₂₈N₄O₇S₂ 573.14;found 573.14 ¹H NMR (400 MHz, d- MeOD) δ 1.25-1.37 (m, 3 H), 1.66-1.77(m, 4 H), 2.58 (s, 3 H), 2.59 (s, 3 H), 2.67 (m, 1 H), 3.34 ( m, 2 H),3.45 (m, 1 H), 3.89 (m, 2 H), 3.96 (s, 3 H), 5.26 (bs, 1 H), 6.68 (s, 1H), 6.75 (d, J = 4 Hz), 6.82 (d, J = 8 Hz, 1 H), 6.85 (d, J = 4 Hz, 1H), 7.55 (d, J = 4 Hz, 1 H), 7.87 (d, J = 8 Hz, 1 H) 63

  (R)-N-(5-methoxythiazolo[5,4- b]pyridin-2-yl)-2-(6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide D calc'd for C₂₆H₂₈N₄O₇S₂ 573.14;found 573.14 64

  (S)-N-(5-chlorothiazol-2-yl)-2- (6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide D calc'd for C₂₂H₂₄ClN3O₆S₂ 526.08; found 526.0 ¹H NMR(400 MHz, d- CDCl₃) δ 1.29-1.42 (m, 3 H), 1.61-1.75 (m, 4 H), 2.52 (s, 3H), 2.58 (s, 3 H), 2.74 (m, 1 H), 3.36 ( m, 2 H), 3.9 (m, 2 H), 4.75(bs, 1 H), 6.50 (s, 1 H), 6.57 (d, J = 4 Hz), 6.89 (s, 1 H), 7.25 (s, 1H), 7.33 (d, J = 4 Hz, 1 H) 65

  (R)-N-(5-chlorothiazol-2-yl)-2- (6-methyl-4-(2-methylfuran-3-ylsulfonyl)-2-oxopyridin-1(2H)- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide D calc'd for C₂₂H₂₄ClN3O₆S₂ 526.08; found 526.0 66

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C2₀H₂₇N₄O₅S 435.16; found 435.1 ¹H NMR (400 MHz, MeOD) δ ppm1.05-1.20 (m, 2 H) 1.21-1.46 (m, 6 H) 1.62 (br. s., 2 H) 1.97- 2.19 (m,2 H) 2.78 (dd, J = 12.51, 3.16 Hz, 1 H) 3.34 (s, 2 H) 3.73-3.82 (m, 3 H)3.84-4.00 (m, 2 H) 5.91 (dd, J = 9.73, 6.44 Hz, 1 H) 6.44 (d, J = 2.02Hz, 1 H) 6.78 (dd, J = 7.20, 1.89 Hz, 1 H) 7.00 (d, J = 2.02 Hz, 1 H)7.43 (d, J = 2.27 Hz, 1 H) 8.10 (d, J = 7.33 Hz, 1 H) 67

  2-(4-(3-hydroxypropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₃H₂₉N₄O₇S₂ 537.14; found 537.1 ¹H NMR (400MHz, MeOD) δ ppm 1.21-1.45 (m, 2 H) 1.60 (d, J = 12.13 Hz, 1 H) 1.68 (d,J = 11.87 Hz, 1 H) 1.89 (dd, J = 9.98, 5.68 Hz, 1 H) 1.99-2.22 (m, 2 H)3.16-3.40 (m, 4 H) 3.59 (t, J = 6.19 Hz, 2 H) 3.75-3.98 (m overlappings, 5 H) 6.00 (dd, J = 10.61, 5.56 Hz, 1 H) 6.80 (d, J = 8.84 Hz, 1 H)6.79 (dd, J = 7.20, 2.15 Hz, 1 H) 7.05 (d, J = 2.02 Hz, 1 H) 7.90 (d, J= 8.84 Hz, 1 H) 8.10 (d, J = 7.33 Hz, 1 H) 68

  3-cyclohexyl-2-(4- (cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)propanamide E calc'd forC₂₄H₂₉N₄O₅S₂ 517.15; found 517.1 ¹H NMR (400 MHz, MeOD) δ ppm 0.98-1.34(m, 10 H) 1.60-1.89 (m, 5 H) 2.00-2.21 (m, 2 H) 2.81 (dd, J = 12.76,3.16 Hz, 1 H) 3.95 (s, 3 H) 6.00 (dd, J = 10.61, 5.56 Hz, 1 H) 6.78-6.91(m, 2H) 7.04 (d, J = 2.27 Hz, 1 H) 7.90-8.00 (m, 1 H) 8.10 (d, J = 7.33Hz, 1 H) 69

  (R)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H- pyran-4-yl)propanamide E calc'd forC₂₀H₂₅N₄O₅S 433.15; found 433.1 ¹HNMR (400 MHz, MeOD) δ ppm 1.12-1.49(m, 7 H) 1.57-1.77 (m, 2 H) 2.04-2.26 (m, 2 H) 2.73-2.87 (m, 1 H) 3.30(d, J = 1.77 Hz, 2 H) 3.90 (dd, J = 9.85, 8.84 Hz, 2 H) 6.03 (dd, J =10.86, 5.56 Hz, 1 H) 6.82 (dd, J = 7.33, 2.02 Hz, 1 H) 7.02 (d, J = 2.02Hz, 1 H) 8.12 (d, J = 7.33 Hz, 1 H) 8.33 (d, J = 2.53 Hz, 1 H) 8.40 (d,J = 1.52 Hz, 1 H) 9.32 (s, 1 H) 70

  (S)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)-3-(tetrahydro-2H- pyran-4-yl)propanamide E calc'd forC₂₀H₂₅N₄O₅S 433.15; found 433.1 71

  (R)-2-(4-(3- hydroxypropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₃H₂₉N₄O₇S₂ 537.14; found 537.1 ¹H NMR (400MHz, MeOD) δ ppm 1.21-1.45 (m, 2H) 1.60 (d, J = 12.13 Hz, 1 H) 1.68 (d,J = 11.87 Hz, 1 H) 1.89 (dd, J = 9.98, 5.68 Hz, 1 H) 1.99-2.22 (m, 2 H)3.16-3.40 (m, 4 H) 3.59 (t, J = 6.19 Hz, 2 H) 3.75-3.98 (m overlappings, 5 H) 6.00 (dd, J = 10.61, 5.56 Hz, 1 H) 6.80 (d, J = 8.84 Hz, 1 H)6.79 (dd, J = 7.20, 2.15 Hz, 1 H) 7.05 (d, J = 2.02 Hz, 1 H) 7.90 (d, J= 8.84 Hz, 1 H) 8.10 (d, J = 7.33 Hz, 1 H) 72

  (S)-2-(4-(3- hydroxypropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4-b]pyridin- 2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₃H₂₉N₄O₇S₂ 537.14; found 537.1 73

  (R)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C₂₀H₂₇N₄O₅S 435.16; found 435.1 ¹H NMR (400 MHz, MeOD) δ ppm1.05-1.20 (m, 2 H) 1.21-1.46 (m, 6 H) 1.62 (br. s., 2H) 1.97- 2.19 (m, 2H) 2.78 (dd, J = 12.51, 3.16 Hz, 1 H) 3.34 (s, 2 H) 3.73-3.82 (m, 3 H)3.84-4.00 (m, 2 H) 5.91 (dd, J = 9.73, 6.44 Hz, 1 H) 6.44 (d, J = 2.02Hz, 1 H) 6.78 (dd, J = 7.20, 1.89 Hz, 1 H) 7.00 (d, J = 2.02 Hz, 1 H)7.43 (d, J = 2.27 Hz, 1 H) 8.10 (d, J = 7.33 Hz, 1 H) 74

  (S)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C₂₀H₂₇N₄O₅S 435.16; found 435.1 75

  (R)-3-cyclohexyl-2-(4- (cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5- methoxythiazolo[5,4-b]pyridin-2-yl)propanamide E calc'd for C₂₄H₂₉N₄O₅S₂ 517;15; found 517.1 76

  (S)-3-cyclohexyl-2-(4- (cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5- methoxythiazolo[5,4-b]pyridin-2-yl)propanamide E calc'd for C₂₄H₂₉N₄O₅S₂ 517;15; found 517.1 77

  (S)-2-(3-chloro-4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- chlorothiazol-2-yl)-3-cyclohexylpropanamide G calc'd for C₂₁H₂₅Cl₂N₃O₄S₂ 518.07; found 518.0¹H NMR (400 MHz, CDCl₃) δ 0.90-2.10 (m, 17 H), 2.43 (s, 3 H), 3.08 (m, 1H), 5.48 (m, 1 H), 7.28 (s, 1 H), 7.34 (s, 1 H) 78

  (R)-2-(3-chloro-4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- chlorothiazol-2-yl)-3-cyclohexylpropanamide G calc'd for C₂₁H₂₅Cl₂N₃O₄S₂ 518.07; found 518.079

  3-cyclohexyl-2-(6-methyl-4- morpholino-2-oxopyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide H calc'd for C₂₂H₃₀N₄O₃S 431.57, found431.557 ¹H NMR (400 MHz, MeOD). δ ppm 0.96 (m, 3H) 1.21 (m, 5H) 1.66 (m,5H) 1.87 (m, 2H) 2.24 (m, 1H) 2.37 m, 4H), 3.76 (m, 5H) 5.58 (m, 1H)6.16n (s, 1H) 6.64 (d, J = 4 Hz, 1H) 7.02 (d, J = 4 Hz, 1H) 80

  N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2- ylmethylsulfonyl)pyridin-1(2H)- yl)propanamide C calc'd forC₂₃H₂₆ClN₃O₄S₃ 541.12; found 541.12 ¹H NMR (400 MHz, MeOD). δ ppm 1.03(m, 2H) 1.26 (m, 4H) 1.71 (m, 2H) 1.79 (m, 2H) 1.87 (m, 2H) 2.45 (m, 1H)2.54 (s, 3H) 4.86 (d, J = 4 Hz, 2H) 5.29 (m, 1H) 6.58 (s, 1H) 6.64 (s,1H) 7.00 (t, J = 4, 4 Hz, 1H) 7.07 (s, 1H) 7.43 (d, J = 4 Hz, 1H) 81

  3-cyclohexyl-2-(4-(furan-2- ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide C calc'd forC₂₃H₂₇N₃O₅S₂, 490; found, 490 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm0.88-1.06 (m, 2 H) 1.07- 1.32 (m, 4 H) 1.64 (m, 4 H) 1.71 (br. s., 3H)2.32- 2.45 (m, 1 H) 2.50 (m, 2 H) 4.45 (d, J = 2.78 Hz, 2 H) 4.83-5.02(m, 1 H) 6.27 (br. s., 1 H) 6.37- 6.41 (m, 1 H) 6.45-6.51 (m, 1 H) 6.87(br. s., 1 H) 6.98-7.04 (m, 1 H) 7.41 (s, 1 H) 7.45 (t, J = 3.54 Hz, 1H) 82

  3-cyclohexyl-2-(4- (cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-(4- fluorobenzyl)thiazol-2- yl)propanamide Ccalc'd for C₃₀H₃₆FN₃O₄S₂, 586; found, 586 ¹H NMR (400 MHz, CHLOROFORM-d)δ ppm 0.85-1.04 (m, 2 H) 1.06- 1.30 (m, 4 H) 1.53-1.76 (m, 3 H)1.75-1.87 (m, 4 H) 1.87-2.01 (m, 4 H) 2.01-2.18 (m, 4 H) 2.33- 2.46 (m,1 H) 2.46-2.61 (m, 2 H) 3.39-3.54 (m, 1 H) 4.02 (d, J = 7.07 Hz, 2 H)4.77-5.00 (m, 1 H) 6.45 (br. s., 1 H) 6.91- 7.05 (m, 3 H) 7.08-7.23 (m,3 H) 83

  N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(4-(2,5-dimethylfuran-3-ylsulfonyl)-6- methyl-2-oxopyridin-1(2H)- yl)propanamideC calc'd for C₂₄H₂₈ClN₃O₅S₂ 539.08; found 539.08 ¹H NMR (400 MHz, MeOD).δ ppm 0.97 (m, 2H) 1.22 (m, 3H) 1.37 (m, 1H) 1.69 (m, 5H) 1.83 (m, 1H)2.26 (s, 3H) 2.54 (m, 7H) 5.24 (m, 1H) 6.32 (s, 1H) 6.64 (s, 1H) 6.81(s, 1H) 7.26 (s, 1H) 84

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(6-hydroxybenzo[d]thiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C₂₃H₂₆N₃O₆S₂ 504.12 found 504 ¹HNMR (400 MHz, MeOD) δ ppm1.15 (dd, J = 7.83, 2.53 Hz, 2 H) 1.23- 1.31 (m, 3H) 1.34 (dd, J = 1.62,4.80 Hz, 2 H) 1.42-1.53 (m, 1 H) 1.53- 1.61 (m, 1 H) 1.82 (d, J = 12.63Hz, 1 H) 2.27 (d, J = 14.40 Hz, 1 H) 2.26 (dd, J = 15.41, 4.04 Hz, 1 H)2.80 (td, J = 8.21, 4.04 Hz, 1 H) 3.34 (t, J = 11.62 Hz, 2 H) 3.80-3.98(m, 2 H) 5.57 (dd, J = 9.60, 5.31 Hz, 1 H) 6.81 (dd, J = 7.33, 2.02 Hz,1 H) 7.05 (d, J = 2.02 Hz, 1 H) 7.19 (dd, J = 8.84, 2.27 Hz, 1 H) 7.45(d, J = 8.84 Hz, 1 H) 7.55 (d, J = 2.27 Hz, 1 H) 8.04 (d, J = 7.07 Hz, 1H) 85

  (S)-N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2- ylmethylsulfonyl)pyridin-1(2H)- yl)propanamide C calc'd forC₂₃H₂₆ClN₃O₄S₃ 541.12; found 541.12 ¹H NMR (400 MHz, MeOD). δ ppm 1.03(m, 2H) 1.26 (m, 4H) 1.71 (m, 2H) 1.79 (m, 2H) 1.87 (m, 2H) 2.45 (m, 1H)2.54 (s, 3H) 4.86 (d, J = 4 Hz, 2H) 5.29 (m, 1H) 6.58 (s, 1H) 6.64 (s,1H) 7.00 (t, J = 4, 4 Hz, 1H) 7.07 (s, 1H) 7.43 (d, J = 4 Hz, 1H) 86

  (R)-N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(6-methyl-2-oxo-4-(thiophen-2- ylmethylsulfonyl)pyridin-1(2H)- yl)propanamide C calc'd forC₂₃H₂₆ClN₃O₄S₃ 541.12; found 541.12 ¹H NMR (400 MHz, MeOD). δ ppm 1.03(m, 2H) 1.26 (m, 4H) 1.71 (m, 2H) 1.79 (m, 2H) 1.87 (m, 2H) 2.45 (m, 1H)2.54 (s, 3H) 4.86 (d, J = 4 Hz, 2H) 5.29 (m, 1H) 6.58 (s, 1H) 6.64 (s,1H) 7.00 (t, J = 4, 4 Hz, 1H) 7.07 (s, 1H) 7.43 (d, J = 4 Hz, 1H 87

  3-cyclohexyl-2-(6-methyl-2-oxo- 4-(pyrrolidin-1-yl)pyridin-1(2H)-yl)-N-(thiazol-2- yl)propanamide H calc'd for C₂₂H₃₀N₄O₂S 415.57.found 415.57 ¹H NMR (400 MHz, MeOD). δ ppm 0.89 (m, 2H) 1.21 (m, 4H)1.65 (m, 4H) 1.87 (m, 2H) 2.06 (m, 4H) 2.30 (m, 1H) 2.49 (s, 3H) 3.43(m, 4H) 5.11 (m, 1H) 6.06 (s, 1H) 6.32 (s, 1H) 6.87 (d, J = 4 Hz, 1H)7.34 (d, J = 4 Hz, 1H) 88

  2-(4-(4-methoxy-2-methylbutan- 2-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5- methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide E calc'd for C₂₆H₃₄N₄O₇S₂579.19; found 579.0 ¹H NMR (400 MHz, CDCl₃) δ ppm 1.28-1.49 (m, 9H)1.53-1.79 (m, 2 H) 2.01 (t, J = 6.57 Hz, 2 H) 2.07-2.29 (m, 2 H) 3.30(d, J = 1.77 Hz, 5 H) 3.56 (t, J = 6.57 Hz, 2 H) 3.85- 3.95 (m, 2 H)3.96 (s, 3 H) 6.02 (dd, J = 10.36, 5.56 Hz, 1 H) 6.77 (dd, J = 7.33,1.77 Hz, 1 H) 6.86 (d, J = 8.84 Hz, 1 H) 7.01 (d, J = 2.02 Hz, 1 H) 7.96(d, J = 8.84 Hz, 1 H) 8.12 (d, J = 7.33 Hz, 1 H) 89

  3-cyclohexyl-2-(4- (cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- (morpholinomethyl)thiazol-2- yl)propanamideC calc'd for C₂₈H₄₀N₄O₅S₂, 577; found, 577 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 0.89-1.10 (m, 2 H) 1.10- 1.35 (m, 4H) 1.36-2.19 (m,15 H) 2.53-2.74 (m, 3 H) 2.89-3.75 (m, 5 H) 3.80-4.11 (m, 4H) 4.33- 4.64(m, 2 H) 4.82-5.06 (m, 1 H) 6.68 (br. s., 1 H) 6.93 (br. s., 1 H) 7.67(br. s., 1 H) 90

  (S)-3-cyclohexyl-2-(6-methyl-2- oxo-4-phenylpyridin-1(2H)-yl)-N-(thiazol-2-yl)propanamide F calc'd for C₂₄H₂₈N₃O₂S 422.19; found 421.991

  (S)-2-(4-(2-chlorophenyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2- yl)propanamide F calc'd for C₂₄H₂₇ClN₃O₂S456.15; found 456.3 92

  (S)-2-(4-(3-chlorophenyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2- yl)propanamide F calc'd for C₂₄H₂₇ClN₃O₂S456.15; found 455.9 93

  (S)-2-(4-(4-chlorophenyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2- yl)propanamide F calc'd for C₂₄H₂₇ClN₃O₂S456.15; found 456.3 94

  (S)-3-cyclohexyl-2-(4-(2- methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₅H₃₀N₃O₃S 452.20; found 451.9 95

  (S)-3-cyclohexyl-2-(4-(3- methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₅H₃₀N₃O₃S 452.20; found 452.3 96

  (S)-3-cyclohexyl-2-(4-(4- methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₅H₃₀N₃O₃S 452.20; found 452.3 97

  (S)-2-(4-(3-cyanophenyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2- yl)propanamide F calc'd for C₂₅H₂₇N₄O₂S447.19; found 447.1 98

  (S)-2-(4-(4-cyanophenyl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2- yl)propanamide F calc'd for C₂₅H₂₇N₄O₂S447.19; found 447.1 99

  (S)-3-cyclohexyl-2-(4-(furan-3- yl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol-2- yl)propanamide F calc'd for C₂₂H₂₆N₃O₃S 412.17;found 412.3 100

  (S)-3-cyclohexyl-2-(6-methyl-2- oxo-4-(pyridin-3-yl)pyridin-1(2H)-yl)-N-(thiazol-2- yl)propanamide F calc'd for C₂₃H₂₇N₄O₂S 423.19;found 423.1 101

  (S)-3-cyclohexyl-2-(6-methyl-4- (4-(methylsulfonyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₅H₃₀N₃O₄S₂ 500.17; found 500.3 102

  (S)-3-cyclohexyl-2-(4-(4- (ethylsulfonyl)phenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N- (thiazol-2-yl)propanamide F calc'd forC₂₆H₃₂N₃O₄S₂ 514.18; found 514.3 103

  (S)-2-(4-(5-chloro-2- methoxyphenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3- cyclohexyl-N-(thiazol-2- yl)propanamide F calc'dfor C₂₅H₂₉ClN₃O₃S 486.16; found 486.3 104

  (S)-2-(4-(benzofuran-2-yl)-6- methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N-(thiazol-2- yl)propanamide F calc'd for C₂₆H₂₈N₃O₃S462.19; found 105

  (S)-3-cyclohexyl-2-(4-(4- fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₄H₂₇FN₃O₂S 440.18; found 440.3 106

  (S)-2-(4-(3-chloro-4- fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3- cyclohexyl-N-(thiazol-2- yl)propanamide F calc'dfor C₂₄H₂₆ClFN₃O₂S 474.14; found 473.9 107

  (S)-2-(4-(benzo[b]thiophen-3- yl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N- (thiazol-2-yl)propanamide F calc'd forC₂₆H₂₈N₃O₂S₂ 478.16; found 477.9 108

  (S)-2-(4-(benzo[b]thiophen-2- yl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-cyclohexyl-N- (thiazol-2-yl)propanamide F calc'd forC₂₆H₂₈N₃O₂S₂ 478.16; found 478.3 109

  (S)-3-cyclohexyl-2-(4-3- fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₄H₂₇FN₃O₂S 440.18; found 440.3 110

  (S)-3-cyclohexyl-2-(4-2- fluorophenyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₄H₂₇FN₃O₂S 440.18; found 440.3 111

  (S)-3-cyclohexyl-2-(6-methyl-4- (4-methylthiophen-2-yl)-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₃H₂₈N₃O₂S₂ 442.16; found 442.3 112

  (S)-3-cyclohexyl-2-(6-methyl-4- (3-methylsulfonamido)phenyl)-2-oxopyridin-1(2H)-yl)-N- (thiazol-2-yl)propanamide F calc'd forC₂₅H₃₁N₄O₄S₂ 515.18; found 515.1 113

  (S)-3-cyclohexyl-2-(6-methyl-2- oxo-4-(1H-pyrazol-4-yl)pyridin-1(2H)-yl)-N-(thiazol-2- yl)propanamide F calc'd for C₂₁H₂₆N₅O₂S 412.18;found 412.3 114

  (S)-3-cyclohexyl-2-(6-methyl-4- (3-(N-methylsulfamoyl)phenyl)-2-oxopyridin-1(2H)-yl)-N- (thiazol-2-yl)propanamide F calc'd forC₂₅H₃₁N₄O₄S₂ 515.18; found 515.5 115

  (S)-3-cyclohexyl-2-(6-methyl-4- (4-(N-methylsulfamoyl)phenyl)-2-oxopyridin-1(2H)-yl)-N- (thiazol-2-yl)propanamide F calc'd forC₂₅H₃₁N₄O₄S₂ 515.18; found 515.1 116

  ethyl 2-(2-(4- (cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)thiazole-5- carboxylate E calc'dfor C₂₂H₂₈N₃O₇S₂ 510.13; found 510 ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm1.15 (ddd, J = 7.96, 4.17, 4.04 Hz, 2 H) 1.25 (s, 1 H) 1.30-1.55 (m, 2H) 1.37 (t, J = 7.20 Hz, 6 H) 1.61- 1.76 (m, 2 H) 1.98 (d, J = 6.06 Hz,1 H) 2.25 (d, J = 7.07 Hz, 1 H) 2.49 (dd, J = 12.63, 3.28 Hz, 1 H)3.25-3.35 (m, 2 H) 3.92 (br. s., 1 H) 3.95 (d, J = 1.77 Hz, 1 H) 4.35(q, J = 7.16 Hz, 2 H) 6.14 (t, J = 7.58 Hz, 1 H) 6.75 (dd, J = 7.20,1.89 Hz, 1 H) 7.59 (d, J = 1.52 Hz, 1 H) 7.87 (d, J = 7.33 Hz, 1 H) 8.13(s, 1 H) 117

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-(2-hydroxypropan-2-yl)thiazol-2- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₂H₃₀N₃O₆S₂ 496.15; found 496.03 ¹H NMR(400 MHz, CHLOROFORM-d). δ ppm 1.17 (d, J = 7.83 Hz, 2 H) 1.22-1.46 (m,6 H) 1.54-1.68 (m, 7 H) 1.68- 1.74 (m, 1 H) 2.03-2.22 (m, 3 H) 2.80 (dd,J = 12.13, 3.28 Hz, 1 H) 3.24-3.40 (m, 1 H) 3.88 (d, J = 10.36 Hz, 2 H)5.96 (dd, J = 10.23, 5.43 Hz, 1 H) 6.81 (d, J = 7.33 Hz, 1 H) 7.01 (s, 1H) 8.09 (d. J = 7.33 Hz, 1 H) 118

  N-(5-chlorothiazol-2-yl)-2-(4- (cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide J calc'd for C₂₄H₃₂ClN₃O₅S₂ 543.11. found 543.11 ¹H NMR(400 MHz, CHLOROFORM-d). δ ppm 1.41 (m, 2H) 1.68 (m, 4H) 1.89 (m, 6H)2.08 (m. 3H) 2.38 (s, 3H) 2.54 (s, 3H) 2.67 (s, 3H) 3.35 (m, 2H) 3.62(m, 1H) 3.97 (m, 2H) 5.44 (m, 1H) 7.25 (s, 1H) 119

  N-(5-chlorothiazol-2-yl)-2-(4- (2,5-dichlorothiophen-3-ylsulfonyl)-6-methyl-2- oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4-yl)propanamide C calc'd for C₂₁H₂₀Cl₃N₃O₅S₃ 597.96. found 597.9 ¹HNMR(400 MHz, CHLOROFORM-d). δ ppm 1.39 (m, 2H) 1.67 (m, 2H) 1.80 (m, 2H)1.99 (m, 2H) 2.51 (s, 3H) 3.36 (m, 2H) 3.95 (m, 2H) 5.71 (m. 1H) 7.22(s, 1H) 7.26 (s, 1H) 7.34 (s, 1H 120

  (R)-2-(4-(4-methoxy-2- methylbutan-2-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5- methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide E calc'd for C₂₆H₃₄N₄O₇S₂579.19; found 579.0 121

  (S)-2-(4-(4-methoxy-2- methylbutan-2-ylsulfonyl)-2-oxopyridin-1(2H)-yl)-N-(5- methoxythiazolo[5,4-b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide E calc'd for C₂₆H₃₄N₄O₇S₂579.19; found 579.0 122

  (R)-3-cyclohexyl-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- methoxythiazolo[5,4-b]pyridin-2-yl)propanamide D calc'd for C₂₅H₃₀N₄O₅S₂ 531.17; found 531.10 123

  (S)-3-cyclohexyl-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- methoxythiazolo[5,4-b]pyridin-2-yl)propanamide D calc'd for C₂₅H₃₀N₄O₅S₂ 531.17; found 531.10 ¹H NMR(400 MHz, d- CDCl₃) δ 0.97-1.39 (m, 11 H), 1.65-1.78 (m, 6 H), 2.51 (m,2 H), 2.58 (s, 3 H), 4.00 (s, 3 H), 5.0 (bs, 1 H), 6.52 (s, 1 H), 6.82(d, J = 8 Hz), 7.0 (s, 1 H), 7.85 (d, J = 8 Hz, 1 H) 124

  2-(7-chloro-4-oxothieno[3,2- c]pyridin-5(4H)-yl)-N-(5-chlorothiazol-2-yl)-3- cyclohexylpropanamide J calc'd forC₁₉H₁₉Cl₂N₃O₂S₂ 457.41; found 457.40 ¹H NMR (400 MHz, d- DMSO) δ0.97-1.25 (m, 7 H), 1.58-1.80 (m, 5 H), 1.98-2.11 (m, 1 H), 6.0 (q, J =4, 8 Hz, 1 H), 7.33 (s, 1 H), 7.59 (s, 2 H), 7.71 (s, 1 H) 125

  2-(4-((S)-3-hydroxypyrrolidin-1- yl)-2-oxopyridin-1(2H)-yl)-N-(5-methoxythiazolo[5,4- b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₄H₃₀N₅O₅S 500.19; found 499.9¹H NMR (400 MHz, MeOD) δ ppm 1.30-1.44 (m, 4 H) 1.58 (d, J = 11.37 Hz, 1H) 1.71 (d, J = 11.87 Hz, 1 H) 2.00-2.19 (m, 4 H) 2.20-2.24 (m, 2 H)3.54 (br. s., 2 H) 3.88 (t, J = 11.37 Hz, 4 H) 3.93 (s, 3 H) 4.53 (d, J= 2.02 Hz, 1 H) 5.85 (dd, J = 11.12, 5.05 Hz, 1 H) 6.31 (d, J = 7.83 Hz,1 H) 6.83 (d, J = 7.83 Hz, 1 H) 7.77 (d, J = 7.83 Hz, 1 H) 7.92 (d, J =9.09 Hz, 1 H) 126

  (S)-3-cyclohexyl-2-(6-methyl-4- (3-(methylsulfonyl)phenyl)-2-oxopyridin-1(2H)-yl)-N-(thiazol- 2-yl)propanamide F calc'd forC₂₅H₃₀N₃O₄S₂ 500.17; found 500.3 127

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(6-methoxybenzo[d]thiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C₂₄H₂₈N₃O₆S₂ 518.13; found 518.3 1HNMR (400 MHz,CHLOROFORM-d) δ ppm 1.16 (d, J = 7.83 Hz, 2H) 1.25-1.50 (m, 5 H) 1.63(br. s., 1 H) 1.72 (d, J = 10.36 Hz, 1 H) 2.01 (d, J = 8.08 Hz, 1 H)2.21 (d, J = 7.33 Hz, 1 H) 2.53 (ddd, J = 7.64, 4.99, 3.03 Hz, 1 H)2.69-3.05 (m, 1 H) 3.24-3.45 (m, 2 H) 3.69- 3.91 (m, 3 H) 3.94 (d, J =10.61 Hz, 2 H) 5.96- 6.08 (m, 1 H) 6.73 (dd, J = 7.33, 2.02 Hz, 1 H)7.09 (dd, J = 8.97, 2.40 Hz, 1 H) 7.27-7.31 (m, 2 H) 7.58- 7.81 (m, 1 H)7.89 (dd, J = 7.33, 2.02 Hz, 1 H) 128

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-(dimethylamino)thiazolo[5,4- b]pyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₄H₃₀N₅O₅S₂ 532.16; found 5321HNMR (400 MHz, MeOD) δ ppm 1.18 (d, J = 7.83 Hz, 2H) 1.24- 1.36 (m, 3H) 1.36-1.49 (m, 3 H) 1.60-1.68 (m, 1 H) 1.68-1.78 (m, 1 H) 2.07-2.17(m, 1 H) 2.18- 2.32 (m, 1 H) 2.81 (t, J = 4.80 Hz, 1 H) 3.28 (s, 6 H)3.29-3.40 (m, 2 H) 3.84-3.97 (m, 2 H) 5.99 (dd, J = 10.74, 5.18 Hz, 1 H)6.83 (dd, J = 7.33, 2.02 Hz, 1 H) 7.03 (d, J = 2.02 Hz, 1 H) 7.08 (d, J= 9.35 Hz, 1 H) 8.06-8.18 (m, 2 H) 129

  N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(2-oxo-4-(pyrrolidine-1-carbonyl)pyridin- 1(2H)-yl)propanamide H calc'd forC₂₂H₂₇ClN₄O₃S 463.99; found 463.99 ¹H NMR (400 MHz, MeOD). δ ppm 1.14(m, 6H) 1.69 (m, 4H) 1.80 (m, 1H) 1.95 (m, 5H) 2.09 (m, 1H) 3.48 (m, 4H)5.94 (m, 1H) 6.50 (d, J = 8 Hz, 1H) 6.62 (s, 1H) 7.34 (s, 1H) 7.90 (d, J= 8 Hz, 1H) 130

  N-(6-chlorobenzo[d]thiazol-2- yl)-2-(4-(cyclopropylsulfonyl)-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide E calc'dfor C₂₃H₂₅ClN₃O₅S₂ 522.08; found 522 1H NMR (400 MHz, CHLOROFORM-d) δppm 1.10-1.22 (m, 1 H) 1.17 (d, J = 7.83 Hz, 1 H) 1.40 (dd, J = 12.38,5.56 Hz, 3 H) 1.36-1.48 (m, 2 H) 1.64 (d, J = 12.13 Hz, 1 H) 1.69-1.77(m, 1 H) 1.95- 2.07 (m, 1 H) 2.10-2.21 (m, 1 H) 2.54 (dd, J = 12.51,3.16 Hz, 1 H) 3.32-3.42 (m, 3 H) 3.90- 4.00 (m, 2 H) 6.04 (dd, J = 9.60,6.32 Hz, 1 H) 6.73 (dd, J = 7.33, 2.02 Hz, 1 H) 7.15 (d, J = 1.77 Hz, 1H) 7.41 (dd, J = 8.59, 2.02 Hz, 1 H) 7.73 (d, J = 8.59 Hz, 1 H) 7.79 (d,J = 2.02 Hz, 1 H) 7.91 (d, J = 7.33 Hz, 1 H) 131

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(6-fluorobenzo[d]thiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C₂₃H₂₅FN₃O₅S₂ 506.11; found 506 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.18 (d, J = 7.58 Hz, 1 H) 1.13-1.24 (m, 1 H) 1.31-1.49 (m, 5 H) 1.60-1.69 (m, 1 H) 1.69-1.79 (m, 1 H) 1.96-2.10 (m, 1 H)2.10-2.23 (m, 1 H) 2.56 (dd, J = 7.45, 4.93 Hz, 1 H) 3.30-3.36 (m, 3 H)3.92- 4.01 (m, 2 H) 6.06 (dd, J = 9.47, 6.19 Hz, 1 H) 6.74 (d, J = 7.33Hz, 1 H) 7.15 (s, 1 H) 7.19 (t, J = 8.21 Hz, 1 H) 7.51 (d, J = 7.83 Hz,1 H) 7.76 (dd, J = 8.72, 4.67 Hz, 1 H) 7.93 (d, J = 6.82 Hz, 1 H) 132

  (R)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-(2-methoxypropan-2-yl)thiazol-2- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₃H₃₂N₃O₆S₂ 510.17; found 510 ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 0.71-0.94 (m, 2 H) 1.10- 1.80 (m, 14 H)1.87-2.02 (m, 1 H) 2.17-2.33 (m, 1 H) 2.48 (t, J = 4.17 Hz, 1 H) 3.12(s, 3 H) 3.24-3.41 (m,2H) 3.93 (d, J = 14.40 Hz, 2 H) 6.09 (s, 1 H) 6.70(d, J = 7.07 Hz, 1 H) 7.36 (s, 1 H) 7.51 (s, 1 H) 7.88 (d, J = 7.33 Hz,1 H) 133

  (S)-2-(4-(cyclopropylsulfonyl)- 2-oxopyridin-1(2H)-yl)-N-(5-(2-methoxypropan-2-yl)thiazol-2- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₃H₃₂N₃O₆S₂ 510.17; found 510 1H NMR (400MHz, CHLOROFORM-d) δ ppm 0.71-0.94 (m, 2 H) 1.10- 1.80 (m, 14 H)1.87-2.02 (m, 1 H) 2.17-2.33 (m, 1 H) 2.48 (t, J = 4. 17 Hz, 1 H) 3.12(s, 3 H) 3.24-3.41 (m, 2 H) 3.93 (d, J = 14.40 Hz, 2 H) 6.09 (s, 1 H)6.70 (d, J = 7.07 Hz, 1 H) 7.36 (s, 1 H) 7.51 (s, 1 H) 7.88 (d, J = 7.33Hz, 1 H) 134

  N-(5-chlorothiazol-2-yl)-2-(6- methyl-2-oxo-4-(thiophen-2-ylmethylsulfonyl)pyridin-1(2H)- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide C calc'd for C₂₂H₂₄ClN₃O₅S₃ 543.09; found 543.09 ¹H NMR(400 MHz, CHLOROFORM-d). δ ppm 1.36 (m, 2H) 1.59 (m, 3H) 2.18 (m, 1H)2.50 (m, 4H) 3.35 (m, 2H) 3.95 (m, 2H) 4.60 (s, 2H) 4.97 (m, 1H) 6.26(s, 1H) 6.85 (s, 1H) 7.02 (m, 1H) 7.07 (d, J = 4 Hz, 1H) 7.27 (s, 1H)7.34 (d, J = 4 Hz, 1H) 135

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide J calc'd for C₂₄H₃₂ClN₃O₅S₂ 543.11. found 543 ¹H NMR (400MHz, CHLOROFORM-d). δ ppm 1.41 (m, 2H) 1.68 (m, 4H) 1.89 (m, 6H) 2.08(m, 3H) 2.38 (s, 3H) 2.54 (s, 3H) 2.67 (s, 3H) 3.35 (m, 2H) 3.62 (m, 1H)3.97 (m, 2H) 5.44 (m, 1H) 7.25 (s, 1H) 136

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopentylsulfonyl)-3,5,6-trimethyl-2-oxopyridin-1(2H)- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide J calc'd for C₂₄H₃₂ClN₃O₅S₂ 543.11. found 543 ¹H NMR (400MHz, CHLOROFORM-d). δ ppm 1.41 (m, 2H) 1.68 (m, 4H) 1.89 (m, 6H) 2.08(m, 3H) 2.38 (s, 3H) 2.54 (s, 3H) 2.67 (s, 3H) 3.35 (m, 2H) 3.62 (m, 1H)3.97 (m, 2H) 5.44 (m, 1H) 7.25 (s, 1H) 137

  N-(5-chlorothiazol-2-yl)-2-(4-(3- hydroxyprop-1-ynyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Icalc'd for C₂₀H₂₃ClN₃O₄S 436.10. found 436.30 1HNMR (400 MHz,CHLOROFORM-d) δ ppm 1.21-1.42 (m, 2 H) 1.51- 1.73 (m, 3 H) 2.26-2.65 (m,2 H) 2.37 (s, 3 H) 3.26- 3.38 (m, 2 H) 3.90 (d, J = 9.60 Hz, 2 H) 4.42(s, 2 H) 6.03-6.13 (m, 1 H) 6.48 (s, 1 H) 7.19 (s, 1 H) 7.22 (s, 1 H)138

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-(4-fluorobenzyl)thiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ecalc'd for C₂₆H₂₉FN₃O₅S₂ 546.15; found 546 1HNMR (400 MHz, CHLOROFORM-d)δ ppm 1.16 (d, J = 7.83 Hz, 2 H) 1.33-1.50 (m, 5 H) 1.61 (br. s., 1 H)1.70 (br. s., 1 H) 1.96 (d, J = 4.80 Hz, 1 H) 2.23 (d, J = 6.82 Hz, 1 H)2.50 (dd, J = 12.51, 3.16 Hz, 1 H) 3.25-3.40 (m, 2 H) 3.94 (d, J = 11.12Hz, 2 H) 3.94 (br. s., 1 H) 4.08 (s, 2 H) 5.93 (t, J = 7.58 Hz, 1 H)6.69 (dd, J = 7.20, 1.89 Hz, 1 H) 7.02 (t, J = 8.46 Hz, 2 H) 7.19 (dd, J= 8.34, 5.31 Hz, 2 H) 7.24 (s, 1 H) 7.33 (s, 1 H) 7.75 (d, J = 7.33 Hz,1 H) 139

  2-(2-oxo-5-(pyrrolidin-1- ylsulfonyl)pyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N- (thiazol-2-yl)propanamide J calc'd forC₂₀H₂₇N₄O₅S₂ 467.13; found 467.30 1H NMR (400 MHz, CHLOROFORM-d) δ ppm1.23-1.38 (m, 2 H) 1.39- 1.51 (m, 1 H) 1.57-1.71 (m, 2 H) 1.83-1.91 (m,4 H) 2.03 (ddd, J = 14.21, 8.78, 5.81 Hz, 1 H) 2.18 (ddd, J = 14.27,7.33, 7.20 Hz, 1 H) 3.19-3.38 (m, 6 H) 3.82-3.92 (m, 2 H) 6.18 (t, J =7.96 Hz, 1 H) 6.82 (d, J = 9.35 Hz, 1 H) 7.06 (d, J = 3.54 Hz, 1 H) 7.69(d, J = 3.54 Hz, 1 H) 7.72 (dd, J = 9.60, 2.53 Hz, 1 H) 8.38 (d, J =2.27 Hz, 1 H) 140

  N-(5-chlorothiazol-2-yl)-2-(2- oxo-5-(pyrrolidin-1-ylsulfonyl)pyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Jcalc'd for C₂₀H₂₆ClN₄O₅S₂, 501.10; found, 501.30 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.26-1.39 (m, 2 H) 1.40- 1.49 (m, 1 H) 1.64 (d, J =12.13 Hz, 2 H) 1.88 (d, J = 13.39 Hz, 4 H) 1.96- 2.07 (m, 1 H) 2.12-2.26(m, 1 H) 3.15-3.43 (m, 6 H) 3.75-4.01 (m, 2 H) 6.07-6.27 (m, 1 H) 6.91(d, J = 9.60 Hz, 1 H) 7.37 (s, 1 H) 7.75 (dd, J = 9.47, 2.40 Hz, 1 H)8.35 (s, 1 H) 141

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideC calc'd for C₂₂H₂₄ClN₃O₆S₂, 527; found, 527 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.27-1.44 (m, 2 H) 1.44- 1.55 (m, 1 H) 1.63 (br. s.,3 H) 2.38-2.60 (m, 4 H) 3.26-3.41 (m, J = 11.81, 11.81, 7.07, 1.89 Hz, 2H) 3.90-4.02 (m, 2 H) 4.48 (s, 2 H) 4.84-5.03 (m, 1 H) 6.27 (br. s., 1H) 6.41 (dd, J = 3.28, 1.77 Hz, 1 H) 6.49 (d, J = 3.28 Hz, 1 H) 6.89 (s,1 H) 7.28 (s, 1 H) 7.40 (d,J = 1.77 Hz, 1 H) 142

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(furan-2-ylmethylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideC calc'd for C₂₂H₂₄ClN₃O₆S₂, 527; found, 527 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.27-1.44 (m, 2 H) 1.44- 1.55 (m, 1 H) 1.63 (br. s.,3 H) 2.38-2.60 (m, 4 H) 3.26-3.41 (m, J = 11.81, 11.81, 7.07, 1.89 Hz, 2H) 3.90-4.02 (m, 2 H) 4.48 (s, 2 H) 4.84-5.03 (m, 1 H) 6.27 (br. s., 1H) 6.41 (dd, J = 3.28, 1.77 Hz, 1 H) 6.49 (d, J = 3.28 Hz, 1 H) 6.89 (s,1 H) 7.28 (s, 1 H) 7.40 (d, J = 1.77 Hz, 1 H) 143

  N-(5-chlorothiazol-2-yl)-3- cyclohexyl-2-(6-methyl-4-(oxazol-2-yl)-2-oxopyridin- 1(2H)-yl)propanamide F calc'd forC₂₁H₂₃ClN₄O₃S 447.12; found 447.10 ¹H NMR (400 MHz, d- DMSO) δ 0.87-0.97(m, 2 H), 1.1-1.22 (m, 5 H), 1.53-1.81 (m, 6 H), 1.98- 2.11 (m, 1 H),2.44 (m, 1 H), 2.51 (s, 3 H), 6.71 (s, 1 H), 6.77 (s, 1 H), 7.47 (s, 1H), 7.51 (s, 3 H), 8.36 (s, 1 H), 144

  N-(5-(4-fluorobenzyl)thiazol-2- yl)-2-(4-(furan-2-ylmethylsulfonyl)-6-methyl-2- oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide C calc'd for C₂₉H₃₀FN₃O₆S₂, 600;found, 600 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.23-1.43 (m, 2 H) 1.45-1.80 (m, 4 H) 2.33-2.61 (m, 4 H) 3.27-3.40 (m, 2 H) 3.94 (dd, J = 11.49,3.66 Hz, 2 H) 4.04 (s, 2 H) 4.46 (s, 2 H) 4.80-4.97 (m, 1 H) 6.25 (br.s., 1 H) 6.37- 6.43 (m, 1 H) 6.48 (d, J = 3.28 Hz, 1 H) 6.87 (br. s., 1H) 6.94-7.04 (m, 2 H) 7.14 (s, 1 H) 7.15-7.23 (m, 2 H) 7.41 (s, 1 H) 145

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-(morpholinomethyl)thiazol-2- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₄H₃₃N₄O₆S₂ 537.18; found 537 1H NMR (400MHz, MeOD) δ ppm 1.20 (d, J = 7.83 Hz, 1 H) 1.27- 1.50 (m, 5 H)1.58-1.78 (m, 2 H) 2.13 (t, J = 6.57 Hz, 1 H) 2.74 (dd, J = 12.63, 3.03Hz, 1 H) 3.17-3.42 (m, 4 H) 3.33 (d, J = 1.77 Hz, 6 H) 3.79- 4.03 (m, 5H) 4.53 (s, 2 H) 6.00 (dd, J = 9.35, 6.32 Hz, 1 H) 6.81 (dd, J = 7.33,2.02 Hz, 1 H) 7.05 (d, J = 1.77 Hz, 1 H) 7.63 (s, 1 H) 8.05 (d, J = 7.33Hz, 1 H) 146

  N-(5-chlorothiazol-2-yl)-2-(2- oxo-4-(2,2,2-trifluoroethylsulfonyl)pyridin- 1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₁₈H₂₀ClF₃N₃O₅S₂ 514.04; found 514.11H NMR (400 MHz, d- CDCl₃) δ ppm 1.36 (d, J = 15.92 Hz, 2H) 1.55- 1.74(m, 4 H) 1.93 (d, J = 6.32 Hz, 1 H) 2.21 (d, J = 6.57 Hz, 1 H) 3.24-3.37 (m, 3 H) 3.88-3.96 (m, 2 H) 6.19-6.29 (m, 1 H) 6.76 (d, 1 H) 7.34(s, 1 H) 7.94 (s, 1 H) 8.07 (d, J = 7.33 Hz, 1 H) 147

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-((4-methylpiperazin-1- yl)methyl)thiazol-2-yl)-3- (tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₂₅H₃₆N₅O₅S₂ 550.21; found 550 1H NMR (400MHz, MeOD) δ ppm 1.21 (d, J = 8.59 Hz, 2 H) 1.38 (d, J = 4.80 Hz, 4 H)1.36 (br. s., 1 H) 1.57-1.78 (m, 2 H) 2.05 (br. s., 1 H) 2.11 (br. s., 1H) 2.50-2.60 (m, 3H) 2.79-2.97 (m, 4 H) 3.26-3.42 (m, 6 H) 3.81 (s, 2 H)3.95 (d, J = 11.62 Hz, 2 H) 4.51 (br. s., 2 H) 6.01 (dd, J = 9.73, 5.94Hz, 1 H) 6.75 (d, J = 7.33 Hz, 1 H) 7.09 (s, 1 H) 7.32 (s, 1 H) 7.96 (d,J = 7.33 Hz, 1 H) 148

  (R)-N-(5-chlorothiazol-2-yl)-2- (2-oxo-4-(2,2,2-trifluoroethylsulfonyl)pyridin- 1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₁₈H₂₀ClF₃N₃O₅S₂ 514.04; found 514.1149

  (S)-N-(5-chlorothiazol-2-yl)-2- (2-oxo-4-(2,2,2-trifluoroethylsulfonyl)pyridin- 1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide E calc'd for C₁₈H₂₀ClF₃N₃O₅S₂ 514.04; found 514.1150

  2-(4-(cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-((4-(2-(dimethylamino)-2- oxoethyl)piperazin-1- yl)methyl)thiazol-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide E calc'd for C₂₈H₄₁N₆O₆S₂ 621.25;found 621 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.19 (d, J = 7.83 Hz, 2H) 1.39 (dd, J = 10.23, 7.45 Hz, 3 H) 1.27-1.50 (m, 2 H) 1.65 (d, J =9.85 Hz, 1 H) 1.72 (d, J = 10.11 Hz, 1 H) 1.84-2.08 (m, 1 H) 2.08-2.31(m, 1 H) 2.58 (dd, J = 12.63, 3.28 Hz, 1 H) 2.98 (d, J = 5.31 Hz, 6 H)3.01-3.09 (m, 4 H) 3.28-3.42 (m, 6 H) 3.87- 4.00 (m, 4 H) 4.04 (s, 2 H)4.09-4.23 (m, 1 H) 6.00 (dd, J = 9.47, 6.19 Hz, 1 H) 6.74 (dd, J = 7.33,2.02 Hz, 1 H) 7.12 (d, J = 2.02 Hz, 1 H) 7.42 (s, 1 H) 7.93 (d, J = 7.33Hz, 1 H) 151

  (S)-2-(4-(cyclopentylsulfonyl)- 5,6-dimethyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide J calc'd for C₂₃H₃₀FN₃O₅S₂ 512.16; found 512.10 ¹H NMR(400 MHz, d- CDCl₃) δ 1.32-1.45 (m, 2 H), 1.64-2.04 (m, 12 H), 2.12-2.20(m, 1 H), 2.47 (s, 3 H), 2.53 (s, 3 H), 3.35 (m, 2 H), 3.60 (m, 1 H),3.94 (m, 2 H), 5.67 (dd, J = 4, 8 Hz, 1 H), 7.04 (d, J = 3 Hz, 1 H),7.33 (s, 1 H) 152

  2-(4-(cyclopropylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ccalc'd for C₂₀H₂₅FN₃O₅S₂ 470.11; found 470 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.17 (dd, J = 7.83, 2.02 Hz, 2 H) 1.35-1.48 (m, 4 H)1.53-1.78 (m, 3 H) 2.45- 2.57 (m, 4 H) 2.58-2.69 (m, 1 H) 3.32-3.47 (m,1 H) 3.39 (s, 3 H) 3.96 (dd, J = 11.49, 2.40 Hz, 2 H) 6.52 (s, 1 H) 6.97(s, 1 H) 7.00 (d, J = 2.53 Hz, 1 H) 153

  (R)-2-(4-(cyclopentylsulfonyl)- 5,6-dimethyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2- yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide J calc'd for C₂₃H₃₀FN₃O₅S₂ 512.16; found 512.10 154

  (R)-2-(3-amino-4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3- cyclopentyl-N-(5-fluorothiazol-2-yl)propanamide G calc'd for C₂₀H₂₅FN₄O₄S₂ 469.13; found 469.10 ¹H NMR(400 MHz, CDCl₃) δ 1.04-1.80 (m, 15 H), 2.39 (s, 3 H), 2.46 (m, 1 H),2.61 (m, 1 H), 4.85 (bs, 1 H), 5.90 bs, 2 H), 6.29 (s, 1 H), 7.02 (d, J= 3 Hz, 1 H) 155

  (S)-2-(3-amino-4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3- cyclopentyl-N-(5-fluorothiazol-2-yl)propanamide G calc'd for C₂₀H₂₅FN₄O₄S₂ 469.13; found 469.10 156

  2-(5-acetamido-2-oxopyridin- 1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide E calc'd for C₁₈H₂₂ClN₄O₄S425.10; found 424.91 ¹H NMR (400 MHz, MeOD) δ ppm 1.31-1.40 (m, 3 H)1.71 (dd, 2 H) 1.99-2.24 (m, 5 H) 3.24- 3.46 (m, 2 H) 3.85-4.01 (m, 2 H)5.91 (dd, J = 10.36, 5.31 Hz, 1 H) 6.58 (d, J = 9.60 Hz, 1 H) 7.33 (s, 1H) 7.54 (dd, J = 9.60, 2.27 Hz, 1 H) 8.35 (d, J = 2.02 Hz, 1 H) 157

  N-(5-chlorothiazol-2-yl)-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ccalc'd for C₂₀H₂₅ClN₃O₅S₂ 486.08; found 486 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.10-1.22 (m, 2 H) 1.29- 1.46 (m, 4 H) 1.59-1.88 (m,2 H) 2.36-2.61 (m, 4 H) 2.66 (d, J = 3.79 Hz, 1 H) 3.40 (td, J = 11.24,5.81 Hz, 2 H) 3.97 (d, J = 11.12 Hz, 5 H) 6.53 (br. s., 1 H) 6.95 (br.s., 1 H) 7.24 (s, 1 H) 158

  N-(5-chlorothiazol-2-yl)-2-(4-(3- fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ccalc'd for C₂₃H₂₄ClFN₃O₅S₂ 540.08; found 540 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.34 (t, J = 12.51 Hz, 2 H) 1.67 (br. s., 4 H) 2.50(s, 3 H) 2.72 (br. s., 1 H) 3.29- 3.44 (m, 3 H) 3.95 (br. s., 2 H) 6.50(s, 1 H) 6.94 (s, 1 H) 7.23 (s, 1 H) 7.38 (td, J = 8.21, 2.27 Hz, 1 H)7.57 (td, J = 7.96, 5.31 Hz, 1 H) 7.65 (d, J = 7.58 Hz, 1 H) 7.73 (d, J= 7.83 Hz, 1 H) 159

  2-(4-(3-fluorophenylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Ccalc'd for C₂₃H₂₄F₂N₃O₅S₂ 524.10; found 524 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.34 (br. s., 2 H) 1.63 (d, J = 11.87 Hz, 4 H) 2.47(br. s., 2 H) 2.61 (br. s. 1H) 3.32-3.43 (m, 4 H) 3.95 (d, J = 11.12 Hz,2 H) 6.47 (s, 1H) 6.98 (br. s., 1 H) 7.34-7.47 (m, 3 H) 7.53- 7.73 (m, 1H) 7.76-7.80 (m, 1H) 160

  N-(5-chlorothiazol-2-yl)-2-(4- (1,1-dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2- oxopyridin-1(2H)-yl)-3- cyclohexylpropanamide Lcalc'd for C₂₃H₃₀ClN₃O₆S₃ 577.15; found 577 ¹H NMR (400 MHz, MeOD). δppm 1.03 (m, 2H) 1.24 (m, 3H) 1.40 (m, 1H) 1.73 (m, 5H) 1.89 (m, 1H)2.27 (m, 2H) 2.52 (m, 3H) 2.60 (s, 3H) 3.22 (m, 4H) 3.61 (m, 1H) 5.32(m, 1H) 6.69 (s, 1H) 6.86 (s, 1H) 7.29 (s, 1H) 161

  N-(5-fluorothiazol-2-yl)-2-(4- (1,1-dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2- oxopyridin-1(2H)-yl)-3- cyclohexylpropanamide Lcalc'd for C₂₃H₃₀FN₃O₆S₃ 560.70; found 5607.06(s, 1H) ¹H NMR (400 MHz,MeOD). δ ppm 1.03 (m, 2H) 1.24 (m, 3H) 1.43 (m, 1H) 1.72 (m, 5H) 1.90(m, 1H) 2.29 (m, 2H) 2.50 9m, 3H) 2.60 (s, 3H) 3.22 (m, 4H) 3.61 (m, 1H)5.31 (m, 1H) 6.69 (s, 1H) 6.86 (s, 1H) 7.06 (s, 1H) 162

  (S)-3-cyclopentyl-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- fluorothiazol-2-yl)propanamide D calc'd forC₂₀H₂₄FN₃O₄S₂ 454.12; found 454.10 ¹H NMR (400 MHz, CDCl₃) δ 1.07-1.80(m, 14 H), 2.45 (m, 1 H), 2.50 (m, 1 H), 2.55 (s, 3 H), 4.89 (bs, 1 H),6.50 (s, 1 H), 6.97 (s, 1 H), 7.01 (d, J = 4 Hz, 1 H) 163

  (R)-3-cyclopentyl-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- fluorothiazol-2-yl)propanamide D calc'd forC₂₀H₂₄FN₃O₄S₂ 454.12; found 454.10 164

  (R)-2-(4-(cyclopentylsulfonyl)- 6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluoropyridin-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Dcalc'd for C₂₄H₃₀FN₃O₅S 492.19; found 492.10 ¹H NMR (400 MHz, d- CDCl₃)δ 1.26-2.14 (m, 14 H), 2.54 (s, 3 H), 2.55 (m, 1 H), 3.36 (m, 2 H), 3.50(m, 1 H), 3.95 (m, 2 H), 4.90 (bs, 1 H), 6.49 (s, 1 H), 7.03 (s, 1 H),7.44 (m, 1 H), 8.14 (s, 1 H), 8.17 (m, 1 H) 165

  (S)-2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluoropyridin-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Dcalc'd for C₂₄H₃₀FN₃O₅S 492.19; found 492.10 166

  (S)-N-(5-chloropyridin-2-yl)-2- (4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideD calc'd for C₂₄H₃₀ClN₃O₅S 508.16; found 508.10 ¹H NMR (400 MHz, d-CDCl₃) δ 1.33-2.12 (m, 14 H), 2.55 (s, 3 H), 2.56 (m, 1 H), 3.36 (m, 2H), 3.50 (m, 1 H), 3.96 (m, 2 H), 4.90 (bs, 1 H), 6.49 (s, 1 H), 7.03(s, 1 H), 7.67 (dd, J = 4, 8 Hz, 1 H), 8.14 (d, J = 8 Hz, 1 H), 8.23 (d,J = 4 Hz, 1 H) 167

  (R)-N-(5-chloropyridin-2-yl)-2- (4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideD calc'd for C₂₄H₃₀ClN₃O₅S 508.16; found 508.10 168

  (S)-2-(4-(3- chlorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide D calc'd for C₂₃H₂₃ClFN₃O₅S₂540.08; found 540.0 ¹H NMR (400 MHz, d- CDCl₃) δ 1.10-1.68 (m, 7 H),2.49 (s, 3 H), 2.62 (m, 1 H), 3.31 (m, 2H), 3.84 (m, 2 H), 4.90 (bs, 1H), 6.60 (s, 1 H), 6.85 (s, 1 H), 7.03 (d, J = 3 Hz, 1 H), 7.68 (t, J =8 Hz, 1 H), 7.76 (m, 1 H), 7.96 (m, 1 H), 8.01 (d, J = 8 Hz, 1 H) 169

  (R)-2-(4-(3- chlorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide D calc'd for C₂₃H₂₃ClFN₃O₅S₂540.08; found 540.0 170

  (R)-3-cyclopentyl-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N- (pyrazin-2-yl)propanamide D calc'd forC₂₁H₂₆N₄O₄S 431.17; found 431.10 ¹H NMR (400 MHz, CDCl₃) δ 1.12-1.17 (m,4 H), 1.35-1.78 (m, 11 H), 2.49 (m, 1 H), 2.59 (s, 3 H), 4.90 (bs, 1 H),6.51 (s, 1 H), 7.00 (s, 1 H), 8.27 (t, J = 4 Hz, 1 H), 8.36 (d, J = 4Hz, 1 H), 9.48 (s, 1 H) 171

  (S)-3-cyclopentyl-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N- (pyrazin-2-yl)propanamide D calc'd forC₂₁H₂₆N₄O₄S 431.17; found 431.10 172

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideK calc'd for C₂₀H₂₅ClN₃O₅S₂ 486.08; found 486 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.10-1.22 (m, 2 H) 1.29- 1.46 (m, 4 H) 1.59-1.88 (m,2 H) 2.36-2.61 (m, 4 H) 2.66 (d, J = 3.79 Hz, 1 H) 3.40 (td, J = 11.24,5.81 Hz, 2 H) 3.97 (d, J = 11.12 Hz, 5 H) 6.53 (br. s., 1 H) 6.95 (br.s., 1 H) 7.24 (s, 1 H) 173

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)- 3-(tetrahydro-2H-pyran-4- yl)propanamideK calc'd for C₂₀H₂₅ClN₃O₅S₂ 486.08; found 486 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.10-1.22 (m, 2 H) 1.29- 1.46 (m, 4 H) 1.59-1.88 (m,2 H) 2.36-2.61 (m, 4 H) 2.66 (d, J = 3.79 Hz, 1 H) 3.40 (td, J = 11.24,5.81 Hz, 2 H) 3.97 (d, J = 11.12 Hz, 5 H) 6.53 (br. s., 1 H) 6.95 (br.s., 1 H) 7.24 (s, 1 H) 174

  N-(5-chlorothiazol-2-yl)-3- cyclopentyl-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4- ylsulfonyl)pyridin-1(2H)- yl)propanamide Lcalc'd for C₂₂H₂₈ClN₃O₅S₂ 515.06; found 515 ¹H NMR (400 MHz, MeOD). δppm 1.04 (m, 1H) 1.28 (m, 1H) 1.59 (m, 5H) 1.84 (m, 6H) 2.12 (m, 1H)2.60 (m, 4H) 3.41 (m, 2H) 3.54 (m, 1H) 4.03 (m, 2H) 5.29 (m, 1H) 6.69(s, 1H) 6.82 (s, 1H) 7.29 (s, 1H) 175

  3-cyclopentyl-N-(5- fluorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4- ylsulfonyl)pyridin-1(2H)- yl)propanamideL calc'd for C₂₂H₂₈FN₃O₅S₂ 498.61; found 498 ¹H NMR (400 MHz, MeOD). δppm 1.02 (m, 1H) 1.26 (m, 1H) 1.58 (m, 5H) 1.83 (m, 6H) 2.11 (m, 1H)2.56 (m, 4H) 3.40 (t, J = 12, 8 Hz, 2H) 3.52 (m, 1H) 4.01 (m, 2H) 5.28(m, 1H) 6.67 (s, 1H) 6.81 (s, 1H) 7.05 (s, 1H) 176

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(1-methyl-1H-pyrazol-3-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide Dcalc'd for C₂₃H₃₂N₄O₅S 477.21; found 477.20 ¹H NMR (400 MHz, d- CDCl₃) δ1.26-1.43 (m, 2 H), 1.62-2.13 (m, 13 H), 2.54 (s, 3 H), 2.76 (m, 1 H),3.39 (m, 2 H), 3.44 (m, 1 H), 3.96 (s, 3 H), 3.98 (m, 2 H), 4.80 (bs, 1H), 6.54 (s, 1 H), 6.88 (s, 1 H), 6.95 (s, 1 H), 7.36 (d, J = 4 Hz, 1 H)177

  2-(4-(cyclopentylsulfonyl)-6- methyl-2-oxopyridin-1(2H)-yl)-N-(pyrazin-2-yl)-3-(tetrahydro- 2H-pyran-4-yl)propanamide D calc'd forC₂₃H₃₀N₄O₅S 475.19; found 475.10 ¹H NMR (400 MHz, d- CDCl₃) δ 1.26-2.12(m, 14 H), 2.60 (s, 3 H), 2.76 (m, 1 H), 3.44 ( m, 2 H), 3.50 (m, 1 H),4.06 (s, 2 H), 4.95 (bs, 1 H), 6.62 (s, 1 H), 7.05 (s, 1 H), 8.34 (s, 1H), 8.47 (s, 1 H), 9.65 (s, 1 H) 178

  N-(5-chlorothiazol-2-yl)-3- cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl- 2-oxopyridin-1(2H)- yl)propanamide Dcalc'd for C₂₀H₂₄ClN₃O₄S₂ 470.09; found 470.0 ¹H NMR (400 MHz, CDCl₃) δ1.09-2.15 (m, 14 H), 2.46 (m, 1 H), 2.57 (s, 3 H), 2.62 (m, 1 H), 4.95(bs, 1 H), 6.54 (s, 1 H), 6.91 (s, 1 H), 7.26 (s, 1 H) 179

  2-(5-chloro-4- (cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide H calc'dfor C₁₉H₂₁Cl₂N₃O₅S₂ 507.43; found 507 ¹H NMR (400 MHz, CHLOROFORM-d). δppm 1.21 (m, 3H) 1.43 (m, 4H) 1.69 (d, J = 12 Hz, 2H) 1.93 (m, 1H) 2.21(m, 1H) 2.96 (m, 1H) 3.33 (m, 2H) 3.92 (m, 2H) 6.21 (t, J = 4, 8 Hz, 1H)7.37 (s, 1H) 8.02 (s, 1H) 8.04 (s, 1H) 180

  (S)-6-(3-cyclopentyl-2-(4- (cyclopropylsulfonyl)-6-methyl-2-oxopyridin-1(2H)- yl)propanamido)nicotinamide D calc'd for C₂₃H₂₈N₄O₅S473.18; found 473.10 181

  (R)-6-(2-(4- (cyclopentylsulfonyl)-6-methyl- 2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)nicotinamide D calc'd forC₂₅H₃₂N₄O₆S 517.20; found 517.20 ¹H NMR (400 MHz, CDCl₃) δ 1.20-2.09 (m,14 H), 2.56 (s, 3 H), 2.59 (m, 1 H), 3.36 (m, 2 H), 3.50 (m, 1 H), 3.97(m, 2 H), 4.95 (bs, 1 H), 6.51 (s, 1 H), 7.04 (s, 1 H), 7.96 (m, 1 H),8.30 (d, J = 8 Hz, 1 H), 8.57 (d, J = 4 Hz, 1 H) 182

  (S)-6-(2-(4- (cyclopentylsulfonyl)-6-methyl- 2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamido)nicotinamide D calc'd forC₂₅H₃₂N₄O₆S 517.20; found 517.20 183

  (S)-N-(5-chlorothiazol-2-yl)-3- cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl- 2-oxopyridin-1(2H)- yl)propanamide Dcalc'd for C₂₀H₂₄ClN₃O₄S₂ 470.09; found 470.0 184

  (R)-N-(5-chlorothiazol-2-yl)-3- cyclopentyl-2-(4-(cyclopropylsulfonyl)-6-methyl- 2-oxopyridin-1(2H)- yl)propanamide Dcalc'd for C₂₀H₂₄ClN₃O₄S₂ 470.09; found 470.0 185

  2-(5-chloro-4- (cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide H calc'dfor C₂₁H₂₅Cl₂N₃O₅S₂ 535.48; found 535 ¹H NMR (400 MHz, CHLOROFORM-d). δppm 1.39 (m, 3H) 1.86 (m, 10H) 2.22 ((m, 2H) 3.33 (m, 2H) 3.95 (m, 3H)6.22 (t, J = 4, 8 Hz, 1H) 7.37 (s, 1H) 8.04 (s, 1H) 8.16 (s, 1H 186

  2-(5-chloro-4- (cyclopentylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide H calc'dfor C₂₁H₂₅ClFN₃O₅S₂ 519.02; found 519 ¹H NMR (400 MHz, CHLOROFORM-d). δppm 1.39 (m, 5H) 1.69 (m, 3H) 1.95 (m, 5H) 2.19 (m, 2H) 3.39 (m, 2H)4.00 (m, 3H) 5.94 (t, J = 8, 8 Hz, 1H) 7.14 (d, J = 4 Hz, 1H) 7.70 (s,1H) 7.80 (s, 1H) 187

  (S)-N-(5-chlorothiazol-2-yl)-2- (4-(1,1- dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2- oxopyridin-1(2H)-yl)-3- cyclohexylpropanamide Lcalc'd for C₂₃H₃₀ClN₃O₆S₃ 577.15; found 577 ¹H NMR (400 MHz, MeOD). δppm 1.03 (m, 2H) 1.24 (3H) 1.40 (m, 1H) 1.73 (m, 5H) 1.89 (m, 1H) 2.27(m, 2H) 2.52 (m, 3H) 2.60 (s, 3H) 3.22 (m, 4H) 3.61 (m, 1H) 5.32 (m, 1H)6.69 (s, 1H) 6.86 (s, 1H) 7.29 (s, 1H) 188

  (R)-N-(5-chlorothiazol-2-yl)-2- (4-(1,1- dioxotetrahydrothiopyran-4-ylsulfonyl)-6-methyl-2- oxopyridin-1(2H)-yl)-3- cyclohexylpropanamide Lcalc'd for C₂₃H₃₀ClN₃O₆S₃ 577.15; found 577 ¹H NMR (400 MHz, MeOD). δppm 1.03 (m, 2H) 1.24 (3H) 1.40 (m, 1H) 1.73 (m, 5H) 1.89 (m, 1H) 2.27(m, 2H) 2.52 (m, 3H) 2.60 (s, 3H) 3.22 (m, 4H) 3.61 (m, 1H) 5.32 (m, 1H)6.69 (s, 1H) 6.86 (s, 1H) 7.29 (s, 1H) 189

  (S)-2-(4-(3- fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide K calc'd for C₂₃H₂₄F₂N₃O₅S₂524.10; found 524 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.34 (br. s., 2H) 1.63 (d, J = 11.87 Hz, 4 H) 2.47 (br. s., 2H) 2.61 (br. s. 1H)3.32-3.43 (m, 4 H) 3.95 (d, J = 11.12 Hz, 2 H) 6.47 (s, 1H) 6.98 (br.s., 1 H) 7.34-7.47 (m, 3 H) 7.53- 7.73 (m, 1 H) 7.76-7.80 (m, 1H) 190

  (R)-2-(4-(3- fluorophenylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5- fluorothiazol-2-yl)-3-(tetrahydro-2H-pyran-4- yl)propanamide K calc'd for C₂₃H₂₄F₂N₃O₅S₂524.10; found 524 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.34 (br. s.,2H)1.63 (d, J = 11.87 Hz, 4 H) 2.47 (br. s., 2H) 2.61 (br. s. 1H) 3.32-3.43(m, 4 H) 3.95 (d, J = 11.12 Hz, 2H) 6.47 (s, 1H) 6.98 (br. s., 1 H)7.34-7.47 (m, 3 H) 7.53- 7.73 (m, 1 H) 7.76-7.80 (m, 1H) 191

  (S)-N-(5-chlorothiazol-2-yl)-3- cyclopentyl-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4- ylsulfonyl)pyridin-1(2H)- yl)propanamide Lcalc'd for C₂₂H₂₈ClN₃O₅S₂ 515.06; found 515 ¹H NMR (400 MHz, MeOD). δppm 1.04 (m, 1H) 1.28 (m, 1H) 1.59 (m, 5H) 1.84 (m, 6H) 2.12 (m, 1H)2.60 (m, 4H) 3.41 (m, 2H) 3.54 (m, 1H) 4.03 (m, 2H) 5.29 (m, 1H) 6.69(s, 1H) 6.82 (s, 1H) 7.29 (s, 1H) 192

  (R)-N-(5-chlorothiazol-2-yl)-3- cyclopentyl-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4- ylsulfonyl)pyridin-1(2H)- yl)propanamide Lcalc'd for C₂₂H₂₈ClN₃O₅S₂ 515.06; found 515 193

  (S)-3-cyclopentyl-N-(5- fluorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4- ylsulfonyl)pyridin-1(2H)- yl)propanamideL calc'd for C₂₂H₂₈FN₃O₅S₂ 498.61; found 498 ¹H NMR (400 MHz, MeOD). δppm 1.02 (m, 1H) 1.26 (m, 1H) 1.58 (m, 5H) 1.83 (m, 6H) 2.11 (m, 1H)2.56 (m, 4H) 3.40 (t, J = 12, 8 Hz, 2H) 3.52 (m, 1H) 4.01 (m, 2H) 5.28(m, 1H) 6.67 (s, 1H) 6.81 (s, 1H) 7.05 (s, 1H) 194

  (R)-3-cyclopentyl-N-(5- fluorothiazol-2-yl)-2-(6-methyl-2-oxo-4-(tetrahydro-2H-pyran-4- ylsulfonyl)pyridin-1(2H)- yl)propanamideL calc'd for C₂₂H₂₈FN₃O₅S₂ 498.61; found 498 195

  (R)-2-(5-chloro-4- (cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide H calc'dfor C₁₉H₂₁Cl₂N₃O₅S₂ 507.43; found 507 196

  (S)-2-(5-chloro-4- (cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-chlorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide H calc'dfor C₁₉H₂₁Cl₂N₃O₅S₂ 507.43; found 507 ¹H NMR (400 MHz, CHLOROFORM-d). δppm 1.21 (m, 3H) 1.43 (m, 4H) 1.69 (d, J = 12 Hz, 2H) 1.93 (m, 1H) 2.21(m, 1H) 2.96 (m, 1H) 3.33 (m, 2H) 3.92 (m, 2H) 6.21 (t, J = 4, 8 Hz, 1H)7.37 (s, 1H) 8.02 (s, 1H) 8.04 (s, 1H) 197

  (R)-2-(5-chloro-4- (cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide H calc'dfor C₁₉H₂₁ClFN₃O₅S₂ 489.97; found 490.0 198

  (S)-2-(5-chloro-4- (cyclopropylsulfonyl)-2- oxopyridin-1(2H)-yl)-N-(5-fluorothiazol-2-yl)-3- (tetrahydro-2H-pyran-4- yl)propanamide H calc'dfor C₁₉H₂₁ClFN₃O₅S₂ 489.97; found 490.0 ¹H NMR (400 MHz, CHLOROFORM-d).δ ppm 1.21 (m, 3H) 1.39 (m, 4H) 1.69 (d, J = 12 Hz, 2H) 1.92 (m, 1H)2.20 (m, 1H) 2.96 (m, 1H) 3.33 (m, 2H) 3.92 (m, 2H) 6.18 (t, J = 8, 4Hz, 1H) 7.13 (s, 1H) 7.96 (s, 1H) 8.02 (s, 1H) 199

  3-cyclohexyl-2-(1- oxoisoquinolin-2(1H)-yl)-N-(thiazol-2-yl)propanamide J calc'd for C₂₁H₂₄N₃O₂S 382.15; found 282.0¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.82-1.00 (m, 2H) 1.01- 1.14 (m, 3H) 1.50-1.64 (m, 1 H) 1.69 (d, J = 12.63 Hz, 1 H) 1.77 (d, J = 12.63 Hz,1 H) 1.92-2.04 (m, 1 H) 2.14 (ddd, J = 14.21, 7.58, 7.26 Hz, 1 H) 6.15(t, J = 7.83 Hz, 1 H) 6.63 (d, J = 8.59 Hz, 1 H) 7.02 (d, J = 5.56 Hz, 1H) 7.43 (d, J = 7.58 Hz, 1 H) 7.48- 7.56 (m, 2 H) 7.67 (t, J = 7.45 Hz,1 H) 7.75 (d, J = 4.29 Hz, 1 H) 8.48 (d, J = 8.08 Hz, 1 H) 11.89 (br.s., 1 H) 200

  2-(2-oxo-1,6-naphthyridin- 1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)-N-(thiazol-2- yl)propanamide J calc'd for C₁₉H₂₁N₄O₃S385.13; found 385.26 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.34 (td, J =12.38, 4.29 Hz, 2 H) 1.59-1.70 (m, 2 H) 1.76-1.87 (m, 1 H) 1.87- 1.93(m, 1 H) 2.03-2.16 (m, 1 H) 3.21-3.39 (m, 4 H) 5.77 (dd, J = 9.60, 3.79Hz, 1 H) 6.93 (d, J = 3.54 Hz, 1 H) 7.33-7.41 (m, 2 H) 7.88 (d, J = 6.82Hz, 1 H) 8.38-8.51 (m, 2 H) 9.32 (s, 1 H)Biological Testing

The activity of compounds as glucokinase activators may be assayed invitro, in vivo or in a cell line. Provided below is an enzymaticglucokinase activity assay.

Purified glucokinase may be obtained as follows. DNA encoding residues12-465 of the full-length sequence of the human enzyme may be amplifiedby PCR and cloned into the HindIII and EcoRI sites of pFLAG-CTC (Sigma).SEQ. I.D. No. 1 corresponds to residues 12-465 of glucokinase.

The expression of recombinant glucokinase protein may be carried out bytransformation and growth of DH10b-T1r E. coli cells incorporating the(pFLAG-CTC) plasmid in LB media. Protein expression can be induced inthis system by the addition of IPTG to the culture medium.

Recombinant protein may be isolated from cellular extracts by passageover Sepharose Q Fast Flow resin (Pharmacia). This partially purified GKextract may then be further purified by a second passage over Poros HQ10(Applied Biosystems). The purity of GK may be determined on denaturingSDS-PAGE gel. Purified GK may then be concentrated to a finalconcentration of 20.0 mg/ml. After flash freezing in liquid nitrogen,the proteins can be stored at −78° C. in a buffer containing 25 mMTRIS-HCl pH 7.6, 50 mM NaCl, and 0.5 mM TCEP.

It should be noted that a variety of other expression systems and hostsare also suitable for the expression of glucokinase, as would be readilyappreciated by one of skill in the art.

The activation properties of compounds for GK may be determined using ablack 384-well-plate format under the following reaction conditions: 25mM Hepes pH 7.2, 25 mM NaCl, 10 mM MgCl₂, 0.01% Brij35, 1 mM DTT, 5 μMATP, 5 mM Glucose 2% DMSO. The amount of ATP consumed may be determinedquantitatively by addition of equal volume of luciferase reagent(luciferase+beetle luciferin—KinaseGlo Luminescent Kinase Assay kit fromPromega). The luminescence intensity may be measured by using theAnalyst HT from LJL Biosystems.

The assay reaction may be initiated as follows: 4 μl of substratemixture (12.5 μM ATP and 12.5 mM Glucose) was added to each well of theplate, followed by the addition of 2 μl of activator (2 fold serialdilutions for 11 data points for each activator) containing 10% DMSO. 4μL of 1.25 nM GK solution may be added to initiate the reaction. Thereaction mixture may then be incubated at room temperature for 60 min,and quenched and developed by addition of 10 μL of luciferase reagent.Luminescence intensities of the resulting reaction mixtures may bemeasured after a 10 min incubation at room temperature. The luminescenceintensity may be measured by using the Analyst HT from LJL Biosystems.

pK_(act) values may be calculated by non-linear curve fitting of thecompound concentrations and luminescence intensities to a standardinhibition/activation equation. K_(act) is the concentration thatdisplays 50% of the maximal increase in GK activity observed using asaturating activator concentration.

pK_(act) values for select compounds of the present invention are givenin Table 2.

TABLE 2 pK_(act) and % ACT_(max) of Exemplified Compounds Against GK Ex.pK_(act) 1 <4.8 2 <4.8 3 4.8-5.8 4 4.8-5.8 5 >5.8 6 >5.8 7 <4.8 8 >5.8 9<4.8 10 <4.8 11 >5.8 12 4.8-5.8 13 >5.8 14 >5.8 15 <4.8 16 4.8-5.8 17<4.8 18 4.8-5.8 19 4.8-5.8 20 <4.8 21 <4.8 22 <4.8 23 4.8-5.8 24 <4.825 >5.8 26 <4.8 27 <4.8 28 <4.8 29 <4.8 30 >5.8 31 <4.8 32 >5.8 334.8-5.8 34 >5.8 35 >5.8 36 <4.8 37 4.8-5.8 38 >5.8 39 <4.8 40 >5.8 41<4.8 42 >5.8 43 4.8-5.8 45 >5.8 46 >5.8 47 <4.8 48 4.8-5.8 49 >5.850 >5.8 51 <4.8 52 4.8-5.8 53 <4.8 54 >5.8 55 4.8-5.8 56 <4.8 57 4.8-5.858 <4.8 59 >5.8 60 >5.8 61 <4.8 62 4.8-5.8 63 <4.8 64 4.8-5.8 65 <4.8 66<4.8 67 <4.8 68 >5.8 69 <4.8 71 <4.8 72 4.8-5.8 73 <4.8 74 4.8-5.8 754.8-5.8 76 >5.8 77 >5.8 78 4.8-5.8 79 <4.8 80 4.8-5.8 81 >5.8 82 >5.883 >5.8 84 <4.8 85 >5.8 87 <4.8 88 4.8-5.8 89 >5.8 90 <4.8 91 <4.8 92<4.8 93 <4.8 95 4.8-5.8 96 <4.8 97 <4.8 98 4.8-5.8 99 <4.8 100 4.8-5.8101 <4.8 102 <4.8 103 <4.8 104 <4.8 105 <4.8 106 <4.8 107 <4.8 108 <4.8109 <4.8 110 <4.8 111 <4.8 112 <4.8 113 <4.8 114 4.8-5.8 115 <4.8 117<4.8 118 >5.8 119 4.8-5.8 120 <4.8 121 4.8-5.8 122 4.8-5.8 123 >5.8 124<4.8 125 <4.8 126 <4.8 127 4.8-5.8 128 >5.8 129 4.8-5.8 130 4.8-5.8 1314.8-5.8 132 4.8-5.8 133 4.8-5.8 134 >5.8 135 >5.8 136 4.8-5.8 137 <4.8138 4.8-5.8 139 4.8-5.8 140 4.8-5.8 141 >5.8 142 <4.8 143 4.8-5.8 1444.8-5.8 145 <4.8 146 <4.8 147 <4.8 148 <4.8 149 4.8-5.8 150 <4.8151 >5.8 153 >5.8 154 4.8-5.8 155 4.8-5.8 156 <4.8 157 4.8-5.8 158 >5.8159 4.8-5.8 160 4.8-5.8 161 4.8-5.8 162 >5.8 163 <4.8 164 <4.8 1654.8-5.8 166 >5.8 167 <4.8 168 >5.8 169 <4.8 170 <4.8 171 4.8-5.8172 >5.8 173 <4.8 174 4.8-5.8 175 4.8-5.8 176 <4.8 177 <4.8 178 >5.8 1794.8-5.8 180 4.8-5.8 181 <4.8 182 4.8-5.8 183 >5.8 185 4.8-5.8 1864.8-5.8 187 4.8-5.8 188 <4.8 189 4.8-5.8 190 <4.8 191 4.8-5.8 192 <4.8193 4.8-5.8 194 <4.8 195 <4.8 196 4.8-5.8 197 <4.8 198 4.8-5.8

It will be apparent to those skilled in the art that variousmodifications and variations can be made in the compounds, compositions,kits, and methods of the present invention without departing from thespirit or scope of the invention. Thus, it is intended that the presentinvention cover the modifications and variations of this inventionprovided they come within the scope of the appended claims and theirequivalents.

What is claimed is:
 1. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein Q is selectedfrom the group consisting of O and CH₂; s is selected from the groupconsisting of 0, 1, 2, 3 and 4; R₄, R₆ and R₇ are each independentlyselected from the group consisting of hydrogen, halo, nitro, cyano,hydroxy, alkoxy, aryloxy, amino, (C₁₋₁₀)alkylamino, —CO—NH—R₁₆,—NH—CO—R₁₆, —SO₂—R₁₆, —NH—SO₂—R₁₆, —SO₂—NH—R₁₆, (C₁₋₁₀)alkyl,halo(C₁₋₁₀)alkyl, amino (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,aryl(C₁₋₁₀)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,(C₉₋₁₂)bicycloalkyl, aryl, and (C₉₋₁₂)bicycloaryl each substituted orunsubstituted; each R₁₆ is independently selected from the groupconsisting of hydrogen, halo, nitro, cyano, hydroxy, (C₁₋₁₀)alkoxy,(C₄₋₁₂)aryloxy, aminocarbonyl, amino, (C₁₋₁₀)alkylamino, (C₁₋₁₀)alkyl,halo(C₁₋₁₀)alkyl, hydroxy(C₁₋₁₀)alkyl, aza(C₁₋₁₀)alkyl, (C₁₋₁₀)oxaalkyl,(C₁₋₁₀)oxoalkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,(C₄₋₁₂)aryl, and (C₉₋₁₂)bicycloaryl, each substituted or unsubstituted;each R₂₀ is independently selected from the group consisting ofhydrogen, halo, nitro, cyano, hydroxy, alkoxy, aryloxy, amino,(C₁₋₁₀)alkylamino, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, amino (C₁₋₁₀)alkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,aryl, and (C₉₋₁₂)bicycloaryl, each substituted or unsubstituted; whereineach optional substituent is independently selected from the groupconsisting of halo, nitro, cyano, hydroxy, (C₁₋₁₀)alkoxy,(C₄₋₁₂)aryloxy, aminocarbonyl, amino, (C₁₋₁₀)alkylamino, (C₁₋₁₀)alkyl,halo (C₁₋₁₀)alkyl, hydroxy(C₁₋₁₀)alkyl, (C₁₋₁₀)azaalkyl,(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,(C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,(C₄₋₁₂)aryl, and (C₉₋₁₂)bicycloaryl.
 2. The compound or pharmaceuticallyacceptable salt according to claim 1, wherein R₄ is selected from thegroup consisting of halo, (C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, —CO—NH—R₁₆,—NH—CO—R₁₆, —SO₂—R₁₆, —NH—SO₂—R₁₆, and —SO₂—NH—R₁₆.
 3. The compound orpharmaceutically acceptable salt according to claim 1, wherein R₄ is asubstituted or unsubstituted (C₁₋₅)alkyl.
 4. The compound orpharmaceutically acceptable salt according to claim 1, wherein R₄ ismethyl.
 5. The compound or pharmaceutically acceptable salt according toclaim 1, wherein R₆ is selected from the group consisting of hydrogen,halo, (C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, —CO—NH—R₁₆, —NH—CO—R₁₆, —SO₂—R₁₆,—NH—SO₂—R₁₆, and —SO₂—NH—R₁₆.
 6. The compound or pharmaceuticallyacceptable salt according to claim 1, wherein R₆ is hydrogen.
 7. Thecompound or pharmaceutically acceptable salt according to claim 1,wherein R₆ is a substituted or unsubstituted (C₁₋₅)alkyl.
 8. Thecompound or pharmaceutically acceptable salt according to claim 1,wherein R₆ is methyl.
 9. The compound or pharmaceutically acceptablesalt according to claim 1, wherein R₇ is selected from the groupconsisting of hydrogen, halo, (C₁₋₁₀)alkyl, (C₁₋₁₀)alkoxy, —CO—NH—R₁₆,—NH—CO—R₁₆, —SO₂—R₁₆, —NH—SO₂—R₁₆, and —SO₂—NH—R₁₆.
 10. The compound orpharmaceutically acceptable salt according to claim 1, wherein R₇ ismethyl.
 11. A compound selected from the group consisting of:6-(3-cyclohexyl-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)propanamido)nicotinamide;(R)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;(S)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;(S)-6-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;(R)-6-(2-(4-(cyclopentylsulfonyl)-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;(R)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluoropyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;(S)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-N-(5-fluoropyridin-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;(S)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;(R)—N-(5-chloropyridin-2-yl)-2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide;(R)-6-(2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;(S)-6-(2-(4-(cyclopentylsulfonyl)-6-methyl-2-oxopyridin-1(2H)-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamido)nicotinamide;and a pharmaceutically acceptable salt of any one of the aforementionedcompounds.
 12. A pharmaceutical composition comprising a compound orpharmaceutically acceptable salt as defined in claim 1, and apharmaceutically acceptable excipient.